|
EP1523496B1
(en)
|
2002-07-18 |
2011-06-29 |
Merus B.V. |
Recombinant production of mixtures of antibodies
|
|
USRE47770E1
(en)
|
2002-07-18 |
2019-12-17 |
Merus N.V. |
Recombinant production of mixtures of antibodies
|
|
CA2527694C
(en)
|
2003-05-30 |
2015-07-14 |
Hendricus Renerus Jacobus Mattheus Hoogenboom |
Fab library for the preparation of anti vegf and anti rabies virus fabs
|
|
US20100069614A1
(en)
|
2008-06-27 |
2010-03-18 |
Merus B.V. |
Antibody producing non-human mammals
|
|
CA2603408C
(en)
|
2005-03-31 |
2018-08-21 |
Chugai Seiyaku Kabushiki Kaisha |
Methods for producing polypeptides by regulating polypeptide association
|
|
CA2647846C
(en)
|
2006-03-31 |
2016-06-21 |
Chugai Seiyaku Kabushiki Kaisha |
Methods for controlling blood pharmacokinetics of antibodies
|
|
ES2654040T3
(es)
|
2006-03-31 |
2018-02-12 |
Chugai Seiyaku Kabushiki Kaisha |
Método de modificación de anticuerpos para la purificación de anticuerpos biespecíficos
|
|
EP2066694B1
(en)
|
2006-09-29 |
2015-11-04 |
Oncomed Pharmaceuticals, Inc. |
Compositions and methods for diagnosing and treating cancer
|
|
CN105061577A
(zh)
|
2006-12-14 |
2015-11-18 |
爱勒让治疗公司 |
双巯基大环化系统
|
|
ES2648687T3
(es)
|
2007-02-23 |
2018-01-05 |
Aileron Therapeutics, Inc. |
Péptidos macrocíclicos unidos a triazol
|
|
KR20160061439A
(ko)
|
2007-03-28 |
2016-05-31 |
프레지던트 앤드 펠로우즈 오브 하바드 칼리지 |
스티칭된 폴리펩티드
|
|
CN104497143B
(zh)
|
2007-03-29 |
2020-08-25 |
健玛保 |
双特异性抗体及其制造方法
|
|
MX336725B
(es)
|
2007-09-26 |
2016-01-28 |
Chugai Pharmaceutical Co Ltd |
Metodo de modificacion del punto isoelectrico de anticuerpos medinate la sustitucion de aminoacidos en region de determinacion de complementariedad (cdr).
|
|
RU2526512C2
(ru)
|
2007-09-26 |
2014-08-20 |
Чугаи Сейяку Кабусики Кайся |
Модифицированная константная область антитела
|
|
US20090162359A1
(en)
|
2007-12-21 |
2009-06-25 |
Christian Klein |
Bivalent, bispecific antibodies
|
|
PL2235064T3
(pl)
*
|
2008-01-07 |
2016-06-30 |
Amgen Inc |
Sposób otrzymywania cząsteczek przeciwciał z heterodimerycznymi fc z zastosowaniem kierujących efektów elektrostatycznych
|
|
EP2282769A4
(en)
|
2008-04-29 |
2012-04-25 |
Abbott Lab |
DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND ITS USES
|
|
NZ589434A
(en)
|
2008-06-03 |
2012-11-30 |
Abbott Lab |
Dual variable domain immunoglobulins and uses thereof
|
|
WO2009158025A2
(en)
|
2008-06-26 |
2009-12-30 |
Acceleron Pharma Inc. |
Methods for dosing an actriib antagonist and monitoring of treated patients
|
|
NZ603698A
(en)
|
2008-07-08 |
2014-03-28 |
Abbvie Inc |
Prostaglandin e2 dual variable domain immunoglobulins and uses thereof
|
|
WO2010019702A2
(en)
|
2008-08-12 |
2010-02-18 |
Oncomed Pharmaceuticals, Inc. |
Ddr1-binding agents and methods of use thereof
|
|
US9175047B2
(en)
|
2009-01-14 |
2015-11-03 |
Aileron Therapeutics, Inc. |
Peptidomimetic macrocycles
|
|
CA2749539C
(en)
|
2009-01-21 |
2022-07-19 |
Amgen Inc. |
Compositions and methods comprising interleukin-2 mutants for treating inflammatory and autoimmune diseases
|
|
US20120020952A1
(en)
*
|
2009-01-26 |
2012-01-26 |
Genmab A/S |
Methods for producing mixtures of antibodies
|
|
US9228017B2
(en)
|
2009-03-19 |
2016-01-05 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody constant region variant
|
|
US20120071634A1
(en)
|
2009-03-19 |
2012-03-22 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody Constant Region Variant
|
|
CA2753988C
(en)
|
2009-03-25 |
2017-04-25 |
Genentech, Inc. |
Novel anti-.alpha.5.beta. integrin antibodies and uses thereof
|
|
US20100256340A1
(en)
|
2009-04-07 |
2010-10-07 |
Ulrich Brinkmann |
Trivalent, bispecific antibodies
|
|
AU2013203859B2
(en)
*
|
2009-04-27 |
2016-09-08 |
Oncomed Pharmaceuticals, Inc. |
Method for making heteromultimeric molecules
|
|
US9067986B2
(en)
*
|
2009-04-27 |
2015-06-30 |
Oncomed Pharmaceuticals, Inc. |
Method for making heteromultimeric molecules
|
|
US9676845B2
(en)
|
2009-06-16 |
2017-06-13 |
Hoffmann-La Roche, Inc. |
Bispecific antigen binding proteins
|
|
MY199658A
(en)
|
2009-06-26 |
2023-11-14 |
Regeneron Pharma |
Readily isolated bispecific antibodies with native immunoglobulin format
|
|
MX2011013455A
(es)
|
2009-07-08 |
2012-02-13 |
Amgen Inc |
Diseño de moleculas de fc de anticuerpo estables y libres de agregacion a traves del diseño de la interfase del dominio de ch3.
|
|
TW201109438A
(en)
*
|
2009-07-29 |
2011-03-16 |
Abbott Lab |
Dual variable domain immunoglobulins and uses thereof
|
|
WO2011028952A1
(en)
*
|
2009-09-02 |
2011-03-10 |
Xencor, Inc. |
Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
|
|
WO2011034605A2
(en)
|
2009-09-16 |
2011-03-24 |
Genentech, Inc. |
Coiled coil and/or tether containing protein complexes and uses thereof
|
|
CN102712675A
(zh)
|
2009-09-22 |
2012-10-03 |
爱勒让治疗公司 |
拟肽大环化合物
|
|
US10150808B2
(en)
|
2009-09-24 |
2018-12-11 |
Chugai Seiyaku Kabushiki Kaisha |
Modified antibody constant regions
|
|
TW201119676A
(en)
|
2009-10-15 |
2011-06-16 |
Abbott Lab |
Dual variable domain immunoglobulins and uses thereof
|
|
PT2488204E
(pt)
|
2009-10-16 |
2016-06-09 |
Oncomed Pharm Inc |
Combinação terapêutica e utilização de anticorpos antagonistas de dll4 e agentes anti-hipertensivos
|
|
UY32979A
(es)
|
2009-10-28 |
2011-02-28 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
|
US9200060B2
(en)
*
|
2009-11-23 |
2015-12-01 |
Amgen Inc. |
Monomeric antibody Fc
|
|
US20130089554A1
(en)
*
|
2009-12-29 |
2013-04-11 |
Emergent Product Development Seattle, Llc |
RON Binding Constructs and Methods of Use Thereof
|
|
US9796788B2
(en)
|
2010-02-08 |
2017-10-24 |
Regeneron Pharmaceuticals, Inc. |
Mice expressing a limited immunoglobulin light chain repertoire
|
|
SG10201913463QA
(en)
|
2010-02-08 |
2020-03-30 |
Regeneron Pharma |
Common light chain mouse
|
|
US20130045492A1
(en)
|
2010-02-08 |
2013-02-21 |
Regeneron Pharmaceuticals, Inc. |
Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
|
|
MX2012008958A
(es)
|
2010-02-18 |
2012-08-23 |
Genentech Inc |
Antagonista de neurogulina y usos de los mismos para el tratamiento contra el cancer.
|
|
JP5889181B2
(ja)
|
2010-03-04 |
2016-03-22 |
中外製薬株式会社 |
抗体定常領域改変体
|
|
JP6093692B2
(ja)
|
2010-03-24 |
2017-03-08 |
ジェネンテック， インコーポレイテッド |
抗ｌｒｐ６抗体
|
|
AR080793A1
(es)
|
2010-03-26 |
2012-05-09 |
Roche Glycart Ag |
Anticuerpos biespecificos
|
|
US10745467B2
(en)
|
2010-03-26 |
2020-08-18 |
The Trustees Of Dartmouth College |
VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
|
|
NZ602634A
(en)
|
2010-03-26 |
2015-06-26 |
Dartmouth College |
Vista regulatory t cell mediator protein, vista binding agents and use thereof
|
|
US20150231215A1
(en)
|
2012-06-22 |
2015-08-20 |
Randolph J. Noelle |
VISTA Antagonist and Methods of Use
|
|
EP2927242A1
(en)
|
2010-04-09 |
2015-10-07 |
Amgen, Inc |
Btnl9 proteins, nucleic acids, and antibodies and uses thereof
|
|
AU2016219622A1
(en)
*
|
2010-04-20 |
2016-09-15 |
Genmab A/S |
Heterodimeric antibody FC-containing proteins and methods for production thereof
|
|
AU2013203221B2
(en)
*
|
2010-04-20 |
2016-06-02 |
Genmab A/S |
Heterodimeric antibody FC-containing proteins and methods for production thereof
|
|
JP2019048814A
(ja)
*
|
2010-04-20 |
2019-03-28 |
ゲンマブ エー／エス |
ヘテロ二量体抗体Ｆｃ含有タンパク質およびその産生方法
|
|
JP6040148B2
(ja)
|
2010-04-20 |
2016-12-07 |
ゲンマブ エー／エス |
ヘテロ二量体抗体Ｆｃ含有タンパク質およびその産生方法
|
|
ES2617777T5
(es)
|
2010-04-23 |
2022-10-13 |
Hoffmann La Roche |
Producción de proteínas heteromultiméricas
|
|
JP6022444B2
(ja)
|
2010-05-14 |
2016-11-09 |
ライナット ニューロサイエンス コーポレイション |
ヘテロ二量体タンパク質ならびにそれを生産および精製するための方法
|
|
WO2011147834A1
(en)
|
2010-05-26 |
2011-12-01 |
Roche Glycart Ag |
Antibodies against cd19 and uses thereof
|
|
CA3051311A1
(en)
|
2010-05-27 |
2011-12-01 |
Genmab A/S |
Monoclonal antibodies against her2
|
|
TW201204388A
(en)
|
2010-06-18 |
2012-02-01 |
Genentech Inc |
Anti-Axl antibodies and methods of use
|
|
WO2011161119A1
(en)
|
2010-06-22 |
2011-12-29 |
F. Hoffmann-La Roche Ag |
Antibodies against insulin-like growth factor i receptor and uses thereof
|
|
WO2011161189A1
(en)
|
2010-06-24 |
2011-12-29 |
F. Hoffmann-La Roche Ag |
Anti-hepsin antibodies and methods of use
|
|
JP2013539962A
(ja)
|
2010-07-09 |
2013-10-31 |
ジェネンテック， インコーポレイテッド |
抗ニューロピリン抗体及び使用方法
|
|
EP2848940A1
(en)
|
2010-07-19 |
2015-03-18 |
F. Hoffmann-La Roche AG |
Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy
|
|
EP2866032A1
(en)
|
2010-07-19 |
2015-04-29 |
F. Hoffmann-La Roche AG |
Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy
|
|
WO2012010582A1
(en)
|
2010-07-21 |
2012-01-26 |
Roche Glycart Ag |
Anti-cxcr5 antibodies and methods of use
|
|
CN105585630B
(zh)
|
2010-07-29 |
2020-09-15 |
Xencor公司 |
具有修改的等电点的抗体
|
|
TW201206473A
(en)
|
2010-08-03 |
2012-02-16 |
Abbott Lab |
Dual variable domain immunoglobulins and uses thereof
|
|
EP2600895A1
(en)
|
2010-08-03 |
2013-06-12 |
Hoffmann-La Roche AG |
Chronic lymphocytic leukemia (cll) biomarkers
|
|
CA2805564A1
(en)
|
2010-08-05 |
2012-02-09 |
Stefan Jenewein |
Anti-mhc antibody anti-viral cytokine fusion protein
|
|
MX2013001336A
(es)
|
2010-08-13 |
2013-03-08 |
Roche Glycart Ag |
Anticuerpos ani-tenascina c a2 y metodos de utilizacion.
|
|
BR112013003361B8
(pt)
|
2010-08-13 |
2022-01-25 |
Roche Glycart Ag |
Anticorpo, composição, conjugado de anticorpo,formulação farmacêutica e uso do anticorpo
|
|
WO2012021875A1
(en)
|
2010-08-13 |
2012-02-16 |
Aileron Therapeutics, Inc. |
Peptidomimetic macrocycles with triazole linkers
|
|
KR101603001B1
(ko)
|
2010-08-25 |
2016-03-11 |
에프. 호프만-라 로슈 아게 |
Il-18r1에 대한 항체 및 그의 용도
|
|
CA2809433A1
(en)
|
2010-08-26 |
2012-03-01 |
Abbvie Inc. |
Dual variable domain immunoglobulins and uses thereof
|
|
US20120089541A1
(en)
|
2010-08-31 |
2012-04-12 |
Genentech, Inc. |
Biomarkers and methods of treatment
|
|
US8551479B2
(en)
|
2010-09-10 |
2013-10-08 |
Oncomed Pharmaceuticals, Inc. |
Methods for treating melanoma
|
|
PL2635607T3
(pl)
*
|
2010-11-05 |
2020-05-18 |
Zymeworks Inc. |
Projekt stabilnego przeciwciała heterodimerowego z mutacjami w domenie FC
|
|
CN103228674B
(zh)
|
2010-11-10 |
2019-07-05 |
霍夫曼-拉罗奇有限公司 |
用于神经疾病免疫疗法的方法和组合物
|
|
EP3318633A1
(en)
|
2010-11-17 |
2018-05-09 |
Chugai Seiyaku Kabushiki Kaisha |
Multi-specific antigen-binding molecule having alternative function to function of blood coagulation factor viii
|
|
EP2643353A1
(en)
|
2010-11-24 |
2013-10-02 |
Novartis AG |
Multispecific molecules
|
|
EP2646470B1
(en)
|
2010-11-30 |
2017-03-01 |
F. Hoffmann-La Roche AG |
Low affinity anti-transferrin receptor antibodies and their use to transfer therapeutic scfv across the blood brain barrier
|
|
SG190726A1
(en)
|
2010-11-30 |
2013-07-31 |
Chugai Pharmaceutical Co Ltd |
Cytotoxicity-inducing therapeutic agent
|
|
EP2652498B1
(en)
|
2010-12-16 |
2018-04-18 |
F.Hoffmann-La Roche Ag |
Diagnosis and treatments relating to th2 inhibition
|
|
UA113838C2
(xx)
|
2010-12-20 |
2017-03-27 |
|
Антитіло, яке зв'язує мезотелін, та імунокон'югат
|
|
MX2013007168A
(es)
|
2010-12-22 |
2013-11-04 |
Genentech Inc |
Anticuerpo anti-pcsk9 y metodos de uso.
|
|
CN103649117B
(zh)
|
2011-02-04 |
2016-09-14 |
霍夫曼-拉罗奇有限公司 |
Fc变体及其生成方法
|
|
US10689447B2
(en)
|
2011-02-04 |
2020-06-23 |
Genentech, Inc. |
Fc variants and methods for their production
|
|
TWI666027B
(zh)
|
2011-02-10 |
2019-07-21 |
羅齊克雷雅公司 |
突變介白素-２多肽
|
|
RU2013141078A
(ru)
|
2011-02-28 |
2015-04-10 |
Ф. Хоффманн-Ля Рош Аг |
Одновалентные антигенсвязывающие белки
|
|
BR112013019975A2
(pt)
|
2011-02-28 |
2017-08-01 |
Hoffmann La Roche |
proteínas de ligação de antígeno, composição farmacêutica, uso de uma proteína de ligação de antígeno, método para o tratamento de um paciente e método para a preparação de uma proteína de ligação de antígeno, ácido nucleico, vetor e célula hospedeira"
|
|
AU2012222833B2
(en)
|
2011-03-03 |
2017-03-16 |
Zymeworks Inc. |
Multivalent heteromultimer scaffold design and constructs
|
|
ES2668895T3
(es)
*
|
2011-03-16 |
2018-05-23 |
Amgen Inc. |
Variantes de Fc
|
|
BR112013023918A2
(pt)
|
2011-03-25 |
2016-12-13 |
Glenmark Pharmaceuticals Sa |
imunoglobulina hetero-dimérica ou fragmento hetero-dimérico da mesma, método para produzir uma imunoglobulina hetero-dimérica ou fragmento hetero-dimérico da mesma, método para construir uma interface proteína-proteína de um domínio de uma proteína de múltiplos domínios e uso de um domínio doador de um primeiro e de um segundo membro de uma super-família de imunoglobulina de ocorrência natural
|
|
BR112013024574B1
(pt)
|
2011-03-29 |
2022-08-09 |
Roche Glycart Ag |
Anticorpo e uso do anticorpo
|
|
KR20140021589A
(ko)
|
2011-04-07 |
2014-02-20 |
제넨테크, 인크. |
항-fgfr4 항체 및 사용 방법
|
|
WO2012138919A2
(en)
|
2011-04-08 |
2012-10-11 |
Amgen Inc. |
Method of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15)
|
|
EP2697257B1
(en)
|
2011-04-13 |
2016-10-19 |
Bristol-Myers Squibb Company |
Fc fusion proteins comprising novel linkers or arrangements
|
|
WO2012143523A1
(en)
*
|
2011-04-20 |
2012-10-26 |
Genmab A/S |
Bispecifc antibodies against her2
|
|
US20140170149A1
(en)
|
2011-04-20 |
2014-06-19 |
Genmab A/S |
Bispecific antibodies against her2 and cd3
|
|
EP4520771A3
(en)
|
2011-04-20 |
2025-07-16 |
Genmab A/S |
Bispecifc antibodies against her2
|
|
KR20140031217A
(ko)
|
2011-04-20 |
2014-03-12 |
로슈 글리카트 아게 |
혈액-뇌 차단벽의 pH 의존적 통과를 위한 방법 및 구축물
|
|
EA201892619A1
(ru)
|
2011-04-29 |
2019-04-30 |
Роше Гликарт Аг |
Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
|
|
WO2012155019A1
(en)
|
2011-05-12 |
2012-11-15 |
Genentech, Inc. |
Multiple reaction monitoring lc-ms/ms method to detect therapeutic antibodies in animal samples using framework signature pepides
|
|
EP2710035B1
(en)
|
2011-05-16 |
2017-04-12 |
F. Hoffmann-La Roche AG |
Fgfr1 agonists and methods of use
|
|
WO2012171996A1
(en)
|
2011-06-15 |
2012-12-20 |
F. Hoffmann-La Roche Ag |
Anti-human epo receptor antibodies and methods of use
|
|
WO2013002362A1
(ja)
*
|
2011-06-30 |
2013-01-03 |
中外製薬株式会社 |
ヘテロ二量化ポリペプチド
|
|
TW201306866A
(zh)
|
2011-06-30 |
2013-02-16 |
Genentech Inc |
抗－ｃ－ｍｅｔ抗體調配物
|
|
UA117901C2
(uk)
|
2011-07-06 |
2018-10-25 |
Ґенмаб Б.В. |
Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування
|
|
EP2543680A1
(en)
*
|
2011-07-07 |
2013-01-09 |
Centre National de la Recherche Scientifique |
Multispecific mutated antibody Fab fragments
|
|
CN103930134B
(zh)
|
2011-07-18 |
2016-12-21 |
阿茨生物股份有限公司 |
长效促黄体激素(lh)化合物
|
|
US9499612B2
(en)
*
|
2011-07-27 |
2016-11-22 |
Glaxo Group Limited |
Antigen binding constructs
|
|
HUE068728T2
(hu)
|
2011-08-05 |
2025-01-28 |
Regeneron Pharma |
Humanizált univerzális könnyûláncú egerek
|
|
CA2842375A1
(en)
|
2011-08-17 |
2013-02-21 |
Erica Jackson |
Neuregulin antibodies and uses thereof
|
|
RS57744B1
(sr)
|
2011-08-23 |
2018-12-31 |
Roche Glycart Ag |
Bispecifični antigen vezujući molekuli
|
|
KR101870555B1
(ko)
|
2011-08-23 |
2018-06-22 |
로슈 글리카트 아게 |
T 세포 활성화 항원 및 종양 항원에 대해 특이적인 이중특이적 항체 및 이의 사용 방법
|
|
WO2013026837A1
(en)
|
2011-08-23 |
2013-02-28 |
Roche Glycart Ag |
Bispecific t cell activating antigen binding molecules
|
|
WO2013026832A1
(en)
|
2011-08-23 |
2013-02-28 |
Roche Glycart Ag |
Anti-mcsp antibodies
|
|
RS56879B1
(sr)
|
2011-08-23 |
2018-04-30 |
Roche Glycart Ag |
Bispecifične molekule koje vezuju antigen za aktiviranje t ćelija
|
|
CA2843158A1
(en)
|
2011-08-26 |
2013-03-07 |
Merrimack Pharmaceuticals, Inc. |
Tandem fc bispecific antibodies
|
|
CA2846083A1
(en)
|
2011-09-15 |
2013-03-21 |
Genentech, Inc. |
Methods of promoting differentiation
|
|
GB201116092D0
(en)
|
2011-09-16 |
2011-11-02 |
Bioceros B V |
Antibodies and uses thereof
|
|
BR112014006419A2
(pt)
|
2011-09-19 |
2018-08-07 |
Genentech Inc |
métodos para tratar um paciente com câncer, kit e artigo
|
|
PE20141151A1
(es)
|
2011-09-22 |
2014-09-25 |
Amgen Inc |
Proteinas de union al antigeno cd27l
|
|
PL2758073T3
(pl)
|
2011-09-23 |
2019-04-30 |
Oncomed Pharm Inc |
Środki wiążące VEGF/DLL4 i ich zastosowania
|
|
CA2791109C
(en)
|
2011-09-26 |
2021-02-16 |
Merus B.V. |
Generation of binding molecules
|
|
SG11201401287SA
(en)
|
2011-10-05 |
2014-05-29 |
Genentech Inc |
Methods of treating liver conditions using notch2 antagonists
|
|
US10851178B2
(en)
|
2011-10-10 |
2020-12-01 |
Xencor, Inc. |
Heterodimeric human IgG1 polypeptides with isoelectric point modifications
|
|
US12466897B2
(en)
|
2011-10-10 |
2025-11-11 |
Xencor, Inc. |
Heterodimeric human IgG1 polypeptides with isoelectric point modifications
|
|
BR112014008684B1
(pt)
|
2011-10-11 |
2021-11-09 |
Genentech, Inc |
Métodos de produção de proteínas heteromultiméricas e método de produção de anticorpo biespecífico
|
|
CA2850032C
(en)
|
2011-10-14 |
2022-06-07 |
Genentech, Inc. |
Anti-htra1 antibodies and methods of use
|
|
US9358250B2
(en)
|
2011-10-15 |
2016-06-07 |
Genentech, Inc. |
Methods of using SCD1 antagonists
|
|
JP6342808B2
(ja)
|
2011-10-18 |
2018-06-13 |
エイルロン セラピューティクス，インコーポレイテッド |
ペプチドミメティック大環状化合物
|
|
WO2013059531A1
(en)
|
2011-10-20 |
2013-04-25 |
Genentech, Inc. |
Anti-gcgr antibodies and uses thereof
|
|
PL2771364T3
(pl)
|
2011-10-27 |
2020-01-31 |
Genmab A/S |
Wytwarzanie heterodimerycznych białek
|
|
EA201490879A1
(ru)
|
2011-10-28 |
2014-08-29 |
Дженентек, Инк. |
Терапевтические комбинации и способы лечения меланомы
|
|
KR102398736B1
(ko)
*
|
2011-10-31 |
2022-05-16 |
추가이 세이야쿠 가부시키가이샤 |
중쇄와 경쇄의 회합이 제어된 항원 결합 분자
|
|
HRP20211773T1
(hr)
|
2011-11-04 |
2022-03-04 |
Zymeworks Inc. |
Stabilna heterodimerni dizajn antitijela s mutacijama u fc domeni
|
|
BR112014012005A2
(pt)
|
2011-11-21 |
2017-12-19 |
Genentech Inc |
composições, métodos, formulação farmacêutica e artigo
|
|
MX2014006241A
(es)
|
2011-11-23 |
2015-03-03 |
Amgen Inc |
Metodos de tratamiento usando un anticuerpo contra interferon gamma.
|
|
WO2013083497A1
(en)
|
2011-12-06 |
2013-06-13 |
F. Hoffmann-La Roche Ag |
Antibody formulation
|
|
CA2859785A1
(en)
|
2011-12-21 |
2013-06-27 |
Amgen Inc. |
Variant fc-polypeptides with enhanced binding to the neonatal fc receptor
|
|
SG10201805622QA
(en)
|
2011-12-22 |
2018-08-30 |
Hoffmann La Roche |
Expression Vector Organization, Novel Production Cell Generation Methods And Their Use For The Recombinant Production Of Polypeptides
|
|
RU2625033C2
(ru)
|
2011-12-22 |
2017-07-11 |
Ф. Хоффманн-Ля Рош Аг |
Система индикации на основе полноразмерного антитела для эукариотических клеток и ее применение
|
|
SG11201403443WA
(en)
|
2011-12-22 |
2014-07-30 |
Hoffmann La Roche |
Expression vector element combinations, novel production cell generation methods and their use for the recombinant production of polypeptides
|
|
WO2013096791A1
(en)
|
2011-12-23 |
2013-06-27 |
Genentech, Inc. |
Process for making high concentration protein formulations
|
|
BR112014015851A2
(pt)
|
2011-12-30 |
2019-09-24 |
Abbvie Inc |
proteínas de ligação específicas duplas direcionadas contra il-13 e/ou il-17
|
|
CN102558355B
(zh)
*
|
2011-12-31 |
2015-02-25 |
苏州康宁杰瑞生物科技有限公司 |
基于电荷网络的异二聚体fc改造方法及异二聚体蛋白的制备方法
|
|
CN104066449B
(zh)
|
2012-01-18 |
2018-04-27 |
霍夫曼-拉罗奇有限公司 |
抗lrp5抗体及使用方法
|
|
KR20140119114A
(ko)
|
2012-01-18 |
2014-10-08 |
제넨테크, 인크. |
Fgf19 조절제의 사용 방법
|
|
BR112014018575A2
(pt)
*
|
2012-01-26 |
2017-07-04 |
Amgen Inc |
polipetídeos de fator de diferenciação de crescimento 15 (gdf-15)
|
|
CN104379601B
(zh)
|
2012-02-03 |
2021-04-09 |
霍夫曼-拉罗奇有限公司 |
双特异性抗体分子和抗原-转染的t-细胞以及它们在医药中的用途
|
|
EP2813568B1
(en)
|
2012-02-09 |
2025-04-23 |
Chugai Seiyaku Kabushiki Kaisha |
Modified fc region of antibody
|
|
US20130209473A1
(en)
|
2012-02-11 |
2013-08-15 |
Genentech, Inc. |
R-spondin translocations and methods using the same
|
|
EP3769776A1
(en)
|
2012-02-15 |
2021-01-27 |
Aileron Therapeutics, Inc. |
Peptidomimetic macrocycles
|
|
CN108912211A
(zh)
|
2012-02-15 |
2018-11-30 |
爱勒让治疗公司 |
三唑交联的和硫醚交联的拟肽大环化合物
|
|
RU2624128C2
(ru)
|
2012-02-15 |
2017-06-30 |
Ф. Хоффманн-Ля Рош Аг |
Аффинная хроматография с применением fc-рецепторов
|
|
JP6254146B2
(ja)
|
2012-03-27 |
2017-12-27 |
エヌジーエム バイオファーマシューティカルス，インコーポレーテッド |
代謝障害を治療するための組成物および方法
|
|
CA2865082A1
(en)
|
2012-03-27 |
2013-10-03 |
Genentech, Inc. |
Diagnosis and treatments relating to her3 inhibitors
|
|
AR090549A1
(es)
|
2012-03-30 |
2014-11-19 |
Genentech Inc |
Anticuerpos anti-lgr5 e inmunoconjugados
|
|
KR101674784B1
(ko)
|
2012-04-05 |
2016-11-09 |
에프. 호프만-라 로슈 아게 |
인간 tweak 및 인간 il17에 대한 이중특이적 항체 및 이의 용도
|
|
CA2870821C
(en)
*
|
2012-04-20 |
2022-06-14 |
Merus B.V. |
Methods and means for the production of ig-like molecules
|
|
US9212227B2
(en)
|
2012-04-30 |
2015-12-15 |
Janssen Biotech, Inc. |
ST2L antibody antagonists for the treatment of ST2L-mediated inflammatory pulmonary conditions
|
|
AR090903A1
(es)
|
2012-05-01 |
2014-12-17 |
Genentech Inc |
Anticuerpos e inmunoconjugados anti-pmel17
|
|
US20130336973A1
(en)
*
|
2012-05-10 |
2013-12-19 |
Zymeworks Inc. |
Heteromultimer Constructs of Immunoglobulin Heavy Chains with Mutations in the Fc Domain
|
|
WO2013166604A1
(en)
*
|
2012-05-10 |
2013-11-14 |
Zymeworks Inc. |
Single-arm monovalent antibody constructs and uses thereof
|
|
WO2013170191A1
(en)
|
2012-05-11 |
2013-11-14 |
Genentech, Inc. |
Methods of using antagonists of nad biosynthesis from nicotinamide
|
|
UY34813A
(es)
|
2012-05-18 |
2013-11-29 |
Amgen Inc |
Proteínas de unión a antígeno dirigidas contra el receptor st2
|
|
US20150353639A1
(en)
|
2012-05-21 |
2015-12-10 |
Genentech, Inc. |
Methods for improving safety of blood-brain barrier transport
|
|
MX2014014086A
(es)
|
2012-05-23 |
2015-01-26 |
Genentech Inc |
Metodo de seleccion para agentes terapeuticos.
|
|
EP4310191A3
(en)
|
2012-06-14 |
2024-05-15 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule containing modified fc region
|
|
WO2013188855A1
(en)
|
2012-06-15 |
2013-12-19 |
Genentech, Inc. |
Anti-pcsk9 antibodies, formulations, dosing, and methods of use
|
|
WO2013192504A1
(en)
|
2012-06-22 |
2013-12-27 |
The Trustees Of Dartmouth College |
Novel vista-ig constructs and the use of vista-ig for treatment of autoimmune, allergic and inflammatory disorders
|
|
US9890215B2
(en)
|
2012-06-22 |
2018-02-13 |
King's College London |
Vista modulators for diagnosis and treatment of cancer
|
|
WO2014004586A1
(en)
|
2012-06-25 |
2014-01-03 |
Zymeworks Inc. |
Process and methods for efficient manufacturing of highly pure asymmetric antibodies in mammalian cells
|
|
JP6148729B2
(ja)
|
2012-07-04 |
2017-06-14 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
共有結合している抗原−抗体結合体
|
|
MX354303B
(es)
|
2012-07-04 |
2018-02-23 |
Hoffmann La Roche |
Anticuerpos de anti-biotina y metodos de uso.
|
|
CA2872184A1
(en)
|
2012-07-04 |
2014-01-09 |
F. Hoffmann-La Roche Ag |
Anti-theophylline antibodies and methods of use
|
|
RU2670491C2
(ru)
|
2012-07-05 |
2018-10-23 |
Дженентек, Инк. |
Система экспрессии и секреции
|
|
SG11201408646VA
(en)
|
2012-07-06 |
2015-01-29 |
Genmab Bv |
Dimeric protein with triple mutations
|
|
EP3632462A1
(en)
|
2012-07-06 |
2020-04-08 |
Genmab B.V. |
Dimeric protein with triple mutations
|
|
CA2873884A1
(en)
|
2012-07-09 |
2014-01-16 |
Genentech, Inc. |
Immunoconjugates comprising anti-cd79b antibodies
|
|
EA201590173A1
(ru)
|
2012-07-09 |
2015-09-30 |
Дженентек, Инк. |
Иммуноконъюгаты, содержащие антитела к cd22
|
|
JP6297550B2
(ja)
|
2012-07-09 |
2018-03-20 |
ジェネンテック， インコーポレイテッド |
抗ｃｄ７９ｂ抗体を含む免疫複合体
|
|
HK1209043A1
(en)
|
2012-07-09 |
2016-03-24 |
基因泰克公司 |
Immunoconjugates comprising anti-cd22 antibodies
|
|
CN104768571B
(zh)
|
2012-07-13 |
2018-11-09 |
酵活有限公司 |
多价异多聚体支架设计和构建体
|
|
NZ702201A
(en)
|
2012-07-13 |
2018-01-26 |
Roche Glycart Ag |
Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases
|
|
BR112015000798A2
(pt)
*
|
2012-07-13 |
2017-06-27 |
Zymeworks Inc |
heterodímeros assimétricos biespecíficos compreendendo construtos anti-cd3
|
|
US9765156B2
(en)
|
2012-07-13 |
2017-09-19 |
The Trustees Of The University Of Pennsylvania |
Enhancing activity of CAR T cells by co-introducing a bispecific antibody
|
|
CN104703999A
(zh)
|
2012-07-19 |
2015-06-10 |
安姆根有限公司 |
人btnl3蛋白、核酸和抗体及其用途
|
|
CN102851338A
(zh)
*
|
2012-07-25 |
2013-01-02 |
苏州康宁杰瑞生物科技有限公司 |
利用电荷排斥作用制备同二聚体蛋白混合物的方法
|
|
CN104662045B
(zh)
|
2012-08-07 |
2019-04-05 |
罗切格利卡特公司 |
包含两种工程化改造成具有降低的和升高的效应器功能的抗体的组合物改进的免疫疗法
|
|
US9771427B2
(en)
|
2012-08-09 |
2017-09-26 |
Roche Glycart Ag |
ASGPR antibodies and uses thereof
|
|
EP2889377B1
(en)
|
2012-08-24 |
2020-01-08 |
Chugai Seiyaku Kabushiki Kaisha |
Fcyriib-specific fc region variant
|
|
WO2014030750A1
(ja)
|
2012-08-24 |
2014-02-27 |
中外製薬株式会社 |
マウスFcγRII特異的Fc抗体
|
|
CN109793893B
(zh)
|
2012-09-07 |
2023-05-26 |
达特茅斯大学理事会 |
用于诊断和治疗癌症的vista调节剂
|
|
IN2015MN00139A
(enExample)
|
2012-09-25 |
2015-10-16 |
Glenmark Pharmaceuticals Sa |
|
|
SI2900694T1
(sl)
|
2012-09-27 |
2018-12-31 |
Merus N.V. |
Bispecifična IGG protitelesa kot vključitelji T-celic
|
|
JP6581505B2
(ja)
|
2012-10-03 |
2019-09-25 |
ザイムワークス，インコーポレイテッド |
重鎖および軽鎖ポリペプチドの対を定量化する方法
|
|
EP2905290B1
(en)
|
2012-10-05 |
2019-12-04 |
Kyowa Kirin Co., Ltd. |
Heterodimeric protein composition
|
|
KR20150064068A
(ko)
|
2012-10-08 |
2015-06-10 |
로슈 글리카트 아게 |
2개의 Fab 단편을 포함하는 FC-부재 항체 및 이용 방법
|
|
AU2013337811A1
(en)
|
2012-10-31 |
2015-05-14 |
Oncomed Pharmaceuticals, Inc. |
Methods and monitoring of treatment with a DLL4 antagonist
|
|
BR112015009470A2
(pt)
|
2012-11-01 |
2019-12-17 |
Aileron Therapeutics Inc |
aminoácidos dissubstituídos e seus métodos de preparação e uso
|
|
SG11201503412RA
(en)
|
2012-11-01 |
2015-05-28 |
Abbvie Inc |
Anti-vegf/dll4 dual variable domain immunoglobulins and uses thereof
|
|
CN104797599A
(zh)
|
2012-11-05 |
2015-07-22 |
全药工业株式会社 |
抗体或抗体组合物的制备方法
|
|
WO2014071419A2
(en)
|
2012-11-05 |
2014-05-08 |
Foundation Medicine, Inc. |
Novel fusion molecules and uses thereof
|
|
WO2014071358A2
(en)
|
2012-11-05 |
2014-05-08 |
Foundation Medicine, Inc. |
Novel ntrk1 fusion molecules and uses thereof
|
|
MX2015005757A
(es)
|
2012-11-08 |
2015-11-18 |
Hoffmann La Roche |
Proteinas ligantes de antigeno her3 de union a la horquilla beta de her3.
|
|
AU2013345072B2
(en)
|
2012-11-13 |
2017-12-07 |
Genentech, Inc. |
Anti-hemagglutinin antibodies and methods of use
|
|
US9562110B2
(en)
|
2012-11-21 |
2017-02-07 |
Wuhan Yzy Biopharma Co., Ltd. |
Bispecific antibody
|
|
UY35148A
(es)
*
|
2012-11-21 |
2014-05-30 |
Amgen Inc |
Immunoglobulinas heterodiméricas
|
|
US9951145B2
(en)
|
2012-11-27 |
2018-04-24 |
Ajou University Industry—Academic Cooperation Foundation |
CH3 domain variant pair inducing formation of heterodimer of heavy chain constant region of antibody at high efficiency, method for preparing same, and use thereof
|
|
CN105026430B
(zh)
|
2012-11-28 |
2025-03-25 |
酵活英属哥伦比亚有限公司 |
工程化免疫球蛋白重链-轻链对及其用途
|
|
US9914785B2
(en)
|
2012-11-28 |
2018-03-13 |
Zymeworks Inc. |
Engineered immunoglobulin heavy chain-light chain pairs and uses thereof
|
|
WO2014104165A1
(ja)
|
2012-12-27 |
2014-07-03 |
中外製薬株式会社 |
ヘテロ二量化ポリペプチド
|
|
SG11201505286TA
(en)
|
2013-01-10 |
2015-08-28 |
Genmab Bv |
Human igg1 fc region variants and uses thereof
|
|
US9701759B2
(en)
|
2013-01-14 |
2017-07-11 |
Xencor, Inc. |
Heterodimeric proteins
|
|
KR102391731B1
(ko)
|
2013-01-14 |
2022-04-27 |
젠코어 인코포레이티드 |
신규한 이형이량체 단백질
|
|
US10487155B2
(en)
*
|
2013-01-14 |
2019-11-26 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US10131710B2
(en)
|
2013-01-14 |
2018-11-20 |
Xencor, Inc. |
Optimized antibody variable regions
|
|
US10968276B2
(en)
|
2013-03-12 |
2021-04-06 |
Xencor, Inc. |
Optimized anti-CD3 variable regions
|
|
US11053316B2
(en)
|
2013-01-14 |
2021-07-06 |
Xencor, Inc. |
Optimized antibody variable regions
|
|
US9605084B2
(en)
|
2013-03-15 |
2017-03-28 |
Xencor, Inc. |
Heterodimeric proteins
|
|
EP2945969A1
(en)
|
2013-01-15 |
2015-11-25 |
Xencor, Inc. |
Rapid clearance of antigen complexes using novel antibodies
|
|
AU2014207342C1
(en)
|
2013-01-18 |
2019-04-04 |
Foundation Medicine, Inc. |
Methods of treating cholangiocarcinoma
|
|
WO2014116749A1
(en)
|
2013-01-23 |
2014-07-31 |
Genentech, Inc. |
Anti-hcv antibodies and methods of using thereof
|
|
WO2014114801A1
(en)
|
2013-01-25 |
2014-07-31 |
Amgen Inc. |
Antibodies targeting cdh19 for melanoma
|
|
KR101993714B1
(ko)
|
2013-01-30 |
2019-06-28 |
엔지엠 바이오파마슈티컬스, 아이엔씨. |
대사 장애를 치료하는데 이용하기 위한 조성물과 방법
|
|
US9161966B2
(en)
|
2013-01-30 |
2015-10-20 |
Ngm Biopharmaceuticals, Inc. |
GDF15 mutein polypeptides
|
|
CA2900764A1
(en)
|
2013-02-08 |
2014-08-14 |
Stemcentrx, Inc. |
Novel multispecific constructs
|
|
WO2014126871A1
(en)
|
2013-02-12 |
2014-08-21 |
Bristol-Myers Squibb Company |
Tangential flow filtration based protein refolding methods
|
|
EP3299378B1
(en)
|
2013-02-12 |
2019-07-31 |
Bristol-Myers Squibb Company |
High ph protein refolding methods
|
|
SG11201506389YA
(en)
*
|
2013-02-15 |
2015-09-29 |
Pharm Cjsc Closed Joint Stock Company R |
IL-1β INHIBITOR COMPOSITION AND USE THEREOF
|
|
CN104994879A
(zh)
|
2013-02-22 |
2015-10-21 |
霍夫曼-拉罗奇有限公司 |
治疗癌症和预防药物抗性的方法
|
|
JP2016512421A
(ja)
|
2013-02-26 |
2016-04-28 |
ロシュ グリクアート アーゲー |
二重特異性ｔ細胞活性化抗原結合分子
|
|
CA2896370A1
(en)
|
2013-02-26 |
2014-09-04 |
Roche Glycart Ag |
Bispecific t cell activating antigen binding molecules
|
|
EP2961772A1
(en)
|
2013-02-26 |
2016-01-06 |
Roche Glycart AG |
Anti-mcsp antibodies
|
|
KR20180023035A
(ko)
|
2013-02-26 |
2018-03-06 |
로슈 글리카트 아게 |
이중특이적 t 세포 활성화 항원 결합 분자
|
|
KR20150123250A
(ko)
|
2013-03-06 |
2015-11-03 |
제넨테크, 인크. |
암 약물 내성의 치료 및 예방 방법
|
|
CA2902505A1
(en)
|
2013-03-06 |
2014-09-12 |
Merrimack Pharmaceuticals, Inc. |
Anti-c-met tandem fc bispecific antibodies
|
|
EP3486255A3
(en)
*
|
2013-03-13 |
2019-11-13 |
Ibentrus Inc. |
Protein in which electrical interaction is introduced within hydrophobic interaction site and preparation method therefor
|
|
US9458246B2
(en)
|
2013-03-13 |
2016-10-04 |
Amgen Inc. |
Proteins specific for BAFF and B7RP1
|
|
PH12022550138A1
(en)
|
2013-03-13 |
2023-03-06 |
Amgen Inc |
Proteins specific for baff and b7rp1 and uses thereof
|
|
KR20150127216A
(ko)
|
2013-03-14 |
2015-11-16 |
제넨테크, 인크. |
암의 치료 및 암 약물 내성의 예방 방법
|
|
US9546203B2
(en)
|
2013-03-14 |
2017-01-17 |
Amgen Inc. |
Aglycosylated Fc-containing polypeptides with cysteine substitutions
|
|
SG11201507477XA
(en)
|
2013-03-14 |
2015-10-29 |
Genentech Inc |
Combinations of a mek inhibitor compound with an her3/egfr inhibitor compound and methods of use
|
|
KR20150127199A
(ko)
|
2013-03-14 |
2015-11-16 |
제넨테크, 인크. |
항-b7-h4 항체 및 면역접합체
|
|
US9562099B2
(en)
|
2013-03-14 |
2017-02-07 |
Genentech, Inc. |
Anti-B7-H4 antibodies and immunoconjugates
|
|
EP3424952A1
(en)
|
2013-03-15 |
2019-01-09 |
Amgen, Inc |
Heterodimeric bispecific antibodies
|
|
EP2970459A2
(en)
|
2013-03-15 |
2016-01-20 |
AbbVie Inc. |
Dual specific binding proteins directed against il-1beta and il-17
|
|
US10106624B2
(en)
|
2013-03-15 |
2018-10-23 |
Xencor, Inc. |
Heterodimeric proteins
|
|
KR20150130451A
(ko)
|
2013-03-15 |
2015-11-23 |
제넨테크, 인크. |
암 치료 방법 및 항암제 내성 예방을 위한 방법
|
|
AU2014235003A1
(en)
|
2013-03-15 |
2015-09-17 |
Janssen Biotech, Inc. |
Interferon alpha and omega antibody antagonists
|
|
KR20220053691A
(ko)
|
2013-03-15 |
2022-04-29 |
제넨테크, 인크. |
Pd-1 및 pd-l1 관련 상태를 치료하기 위한 바이오마커 및 방법
|
|
US10519242B2
(en)
|
2013-03-15 |
2019-12-31 |
Xencor, Inc. |
Targeting regulatory T cells with heterodimeric proteins
|
|
US10858417B2
(en)
|
2013-03-15 |
2020-12-08 |
Xencor, Inc. |
Heterodimeric proteins
|
|
BR112015021521A2
(pt)
|
2013-03-15 |
2017-10-10 |
Genentech Inc |
anticorpos anti-crth2 e métodos para seu uso
|
|
US20140302037A1
(en)
|
2013-03-15 |
2014-10-09 |
Amgen Inc. |
BISPECIFIC-Fc MOLECULES
|
|
MX2015011444A
(es)
|
2013-03-15 |
2015-12-16 |
Genentech Inc |
Composiciones y metodos para el diagnostico y tratamiento del cancer hepatico.
|
|
DK2970486T3
(en)
|
2013-03-15 |
2018-08-06 |
Xencor Inc |
MODULATION OF T-CELLS WITH BISPECIFIC ANTIBODIES AND FC-FUSIONS
|
|
EP2951203B1
(en)
*
|
2013-03-15 |
2019-05-22 |
Xencor, Inc. |
Heterodimeric proteins
|
|
CA2902910A1
(en)
|
2013-03-15 |
2014-09-25 |
Ac Immune S.A. |
Anti-tau antibodies and methods of use
|
|
PE20160690A1
(es)
|
2013-03-18 |
2016-08-14 |
Biocerox Prod Bv |
Anticuerpos anti-cd134 (ox40) humanizados y usos de los mismos
|
|
EP2982689B1
(en)
|
2013-04-02 |
2020-08-26 |
Chugai Seiyaku Kabushiki Kaisha |
Fc region variant
|
|
UA118028C2
(uk)
|
2013-04-03 |
2018-11-12 |
Рош Глікарт Аг |
Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування
|
|
KR102266819B1
(ko)
*
|
2013-04-29 |
2021-06-18 |
에프. 호프만-라 로슈 아게 |
Fc-수용체 결합 개질된 비대칭 항체 및 이의 사용 방법
|
|
CN105164158A
(zh)
|
2013-04-29 |
2015-12-16 |
豪夫迈·罗氏有限公司 |
消除对FcRn-结合的抗-IGF-1R抗体及其在血管性眼病治疗中的用途
|
|
SG10201800492PA
(en)
|
2013-04-29 |
2018-03-28 |
Hoffmann La Roche |
Human fcrn-binding modified antibodies and methods of use
|
|
US10239951B2
(en)
|
2013-05-08 |
2019-03-26 |
Zymeworks Inc. |
Bispecific HER2 and HER3 antigen binding constructs
|
|
MX380520B
(es)
|
2013-05-20 |
2025-03-12 |
Genentech Inc |
Anticuerpos receptores de antitransferina y métodos de uso.
|
|
PT3004167T
(pt)
|
2013-05-30 |
2018-11-13 |
Kiniksa Pharmaceuticals Ltd |
Proteínas de ligação ao antigénio do recetor da oncostatina m
|
|
ES2776706T3
(es)
|
2013-07-05 |
2020-07-31 |
Genmab As |
Anticuerpos contra CD3 humanizados o quiméricos
|
|
EP3027642B1
(en)
|
2013-07-31 |
2020-08-19 |
Amgen Inc. |
Growth differentiation factor 15 (gdf-15) constructs
|
|
JP6721505B2
(ja)
*
|
2013-09-05 |
2020-07-15 |
アイジーエム バイオサイエンシズ インコーポレイテッド |
定常領域が修飾された（ｃｏｎｓｔａｎｔ ｃｈａｉｎ ｍｏｄｉｆｉｅｄ）二重特異性五価及び六価Ｉｇ−Ｍ抗体
|
|
CA2922889A1
(en)
|
2013-09-17 |
2015-03-26 |
Genentech, Inc. |
Methods of using anti-lgr5 antibodies
|
|
US20160257748A1
(en)
|
2013-09-25 |
2016-09-08 |
Amgen Inc. |
V-c-fc-v-c antibody
|
|
WO2015046467A1
(ja)
*
|
2013-09-27 |
2015-04-02 |
中外製薬株式会社 |
ポリペプチド異種多量体の製造方法
|
|
CA2926084A1
(en)
|
2013-10-11 |
2015-04-16 |
Genentech, Inc. |
Nsp4 inhibitors and methods of use
|
|
CA2922912A1
(en)
|
2013-10-11 |
2015-04-16 |
F. Hoffmann-La Roche Ag |
Multispecific domain exchanged common variable light chain antibodies
|
|
MX2016004802A
(es)
|
2013-10-18 |
2016-07-18 |
Genentech Inc |
Anticuerpos anti-r-espondina (anti-rspo) y metodos de uso.
|
|
CA2924873A1
(en)
|
2013-10-23 |
2015-04-30 |
Genentech, Inc. |
Methods of diagnosing and treating eosinophilic disorders
|
|
JP6556742B2
(ja)
|
2013-11-06 |
2019-08-07 |
ヤンセン バイオテツク，インコーポレーテツド |
抗ｃｃｌ１７抗体
|
|
JP2016538283A
(ja)
|
2013-11-13 |
2016-12-08 |
ザイムワークス，インコーポレイテッド |
Ｅｇｆｒ及び／またはｈｅｒ２を標的にする一価抗原結合性構築物及びその使用
|
|
KR102399292B1
(ko)
|
2013-11-21 |
2022-05-17 |
에프. 호프만-라 로슈 아게 |
항-알파-시누클레인 항체 및 사용 방법
|
|
HUE071428T2
(hu)
|
2013-11-27 |
2025-09-28 |
Zymeworks Bc Inc |
HER2-T célzó bispecifikus antigénkötõ-konstrukciók
|
|
AU2014362238A1
(en)
|
2013-12-13 |
2016-06-09 |
Genentech, Inc. |
Anti-CD33 antibodies and immunoconjugates
|
|
EA201600473A1
(ru)
|
2013-12-20 |
2016-12-30 |
Ф. Хоффманн-Ля Рош Аг |
ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА К Tau(PS422) И СПОСОБЫ ПРИМЕНЕНИЯ
|
|
TWI728373B
(zh)
|
2013-12-23 |
2021-05-21 |
美商建南德克公司 |
抗體及使用方法
|
|
US11014987B2
(en)
|
2013-12-24 |
2021-05-25 |
Janssen Pharmaceutics Nv |
Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
|
|
CN114163529B
(zh)
|
2013-12-24 |
2024-12-13 |
杨森制药公司 |
抗vista抗体及片段
|
|
EP3089758B1
(en)
|
2014-01-03 |
2021-01-27 |
F.Hoffmann-La Roche Ag |
Covalently linked helicar-anti-helicar antibody conjugates and uses thereof
|
|
KR20160104628A
(ko)
|
2014-01-03 |
2016-09-05 |
에프. 호프만-라 로슈 아게 |
이중특이성 항-합텐/항-혈액뇌장벽 수용체 항체, 그의 복합체 및 혈액뇌장벽 셔틀로서 그의 용도
|
|
BR112016014945A2
(pt)
|
2014-01-03 |
2018-01-23 |
F. Hoffmann-La Roche Ag |
conjugado, formulação farmacêutica e uso
|
|
CN111057147B
(zh)
|
2014-01-06 |
2023-11-10 |
豪夫迈·罗氏有限公司 |
单价血脑屏障穿梭模块
|
|
AU2014377106B2
(en)
|
2014-01-08 |
2019-10-03 |
Jiangsu Hengrui Medicine Co., Ltd. |
IL-15 heterodimeric protein and uses thereof
|
|
RU2727639C2
(ru)
|
2014-01-15 |
2020-07-22 |
Ф.Хоффманн-Ля Рош Аг |
Варианты fc-области с модифицированной способностью связываться с fcrn и с сохраненной способностью связываться с белком а
|
|
JP6778110B2
(ja)
|
2014-01-15 |
2020-10-28 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
改善されたプロテインＡ結合を有するＦｃ領域バリアント
|
|
MX2016009515A
(es)
|
2014-01-24 |
2016-10-26 |
Genentech Inc |
Metodos para utilizar anticuerpos anti-steap1 e inmunoconjugados.
|
|
JOP20200094A1
(ar)
|
2014-01-24 |
2017-06-16 |
Dana Farber Cancer Inst Inc |
جزيئات جسم مضاد لـ pd-1 واستخداماتها
|
|
JOP20200096A1
(ar)
|
2014-01-31 |
2017-06-16 |
Children’S Medical Center Corp |
جزيئات جسم مضاد لـ tim-3 واستخداماتها
|
|
JP6685912B2
(ja)
|
2014-02-08 |
2020-04-22 |
ジェネンテック， インコーポレイテッド |
アルツハイマー病治療方法
|
|
BR112016018205A8
(pt)
|
2014-02-08 |
2018-04-17 |
Genentech Inc |
métodos de tratamento de mal de alzheimer, de seleção de pacientes, de identificação de pacientes, de previsão, de otimização da eficácia terapêutica, kit, uso de agente e uso in vitro de agente
|
|
SG10201808259TA
(en)
|
2014-02-12 |
2018-10-30 |
Genentech Inc |
Anti-jagged1 antibodies and methods of use
|
|
JP2017507939A
(ja)
|
2014-02-21 |
2017-03-23 |
ジェネンテック， インコーポレイテッド |
抗ｉｌ−１３／ｉｌ−１７二重特異性抗体及びその使用
|
|
US9732154B2
(en)
|
2014-02-28 |
2017-08-15 |
Janssen Biotech, Inc. |
Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
|
|
IL301147A
(en)
|
2014-02-28 |
2023-05-01 |
Merus Nv |
An antibody that binds to ErbB-2 and ErbB-3
|
|
EP3786186A1
(en)
|
2014-02-28 |
2021-03-03 |
Merus N.V. |
Antibodies that bind egfr and erbb3
|
|
HRP20211748T1
(hr)
|
2014-03-14 |
2022-02-18 |
F. Hoffmann - La Roche Ag |
Postupci i sastavi za sekreciju heterolognih polipeptida
|
|
EP3116909B1
(en)
|
2014-03-14 |
2019-11-13 |
Novartis Ag |
Antibody molecules to lag-3 and uses thereof
|
|
CN106163547A
(zh)
|
2014-03-15 |
2016-11-23 |
诺华股份有限公司 |
使用嵌合抗原受体治疗癌症
|
|
WO2015140591A1
(en)
|
2014-03-21 |
2015-09-24 |
Nordlandssykehuset Hf |
Anti-cd14 antibodies and uses thereof
|
|
SG10201808225TA
(en)
|
2014-03-21 |
2018-10-30 |
Regeneron Pharma |
Non-human animals that make single domain binding proteins
|
|
WO2015148531A1
(en)
|
2014-03-24 |
2015-10-01 |
Genentech, Inc. |
Cancer treatment with c-met antagonists and correlation of the latter with hgf expression
|
|
US12180264B2
(en)
|
2014-03-24 |
2024-12-31 |
R-Pharm Overseas, Inc. |
IL1-R1 derived inhibitor of IL-1β and use thereof
|
|
TN2017000532A1
(en)
|
2014-03-28 |
2019-04-12 |
Xencor Inc |
Bispecific antibodies that bind to cd38 and cd3.
|
|
HUE046767T2
(hu)
|
2014-03-31 |
2020-03-30 |
Hoffmann La Roche |
Anti-OX40 antitestek és alkalmazási eljárások
|
|
JP6588461B2
(ja)
|
2014-03-31 |
2019-10-09 |
ジェネンテック， インコーポレイテッド |
抗血管新生剤及びｏｘ４０結合アゴニストを含む併用療法
|
|
EP3825326A1
(en)
|
2014-04-01 |
2021-05-26 |
Adimab, LLC |
Multispecific antibody analogs comprising a common light chain, and methods of their preparation and use
|
|
CN113092788A
(zh)
|
2014-04-02 |
2021-07-09 |
豪夫迈·罗氏有限公司 |
检测多特异性抗体轻链错配的方法
|
|
UA117289C2
(uk)
|
2014-04-02 |
2018-07-10 |
Ф. Хоффманн-Ля Рош Аг |
Мультиспецифічне антитіло
|
|
WO2015156268A1
(ja)
|
2014-04-07 |
2015-10-15 |
中外製薬株式会社 |
免疫活性化抗原結合分子
|
|
US20190202908A1
(en)
*
|
2014-04-15 |
2019-07-04 |
President And Fellows Of Harvard College |
Bi-specific agents
|
|
WO2015164615A1
(en)
|
2014-04-24 |
2015-10-29 |
University Of Oslo |
Anti-gluten antibodies and uses thereof
|
|
CN113501880A
(zh)
|
2014-05-02 |
2021-10-15 |
动量制药公司 |
涉及工程化Fc构建体的组合物和方法
|
|
HUE063273T2
(hu)
|
2014-05-06 |
2024-01-28 |
Hoffmann La Roche |
Heteromultimer fehérjék elõállítása emlõssejtek felhasználásával
|
|
CN106459954A
(zh)
|
2014-05-13 |
2017-02-22 |
中外制药株式会社 |
用于具有免疫抑制功能的细胞的t细胞重定向的抗原结合分子
|
|
WO2015175375A1
(en)
|
2014-05-13 |
2015-11-19 |
Short Jay M |
Conditionally active biological proteins
|
|
ES2936810T3
(es)
*
|
2014-05-16 |
2023-03-22 |
Pfizer |
Anticuerpos biespecíficos con interfaces CH1-CL de ingeniería
|
|
MX2016015162A
(es)
|
2014-05-22 |
2017-03-03 |
Genentech Inc |
Anticuerpos anti - gpc3 e inmunoconjugados.
|
|
RU2016144405A
(ru)
|
2014-05-23 |
2018-06-26 |
Дженентек, Инк. |
MiT БИОМАРКЕРЫ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
|
|
CA2946503C
(en)
|
2014-05-28 |
2022-11-22 |
Zymeworks Inc. |
Modified antigen binding polypeptide constructs and uses thereof
|
|
US10010498B2
(en)
|
2014-06-04 |
2018-07-03 |
Acceleron Pharma Inc. |
Methods for treatment of amyotrophic lateral sclerosis with follistatin fusion proteins
|
|
CN106795224B
(zh)
|
2014-06-04 |
2021-05-18 |
阿塞勒隆制药公司 |
用促滤泡素抑制素多肽治疗病症的方法和组合物
|
|
CN106459202A
(zh)
|
2014-06-11 |
2017-02-22 |
豪夫迈·罗氏有限公司 |
抗LgR5抗体及其用途
|
|
CN107073109B
(zh)
|
2014-06-11 |
2021-08-06 |
凯西·A·格林 |
Vista激动剂和拮抗剂抑制或增强体液免疫的用途
|
|
US20230190750A1
(en)
|
2014-06-13 |
2023-06-22 |
Genentech, Inc. |
Methods of treating and preventing cancer drug resistance
|
|
TWI713453B
(zh)
|
2014-06-23 |
2020-12-21 |
美商健生生物科技公司 |
干擾素α及ω抗體拮抗劑
|
|
RU2705299C2
(ru)
|
2014-06-26 |
2019-11-06 |
Ф. Хоффманн-Ля Рош Аг |
Антитела против 5-бром-2'-дезоксиуридина и способы применения
|
|
AR100978A1
(es)
|
2014-06-26 |
2016-11-16 |
Hoffmann La Roche |
LANZADERAS CEREBRALES DE ANTICUERPO HUMANIZADO ANTI-Tau(pS422) Y USOS DE LAS MISMAS
|
|
JP6822849B2
(ja)
|
2014-06-27 |
2021-01-27 |
イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． |
多重特異的ＮＫｐ４６結合タンパク質
|
|
WO2015197598A2
(en)
|
2014-06-27 |
2015-12-30 |
Innate Pharma |
Multispecific antigen binding proteins
|
|
TW201623329A
(zh)
|
2014-06-30 |
2016-07-01 |
亞佛瑞司股份有限公司 |
針對骨調素截斷變異體的疫苗及單株抗體暨其用途
|
|
HRP20192243T1
(hr)
|
2014-07-03 |
2020-03-06 |
F. Hoffmann - La Roche Ag |
Polipeptidni ekspresijski sustavi
|
|
RU2742493C2
(ru)
|
2014-07-10 |
2021-02-08 |
Аффирис Аг |
Вещества и способы для применения при предупреждении и/или лечении болезни гентингтона
|
|
CA2954868C
(en)
|
2014-07-11 |
2023-08-29 |
Genentech, Inc. |
Anti-pd-l1 antibodies and diagnostic uses thereof
|
|
EP3166627A1
(en)
|
2014-07-11 |
2017-05-17 |
Genentech, Inc. |
Notch pathway inhibition
|
|
PT3169706T
(pt)
|
2014-07-11 |
2020-03-13 |
Genmab As |
Anticorpos que se ligam a axl
|
|
WO2016014553A1
(en)
|
2014-07-21 |
2016-01-28 |
Novartis Ag |
Sortase synthesized chimeric antigen receptors
|
|
US9777073B2
(en)
*
|
2014-07-21 |
2017-10-03 |
Wuhan Yzy Biopharma Co., Ltd. |
Construction and application of bispecific antibody EpCAM×CD3
|
|
CN107109419B
(zh)
|
2014-07-21 |
2020-12-22 |
诺华股份有限公司 |
使用cd33嵌合抗原受体治疗癌症
|
|
WO2016014530A1
(en)
|
2014-07-21 |
2016-01-28 |
Novartis Ag |
Combinations of low, immune enhancing. doses of mtor inhibitors and cars
|
|
BR112017001183A2
(pt)
|
2014-07-21 |
2017-11-28 |
Novartis Ag |
tratamento de câncer usando receptor de antígeno quimérico anti-bcma humanizado
|
|
CN106573986A
(zh)
*
|
2014-07-29 |
2017-04-19 |
豪夫迈·罗氏有限公司 |
多特异性抗体
|
|
CR20170027A
(es)
|
2014-07-30 |
2017-05-09 |
Ngm Biopharmaceuticals Inc |
Composiciones y métodos de uso para tratar trastornos metabólicos
|
|
EP4205749A1
(en)
|
2014-07-31 |
2023-07-05 |
Novartis AG |
Subset-optimized chimeric antigen receptor-containing cells
|
|
EP2982692A1
(en)
|
2014-08-04 |
2016-02-10 |
EngMab AG |
Bispecific antibodies against CD3epsilon and BCMA
|
|
JP6464255B2
(ja)
|
2014-08-04 |
2019-02-06 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
二重特異性ｔ細胞活性化抗原結合分子
|
|
CA2958200A1
(en)
|
2014-08-14 |
2016-02-18 |
Novartis Ag |
Treatment of cancer using a gfr alpha-4 chimeric antigen receptor
|
|
ES2791248T3
(es)
|
2014-08-19 |
2020-11-03 |
Novartis Ag |
Receptor antigénico quimérico (CAR) anti-CD123 para su uso en el tratamiento del cáncer
|
|
US11111288B2
(en)
|
2014-08-28 |
2021-09-07 |
Bioatla, Inc. |
Conditionally active chimeric antigen receptors for modified t-cells
|
|
DK3186284T3
(da)
|
2014-08-28 |
2022-05-09 |
Bioatla Inc |
Betinget aktive kimæriske antigenreceptorer til modificerede t-celler
|
|
CA2959786A1
(en)
|
2014-09-03 |
2016-03-10 |
Bioatla, Llc |
Discovering and producing conditionally active biologic proteins in the same eukaryotic cell production hosts
|
|
SG11201701867SA
(en)
|
2014-09-09 |
2017-04-27 |
Janssen Biotech Inc |
Combination therapies with anti-cd38 antibodies
|
|
MX2017003123A
(es)
|
2014-09-12 |
2017-05-12 |
Genentech Inc |
Anticuerpos y conjugados modificados geneticamente con cisteina.
|
|
EP3191518B1
(en)
|
2014-09-12 |
2020-01-15 |
Genentech, Inc. |
Anti-b7-h4 antibodies and immunoconjugates
|
|
AU2015314744A1
(en)
|
2014-09-12 |
2017-03-02 |
Genentech, Inc. |
Anti-CLL-1 antibodies and immunoconjugates
|
|
ES2830385T3
(es)
|
2014-09-12 |
2021-06-03 |
Genentech Inc |
Anticuerpos e inmunoconjugados anti-HER2
|
|
WO2016044224A1
(en)
|
2014-09-15 |
2016-03-24 |
Amgen Inc. |
Bi-specific anti-cgrp receptor/pac1 receptor antigen binding proteins and uses thereof
|
|
EA201790624A1
(ru)
|
2014-09-17 |
2017-08-31 |
Новартис Аг |
Нацеливание цитотоксических клеток с химерными рецепторами для адоптивной иммунотерапии
|
|
HK1243629A1
(zh)
|
2014-09-17 |
2018-07-20 |
基因泰克公司 |
包含抗her2抗体和吡咯并苯并二氮杂䓬的免疫缀合物
|
|
DK3262071T3
(da)
|
2014-09-23 |
2020-06-15 |
Hoffmann La Roche |
Fremgangsmåde til anvendelse af anti-CD79b-immunkonjugater
|
|
EP3197477A4
(en)
|
2014-09-24 |
2018-07-04 |
Aileron Therapeutics, Inc. |
Peptidomimetic macrocycles and formulations thereof
|
|
SG10201902594QA
(en)
|
2014-09-24 |
2019-04-29 |
Aileron Therapeutics Inc |
Peptidomimetic macrocycles and uses thereof
|
|
WO2016046778A2
(en)
|
2014-09-25 |
2016-03-31 |
Amgen Inc |
Protease-activatable bispecific proteins
|
|
MA40764A
(fr)
|
2014-09-26 |
2017-08-01 |
Chugai Pharmaceutical Co Ltd |
Agent thérapeutique induisant une cytotoxicité
|
|
US11952421B2
(en)
|
2014-10-09 |
2024-04-09 |
Bristol-Myers Squibb Company |
Bispecific antibodies against CD3EPSILON and ROR1
|
|
CN114920840A
(zh)
|
2014-10-14 |
2022-08-19 |
诺华股份有限公司 |
针对pd-l1的抗体分子及其用途
|
|
US9732148B2
(en)
|
2014-10-16 |
2017-08-15 |
Genentech, Inc. |
Anti-α-synuclein antibodies and methods of use
|
|
PL3212226T3
(pl)
|
2014-10-31 |
2020-11-02 |
Ngm Biopharmaceuticals, Inc. |
Kompozycje i sposoby stosowania w leczeniu zaburzeń metabolicznych
|
|
EP3212225B1
(en)
|
2014-10-31 |
2025-11-19 |
The Trustees of the University of Pennsylvania |
Methods and compositions for modified t cells
|
|
CA2966042A1
(en)
|
2014-10-31 |
2016-05-06 |
Oncomed Pharmaceuticals, Inc. |
Combination therapy for treatment of disease
|
|
AU2015343339A1
(en)
|
2014-11-03 |
2017-06-15 |
Genentech, Inc. |
Methods and biomarkers for predicting efficacy and evaluation of an OX40 agonist treatment
|
|
SG11201703448QA
(en)
|
2014-11-03 |
2017-05-30 |
Genentech Inc |
Assays for detecting t cell immune subsets and methods of use thereof
|
|
US11773166B2
(en)
|
2014-11-04 |
2023-10-03 |
Ichnos Sciences SA |
CD3/CD38 T cell retargeting hetero-dimeric immunoglobulins and methods of their production
|
|
KR20170078677A
(ko)
|
2014-11-06 |
2017-07-07 |
에프. 호프만-라 로슈 아게 |
Fcrn-결합이 개질된 fc-영역 변이체 및 이의 사용 방법
|
|
JP6576456B2
(ja)
|
2014-11-06 |
2019-09-18 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
修飾されたＦｃＲｎ結合特性およびプロテインＡ結合特性を有するＦｃ領域変種
|
|
WO2016073157A1
(en)
|
2014-11-06 |
2016-05-12 |
Genentech, Inc. |
Anti-ang2 antibodies and methods of use thereof
|
|
CR20170240A
(es)
|
2014-11-10 |
2018-04-03 |
Genentech Inc |
Anticuerpos anti-interleucina-33 y sus usos
|
|
WO2016077369A1
(en)
|
2014-11-10 |
2016-05-19 |
Genentech, Inc. |
Animal model for nephropathy and agents for treating the same
|
|
EP3224275B1
(en)
|
2014-11-14 |
2020-03-04 |
F.Hoffmann-La Roche Ag |
Antigen binding molecules comprising a tnf family ligand trimer
|
|
WO2016081639A1
(en)
|
2014-11-19 |
2016-05-26 |
Genentech, Inc. |
Antibodies against bace1 and use thereof for neural disease immunotherapy
|
|
EP3221361B1
(en)
|
2014-11-19 |
2021-04-21 |
Genentech, Inc. |
Anti-transferrin receptor / anti-bace1 multispecific antibodies and methods of use
|
|
WO2016081643A1
(en)
|
2014-11-19 |
2016-05-26 |
Genentech, Inc. |
Anti-transferrin receptor antibodies and methods of use
|
|
EA201791121A1
(ru)
|
2014-11-20 |
2018-04-30 |
Ф. Хоффманн-Ля Рош Аг |
Активирующие т-клетки биспецифические антигенсвязывающие молекулы против folri и cd3
|
|
DK3221357T3
(da)
|
2014-11-20 |
2020-08-10 |
Hoffmann La Roche |
Fælles letkæder og fremgangsmåder til anvendelse
|
|
EP3023437A1
(en)
|
2014-11-20 |
2016-05-25 |
EngMab AG |
Bispecific antibodies against CD3epsilon and BCMA
|
|
EP3221355B1
(en)
|
2014-11-20 |
2020-10-07 |
F.Hoffmann-La Roche Ag |
Combination therapy of t cell activating bispecific antigen binding molecules cd3 and folate receptor 1 (folr1) and pd-1 axis binding antagonists
|
|
BR112017011092A2
(pt)
|
2014-11-26 |
2017-12-26 |
Xencor Inc |
anticorpos heterodiméricos que ligam cd3 e antígenos de tumor
|
|
CN107406512A
(zh)
|
2014-11-26 |
2017-11-28 |
Xencor公司 |
结合cd3和cd38的异二聚体抗体
|
|
US10259887B2
(en)
|
2014-11-26 |
2019-04-16 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and tumor antigens
|
|
WO2016082044A1
(en)
|
2014-11-27 |
2016-06-02 |
Zymeworks Inc. |
Methods of using bispecific antigen-binding constructs targeting her2
|
|
CN107001482B
(zh)
|
2014-12-03 |
2021-06-15 |
豪夫迈·罗氏有限公司 |
多特异性抗体
|
|
WO2016090034A2
(en)
|
2014-12-03 |
2016-06-09 |
Novartis Ag |
Methods for b cell preconditioning in car therapy
|
|
UA123697C2
(uk)
|
2014-12-04 |
2021-05-19 |
Янссен Байотек, Інк. |
Спосіб лікування гострого мієлоїдного лейкозу шляхом застосування антитіла до cd38
|
|
CN107108739B
(zh)
|
2014-12-05 |
2022-01-04 |
豪夫迈·罗氏有限公司 |
抗CD79b抗体和使用方法
|
|
CA2969730A1
(en)
|
2014-12-05 |
2016-06-09 |
Immunext, Inc. |
Identification of vsig8 as the putative vista receptor and its use thereof to produce vista/vsig8 modulators
|
|
EP3230317A2
(en)
|
2014-12-10 |
2017-10-18 |
F. Hoffmann-La Roche AG |
Blood brain barrier receptor antibodies and methods of use
|
|
US10093733B2
(en)
|
2014-12-11 |
2018-10-09 |
Abbvie Inc. |
LRP-8 binding dual variable domain immunoglobulin proteins
|
|
WO2016096788A1
(en)
|
2014-12-18 |
2016-06-23 |
F. Hoffmann-La Roche Ag |
Assay and method for determining cdc eliciting antibodies
|
|
NZ730607A
(en)
|
2014-12-19 |
2022-07-01 |
Chugai Pharmaceutical Co Ltd |
Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
|
|
RS62749B1
(sr)
|
2014-12-19 |
2022-01-31 |
Chugai Pharmaceutical Co Ltd |
Anti-c5 antitela i načini njihove upotrebe
|
|
US10865253B2
(en)
|
2014-12-19 |
2020-12-15 |
Genmab A/S |
Rodent bispecific heterodimeric proteins
|
|
US10428155B2
(en)
|
2014-12-22 |
2019-10-01 |
Xencor, Inc. |
Trispecific antibodies
|
|
CN110655582B
(zh)
*
|
2015-01-08 |
2022-12-16 |
江苏康宁杰瑞生物制药有限公司 |
具有共同轻链的双特异性抗体或抗体混合物
|
|
CN113956354A
(zh)
|
2015-01-22 |
2022-01-21 |
中外制药株式会社 |
两种以上抗-c5抗体的组合与使用方法
|
|
MA41375A
(fr)
|
2015-01-22 |
2017-11-28 |
Lilly Co Eli |
Anticorps igg bispécifiques et leurs procédés de préparation
|
|
US10828353B2
(en)
|
2015-01-31 |
2020-11-10 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for T cell delivery of therapeutic molecules
|
|
CA2974547A1
(en)
|
2015-02-05 |
2016-08-11 |
Chugai Seiyaku Kabushiki Kaisha |
Antibodies comprising an ion concentration dependent antigen-binding domain, fc region variants, il-8-binding antibodies, and uses thereof
|
|
KR102790523B1
(ko)
|
2015-02-24 |
2025-04-02 |
바이오아트라, 인코퍼레이티드 |
조건부 활성 생체 단백질
|
|
WO2016141110A1
(en)
|
2015-03-03 |
2016-09-09 |
Schlumberger Technology Corporation |
Multi-mode acoustic tool and method
|
|
US10227411B2
(en)
|
2015-03-05 |
2019-03-12 |
Xencor, Inc. |
Modulation of T cells with bispecific antibodies and FC fusions
|
|
HRP20192217T1
(hr)
|
2015-03-06 |
2020-02-21 |
F. Hoffmann - La Roche Ag |
ULTRA-PROČIŠĆENI DsbA I DsbC TE POSTUPCI NJIHOVE IZRADE I UPORABE
|
|
WO2016149276A1
(en)
|
2015-03-16 |
2016-09-22 |
Genentech, Inc. |
Methods of detecting and quantifying il-13 and uses in diagnosing and treating th2-associated diseases
|
|
EP3271403A1
(en)
|
2015-03-19 |
2018-01-24 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals that select for light chain variable regions that bind antigen
|
|
WO2016146833A1
(en)
|
2015-03-19 |
2016-09-22 |
F. Hoffmann-La Roche Ag |
Biomarkers for nad(+)-diphthamide adp ribosyltransferase resistance
|
|
AU2016235424A1
(en)
|
2015-03-20 |
2017-10-05 |
Aileron Therapeutics, Inc. |
Peptidomimetic macrocycles and uses thereof
|
|
AU2016238254B2
(en)
|
2015-03-26 |
2022-05-05 |
Acceleron Pharma Inc. |
Follistatin-related fusion proteins and uses thereof
|
|
US11142587B2
(en)
|
2015-04-01 |
2021-10-12 |
Chugai Seiyaku Kabushiki Kaisha |
Method for producing polypeptide hetero-oligomer
|
|
CN114456272A
(zh)
|
2015-04-03 |
2022-05-10 |
优瑞科生物技术公司 |
靶向afp肽/mhc复合体的构建体及其用途
|
|
KR20180002659A
(ko)
|
2015-04-06 |
2018-01-08 |
악셀레론 파마 인코포레이티드 |
Tgf-베타 슈퍼패밀리 유형 i 및 유형 ii 수용체 이형다합체들과 이의 용도
|
|
US10358476B2
(en)
|
2015-04-06 |
2019-07-23 |
Acceleron Pharma Inc. |
Single arm type I and type II receptor fusion proteins and uses thereof
|
|
MA41919A
(fr)
|
2015-04-06 |
2018-02-13 |
Acceleron Pharma Inc |
Hétéromultimères alk4:actriib et leurs utilisations
|
|
AU2016246695A1
(en)
|
2015-04-07 |
2017-10-26 |
Genentech, Inc. |
Antigen binding complex having agonistic activity and methods of use
|
|
CA2981851A1
(en)
|
2015-04-07 |
2016-10-13 |
Alector Llc |
Anti-sortilin antibodies and methods of use thereof
|
|
SG11201708191XA
(en)
|
2015-04-08 |
2017-11-29 |
Novartis Ag |
Cd20 therapies, cd22 therapies, and combination therapies with a cd19 chimeric antigen receptor (car) - expressing cell
|
|
IL283764B2
(en)
|
2015-04-10 |
2024-01-01 |
Amgen Inc |
Interleukin-2 muteins for the expansion of t-regulatory cells
|
|
CN108472360B
(zh)
|
2015-04-10 |
2023-01-17 |
阿迪马布有限责任公司 |
从亲代同源二聚抗体种类中纯化异源二聚多特异性抗体的方法
|
|
US20180105596A1
(en)
|
2015-04-17 |
2018-04-19 |
Elsalys Biotech |
Anti-tyro3 antibodies and uses thereof
|
|
US12128069B2
(en)
|
2015-04-23 |
2024-10-29 |
The Trustees Of The University Of Pennsylvania |
Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
|
|
CN107810197B
(zh)
|
2015-04-24 |
2022-10-25 |
豪夫迈·罗氏有限公司 |
鉴定包含结合多肽的细菌的方法
|
|
KR102668727B1
(ko)
|
2015-04-24 |
2024-05-28 |
제넨테크, 인크. |
다중특이적 항원-결합 단백질
|
|
HK1248577A1
(zh)
|
2015-05-11 |
2018-10-19 |
F. Hoffmann-La Roche Ag |
治疗狼疮性肾炎的组合物和方法
|
|
KR20180008449A
(ko)
|
2015-05-12 |
2018-01-24 |
제넨테크, 인크. |
암에 대한 치료 및 진단 방법
|
|
AU2016264725B2
(en)
|
2015-05-20 |
2021-05-27 |
Janssen Biotech, Inc. |
Anti-CD38 antibodies for treatment of light chain amyloidosis and other CD38-positive hematological malignancies
|
|
CN107646038B
(zh)
|
2015-05-28 |
2021-08-20 |
基因泰克公司 |
用于检测抗cd3同二聚体的基于细胞的测定
|
|
CN107771182A
(zh)
|
2015-05-29 |
2018-03-06 |
豪夫迈·罗氏有限公司 |
人源化抗埃博拉病毒糖蛋白抗体和使用方法
|
|
ES2789500T5
(es)
|
2015-05-29 |
2023-09-20 |
Hoffmann La Roche |
Procedimientos terapéuticos y de diagnóstico para el cáncer
|
|
HK1249016A1
(zh)
|
2015-06-02 |
2018-10-26 |
豪夫迈‧罗氏有限公司 |
使用抗il-34抗体治疗神经疾病的组合物和方法
|
|
CA2986942C
(en)
|
2015-06-05 |
2025-07-22 |
Ac Immune Sa |
Anti-tau antibodies and their methods of use
|
|
KR20180025888A
(ko)
|
2015-06-08 |
2018-03-09 |
제넨테크, 인크. |
항-ox40 항체 및 pd-1 축 결합 길항제를 사용하여 암을 치료하는 방법
|
|
CA2985483A1
(en)
|
2015-06-08 |
2016-12-15 |
Genentech, Inc. |
Methods of treating cancer using anti-ox40 antibodies
|
|
TW201710286A
(zh)
|
2015-06-15 |
2017-03-16 |
艾伯維有限公司 |
抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
|
|
AR104987A1
(es)
|
2015-06-15 |
2017-08-30 |
Genentech Inc |
Inmunoconjugados anticuerpo-fármaco unidos por enlazadores no peptídicos
|
|
TW201718647A
(zh)
|
2015-06-16 |
2017-06-01 |
建南德克公司 |
抗-cll-1抗體及使用方法
|
|
PT3310814T
(pt)
|
2015-06-16 |
2023-10-02 |
H Hoffnabb La Roche Ag |
Anticorpos humanizados e de afinidade amadurecida para fcrh5 e métodos de utilização
|
|
JP2018526972A
(ja)
|
2015-06-16 |
2018-09-20 |
ジェネンテック， インコーポレイテッド |
抗ｃｄ３抗体及び使用方法
|
|
HRP20251150T1
(hr)
|
2015-06-17 |
2025-12-05 |
F. Hoffmann - La Roche Ag |
Anti-her2 protutijela i postupci uporabe
|
|
PE20181323A1
(es)
|
2015-06-22 |
2018-08-14 |
Janssen Biotech Inc |
Terapias de combinacion para enfermedades malignas hematologicas con anticuerpos anti-cd38 e inhibidores de survivina
|
|
JP6971153B2
(ja)
|
2015-06-23 |
2021-11-24 |
イナート・ファルマ・ソシエテ・アノニムInnate Pharma Pharma S.A. |
多重特異的ｎｋエンゲイジャータンパク質
|
|
EP3313882B1
(en)
|
2015-06-24 |
2020-03-11 |
Janssen Pharmaceutica NV |
Anti-vista antibodies and fragments
|
|
FI3313441T3
(fi)
|
2015-06-24 |
2024-03-28 |
Janssen Biotech Inc |
Kiinteiden kasvainten immunomodulaatio ja hoito spesifisesti cd38:aa sitovilla vasta-aineilla
|
|
WO2016207091A1
(en)
|
2015-06-24 |
2016-12-29 |
F. Hoffmann-La Roche Ag |
Trispecific antibodies specific for her2 and a blood brain barrier receptor and methods of use
|
|
ES2809728T3
(es)
|
2015-06-24 |
2021-03-05 |
Hoffmann La Roche |
Anticuerpos anti-tau(pS422) humanizados y procedimientos de uso
|
|
JP6782716B2
(ja)
|
2015-06-25 |
2020-11-11 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
抗体またはリガンドの結合および機能を明らかにするための細胞ベースアッセイ法
|
|
EP3514174B1
(en)
|
2015-06-29 |
2021-03-31 |
Ventana Medical Systems, Inc. |
Materials and methods for performing histochemical assays for human pro-epiregulin and amphiregulin
|
|
MX2017016645A
(es)
|
2015-06-29 |
2018-11-09 |
Genentech Inc |
Anticuerpo anti-cd20 de tipo ii para su uso en el trasplante de órganos.
|
|
WO2017004548A1
(en)
|
2015-07-01 |
2017-01-05 |
Aileron Therapeutics, Inc. |
Peptidomimetic macrocycles
|
|
WO2017005649A1
(en)
|
2015-07-09 |
2017-01-12 |
Genmab A/S |
Bispecific and multispecific antibodies and method for isolation of such
|
|
MX2018000344A
(es)
|
2015-07-10 |
2018-03-14 |
Merus Nv |
Anticuerpo que se une a grupo de diferenciacion 3 (cd3) humano.
|
|
HRP20200551T1
(hr)
|
2015-07-10 |
2020-07-10 |
Genmab A/S |
Axl-specifični konjugati protutijelo-lijek za liječenje raka
|
|
WO2017009442A1
(en)
|
2015-07-15 |
2017-01-19 |
Genmab A/S |
Humanized or chimeric cd3 antibodies
|
|
WO2017019897A1
(en)
|
2015-07-29 |
2017-02-02 |
Novartis Ag |
Combination therapies comprising antibody molecules to tim-3
|
|
CN114272371A
(zh)
|
2015-07-29 |
2022-04-05 |
诺华股份有限公司 |
包含抗pd-1抗体分子的联合疗法
|
|
PT3317301T
(pt)
|
2015-07-29 |
2021-07-09 |
Novartis Ag |
Terapias de associação compreendendo moléculas de anticorpo contra lag-3
|
|
WO2017019846A1
(en)
|
2015-07-30 |
2017-02-02 |
Macrogenics, Inc. |
Pd-1-binding molecules and methods use thereof
|
|
MA45573A
(fr)
|
2015-08-05 |
2019-05-15 |
Janssen Biotech Inc |
Anticorps anti-cd154 et procédés d'utilisation correspondant
|
|
BR102016018074A2
(pt)
|
2015-08-07 |
2021-11-16 |
ALX Oncology Inc. |
Construção variante de sirp-alfa, seu método de preparação e seus usos, molécula de ácido nucleico, vetor, célula hospedeira, e composição farmacêutica
|
|
CA2993835A1
(en)
|
2015-08-07 |
2017-02-16 |
Alexo Therapeutics Inc. |
Constructs having a sirp-alpha domain or variant thereof
|
|
CN105384825B
(zh)
|
2015-08-11 |
2018-06-01 |
南京传奇生物科技有限公司 |
一种基于单域抗体的双特异性嵌合抗原受体及其应用
|
|
SG10202101105XA
(en)
|
2015-08-13 |
2021-03-30 |
Amgen Inc |
Charged depth filtration of antigen-binding proteins
|
|
CA2985119C
(en)
*
|
2015-08-26 |
2021-01-26 |
Bison Therapeutics Inc. |
Multispecific antibody platform and related methods
|
|
WO2017040195A1
(en)
|
2015-08-28 |
2017-03-09 |
The Trustees Of The University Of Pennsylvania |
Methods and compositions for cells expressing a chimeric intracellular signaling molecule
|
|
WO2017040324A1
(en)
|
2015-08-28 |
2017-03-09 |
The Trustees Of The University Of Pennsylvania |
Methods and compositions for cells expressing a chimeric intracellular signaling molecule
|
|
WO2017044859A1
(en)
|
2015-09-10 |
2017-03-16 |
Affigen, Inc. |
Sequencing-directed selection of tumor theranostics
|
|
CN108368161A
(zh)
|
2015-09-10 |
2018-08-03 |
艾瑞朗医疗公司 |
作为mcl-1调节剂的拟肽大环化合物
|
|
WO2017049004A1
(en)
|
2015-09-15 |
2017-03-23 |
Amgen Inc. |
Tetravalent bispecific and tetraspecific antigen binding proteins and uses thereof
|
|
IL285375B2
(en)
|
2015-09-18 |
2025-11-01 |
Chugai Pharmaceutical Co Ltd |
Il-8-binding antibodies and uses thereof
|
|
CA2999369C
(en)
|
2015-09-22 |
2023-11-07 |
Spring Bioscience Corporation |
Anti-ox40 antibodies and diagnostic uses thereof
|
|
ES2968074T3
(es)
|
2015-09-23 |
2024-05-07 |
Mereo Biopharma 5 Inc |
Anticuerpo bi-específico anti-VEGF/DLL4 para su uso en el tratamiento del cáncer de ovario resistente al platino
|
|
TWI748962B
(zh)
|
2015-09-23 |
2021-12-11 |
美商建南德克公司 |
抗ｖｅｇｆ抗體之最佳化變異體
|
|
MX390255B
(es)
|
2015-09-24 |
2025-03-20 |
Abvitro Llc |
Composiciones de anticuerpo de virus de inmunodeficiencia humana (vih) y metodos de uso
|
|
LT3353210T
(lt)
|
2015-09-25 |
2025-01-27 |
F. Hoffmann-La Roche Ag |
Antikūnai prieš tigit ir jų naudojimo būdai
|
|
US10358497B2
(en)
|
2015-09-29 |
2019-07-23 |
Amgen Inc. |
Methods of treating cardiovascular disease with an ASGR inhibitor
|
|
AR106188A1
(es)
|
2015-10-01 |
2017-12-20 |
Hoffmann La Roche |
Anticuerpos anti-cd19 humano humanizados y métodos de utilización
|
|
US20170096495A1
(en)
|
2015-10-02 |
2017-04-06 |
Hoffmann-La Roche Inc. |
Bispecific t cell activating antigen binding molecules
|
|
AR106201A1
(es)
|
2015-10-02 |
2017-12-20 |
Hoffmann La Roche |
Moléculas biespecíficas de unión a antígeno activadoras de células t
|
|
WO2017055393A1
(en)
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Anti-cd3xtim-3 bispecific t cell activating antigen binding molecules
|
|
PL3356411T3
(pl)
|
2015-10-02 |
2021-12-06 |
F. Hoffmann-La Roche Ag |
Przeciwciała dwuswoiste swoiste dla PD1 i TIM3
|
|
RU2746409C1
(ru)
|
2015-10-02 |
2021-04-13 |
Ф. Хоффманн-Ля Рош Аг |
Антитела к pd1 и способы их применения
|
|
JP6734919B2
(ja)
|
2015-10-02 |
2020-08-05 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
同時結合を測定するための細胞ベースのｆｒｅｔアッセイ法
|
|
WO2017055539A1
(en)
*
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Multispecific antibodies
|
|
MA43345A
(fr)
|
2015-10-02 |
2018-08-08 |
Hoffmann La Roche |
Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation
|
|
CN115594765A
(zh)
|
2015-10-02 |
2023-01-13 |
豪夫迈·罗氏有限公司（Ch） |
对共刺激性tnf受体特异性的双特异性抗体
|
|
WO2017055392A1
(en)
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Anti-cd3xcd44v6 bispecific t cell activating antigen binding molecules
|
|
WO2017055385A1
(en)
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Anti-cd3xgd2 bispecific t cell activating antigen binding molecules
|
|
JP2018536389A
(ja)
|
2015-10-02 |
2018-12-13 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
メソテリンとｃｄ３に結合する二重特異性細胞活性化抗原結合分子
|
|
EP3150637A1
(en)
|
2015-10-02 |
2017-04-05 |
F. Hoffmann-La Roche AG |
Multispecific antibodies
|
|
EP3913000A1
(en)
|
2015-10-02 |
2021-11-24 |
F. Hoffmann-La Roche AG |
Bispecific anti-cd19xcd3 t cell activating antigen binding molecules
|
|
US20180282410A1
(en)
|
2015-10-02 |
2018-10-04 |
Hoffmann-La Roche Inc. |
Anti-cd3xrob04 bispecific t cell activating antigen binding molecules
|
|
WO2017060144A1
(en)
|
2015-10-07 |
2017-04-13 |
F. Hoffmann-La Roche Ag |
Bispecific antibodies with tetravalency for a costimulatory tnf receptor
|
|
KR20180069839A
(ko)
|
2015-10-08 |
2018-06-25 |
자임워크스 인코포레이티드 |
카파 및 람다 경사슬을 포함하는 항원-결합 폴리펩티드 구조체 및 이의 용도
|
|
KR101851380B1
(ko)
|
2015-10-12 |
2018-04-23 |
아주대학교산학협력단 |
효모접합을 이용한 항체 ch3 도메인 이종이중체 돌연변이쌍 제조 방법 및 이에 의하여 제조된 ch3 돌연변이체 쌍
|
|
MA43354A
(fr)
|
2015-10-16 |
2018-08-22 |
Genentech Inc |
Conjugués médicamenteux à pont disulfure encombré
|
|
MA45326A
(fr)
|
2015-10-20 |
2018-08-29 |
Genentech Inc |
Conjugués calichéamicine-anticorps-médicament et procédés d'utilisation
|
|
WO2017069628A2
(en)
|
2015-10-23 |
2017-04-27 |
Merus N.V. |
Binding molecules that inhibit cancer growth
|
|
EP3184547A1
(en)
|
2015-10-29 |
2017-06-28 |
F. Hoffmann-La Roche AG |
Anti-tpbg antibodies and methods of use
|
|
CA3000048A1
(en)
|
2015-10-29 |
2017-05-04 |
F. Hoffmann-La Roche Ag |
Anti-variant fc-region antibodies and methods of use
|
|
WO2017075173A2
(en)
|
2015-10-30 |
2017-05-04 |
Genentech, Inc. |
Anti-factor d antibodies and conjugates
|
|
JP6750010B2
(ja)
|
2015-10-30 |
2020-09-02 |
ジェネンテック， インコーポレイテッド |
抗ＨｔｒＡ１抗体及びその使用方法
|
|
SI3370770T1
(sl)
|
2015-11-03 |
2021-03-31 |
Janssen Biotech, Inc. |
Subkutane formulacije protiteles proti CD38 in njihove uporabe
|
|
JP6998869B2
(ja)
|
2015-11-08 |
2022-02-04 |
ジェネンテック， インコーポレイテッド |
多重特異性抗体のスクリーニング方法
|
|
US11660340B2
(en)
|
2015-11-18 |
2023-05-30 |
Chugai Seiyaku Kabushiki Kaisha |
Combination therapy using T cell redirection antigen binding molecule against cell having immunosuppressing function
|
|
JP6925278B2
(ja)
|
2015-11-18 |
2021-08-25 |
中外製薬株式会社 |
液性免疫応答の増強方法
|
|
US20190202926A1
(en)
|
2015-12-01 |
2019-07-04 |
Genmab B.V. |
Anti-death receptor antibodies and methods of use thereof
|
|
CN108699136B
(zh)
|
2015-12-07 |
2022-03-18 |
Xencor股份有限公司 |
结合cd3和psma的异二聚抗体
|
|
IL313608A
(en)
|
2015-12-09 |
2024-08-01 |
Hoffmann La Roche |
Antibody against CD20 type II to reduce the formation of antibodies against drugs
|
|
EP3178848A1
(en)
|
2015-12-09 |
2017-06-14 |
F. Hoffmann-La Roche AG |
Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies
|
|
CR20180318A
(es)
|
2015-12-14 |
2018-09-19 |
Macrogenics Inc |
Moléculas biespecíficas que tienen inmunorreactividad con pd-1 y ctla-4, y métodos de uso de las mismas
|
|
CN106883297B
(zh)
|
2015-12-16 |
2019-12-13 |
苏州康宁杰瑞生物科技有限公司 |
基于ch3结构域的异二聚体分子、其制备方法及用途
|
|
CR20180365A
(es)
|
2015-12-16 |
2018-09-28 |
Amgen Inc |
PROTEÍNAS DE UNIÓN AL ANTÍGENO BISPECÍFICO DE ANTI-TL1A/ANTI-TNF-a Y SUS USOS
|
|
JP2019502698A
(ja)
|
2015-12-17 |
2019-01-31 |
ヤンセン バイオテツク，インコーポレーテツド |
Ｈｌａ−ｄｒに特異的に結合する抗体及びその使用
|
|
EP4424322A3
(en)
|
2015-12-17 |
2025-04-16 |
Novartis AG |
Antibody molecules to pd-1 and uses thereof
|
|
AU2016369623A1
(en)
|
2015-12-17 |
2018-06-28 |
Novartis Ag |
Combination of c-Met inhibitor with antibody molecule to PD-1 and uses thereof
|
|
JP6142069B1
(ja)
|
2015-12-18 |
2017-06-07 |
中外製薬株式会社 |
抗ミオスタチン抗体、変異Ｆｃ領域を含むポリペプチド、および使用方法
|
|
SG10201709415WA
(en)
|
2015-12-18 |
2017-12-28 |
Chugai Pharmaceutical Co Ltd |
Anti-c5 antibodies and methods of use
|
|
MA44140A
(fr)
|
2015-12-22 |
2021-05-19 |
Dana Farber Cancer Inst Inc |
Récepteur d'antigène chimérique (car) contre la mésothéline et anticorps contre l'inhibiteur de pd-l1 pour une utilisation combinée dans une thérapie anticancéreuse
|
|
US20200270363A1
(en)
|
2015-12-25 |
2020-08-27 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody having enhanced activity, and method for modifying same
|
|
CN108779182A
(zh)
*
|
2015-12-28 |
2018-11-09 |
麻省理工学院 |
具有恒定区突变的双特异性抗体及其用途
|
|
EP3398965A4
(en)
|
2015-12-28 |
2019-09-18 |
Chugai Seiyaku Kabushiki Kaisha |
METHOD FOR PROMOTING THE EFFICIENCY OF CLEANING POLYPEPTIDE WITH FC REGION
|
|
CN108368179B
(zh)
|
2016-01-08 |
2022-08-23 |
豪夫迈·罗氏有限公司 |
使用pd-1轴结合拮抗剂和抗cea/抗cd3双特异性抗体治疗cea阳性癌症的方法
|
|
CN108602883A
(zh)
|
2016-01-20 |
2018-09-28 |
基因泰克公司 |
用于阿尔茨海默氏病的高剂量治疗
|
|
EP3851457A1
(en)
|
2016-01-21 |
2021-07-21 |
Novartis AG |
Multispecific molecules targeting cll-1
|
|
CA3014013A1
(en)
|
2016-02-12 |
2017-08-17 |
Janssen Pharmaceutica Nv |
Anti-vista (b7h5) antibodies
|
|
AU2017225854B2
(en)
|
2016-02-29 |
2020-11-19 |
Foundation Medicine, Inc. |
Therapeutic and diagnostic methods for cancer
|
|
WO2017151971A2
(en)
|
2016-03-02 |
2017-09-08 |
Momenta Pharmaceuticals, Inc. |
METHODS RELATED TO ENGINEERED Fc CONSTRUCTS
|
|
EP3423482A1
(en)
|
2016-03-04 |
2019-01-09 |
Novartis AG |
Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore
|
|
TW201735947A
(zh)
|
2016-03-14 |
2017-10-16 |
Chugai Pharmaceutical Co Ltd |
用於癌之治療的細胞傷害誘導治療劑
|
|
AU2017238172B2
(en)
|
2016-03-21 |
2024-06-27 |
Marengo Therapeutics, Inc. |
Multispecific and multifunctional molecules and uses thereof
|
|
SG11201808085WA
(en)
|
2016-03-22 |
2018-10-30 |
Hoffmann La Roche |
Protease-activated t cell bispecific molecules
|
|
HUE061946T2
(hu)
|
2016-03-22 |
2023-09-28 |
Hoffmann La Roche |
Proteáz-aktivált T-sejt bispecifikus molekulák
|
|
EP3432924A1
(en)
|
2016-03-23 |
2019-01-30 |
Novartis AG |
Cell secreted minibodies and uses thereof
|
|
EP4273551A3
(en)
|
2016-03-25 |
2024-01-17 |
F. Hoffmann-La Roche AG |
Multiplexed total antibody and antibody-conjugated drug quantification assay
|
|
CA3016035A1
(en)
|
2016-03-31 |
2017-10-05 |
Ngm Biopharmaceuticals, Inc. |
Binding proteins and methods of use thereof
|
|
EP3439741A4
(en)
|
2016-04-06 |
2020-05-06 |
Acceleron Pharma Inc. |
ALK7 ANTAGONISTS AND USES THEREOF
|
|
WO2017180864A1
(en)
|
2016-04-14 |
2017-10-19 |
Genentech, Inc. |
Anti-rspo3 antibodies and methods of use
|
|
CN118108843A
(zh)
|
2016-04-15 |
2024-05-31 |
伊穆奈克斯特股份有限公司 |
抗人vista抗体及其用途
|
|
AU2017250296A1
(en)
|
2016-04-15 |
2018-11-01 |
Genentech, Inc. |
Methods for monitoring and treating cancer
|
|
JP2019515670A
(ja)
|
2016-04-15 |
2019-06-13 |
ジェネンテック， インコーポレイテッド |
がんをモニタリングし治療するための方法
|
|
JP6735355B2
(ja)
|
2016-04-15 |
2020-08-05 |
バイオアトラ、エルエルシー |
抗Ａｘｌ抗体、抗体断片およびそれらの免疫コンジュゲートならびにそれらの使用
|
|
WO2017181119A2
(en)
|
2016-04-15 |
2017-10-19 |
Novartis Ag |
Compositions and methods for selective protein expression
|
|
EP3445780A1
(en)
|
2016-04-20 |
2019-02-27 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for making antibodies based on use of an expression-enhancing locus
|
|
CN109195986B
(zh)
|
2016-04-20 |
2023-01-03 |
瑞泽恩制药公司 |
基于使用表达增强性基因座来制备抗体的组合物和方法
|
|
MA44780A
(fr)
|
2016-04-28 |
2019-03-06 |
Chugai Pharmaceutical Co Ltd |
Préparation contenant un anticorps
|
|
BR112018069890A2
(pt)
|
2016-05-02 |
2019-02-05 |
Hoffmann La Roche |
polipeptídio de fusão que se liga de forma específica a um alvo, polipeptídio de fusão dimérico, ácido nucleico isolado, par de ácidos nucleicos isolados, célula hospedeira, método para produzir um polipeptídio de fusão, imunoconjugado, formulação farmacêutica, polipeptídio de fusão e uso do polipeptídio de fusão
|
|
CN109071623B
(zh)
|
2016-05-04 |
2022-05-27 |
美国安进公司 |
用于扩增t调节性细胞的白细胞介素-2突变蛋白
|
|
CN109071640B
(zh)
|
2016-05-11 |
2022-10-18 |
豪夫迈·罗氏有限公司 |
经修饰抗生腱蛋白抗体及使用方法
|
|
WO2017194442A1
(en)
|
2016-05-11 |
2017-11-16 |
F. Hoffmann-La Roche Ag |
Antigen binding molecules comprising a tnf family ligand trimer and a tenascin binding moiety
|
|
EP3243836A1
(en)
|
2016-05-11 |
2017-11-15 |
F. Hoffmann-La Roche AG |
C-terminally fused tnf family ligand trimer-containing antigen binding molecules
|
|
TW202434312A
(zh)
|
2016-05-13 |
2024-09-01 |
美商拜奧亞特拉公司 |
抗-ror2抗體、抗體片段、其免疫結合物及其用途
|
|
EP3243832A1
(en)
|
2016-05-13 |
2017-11-15 |
F. Hoffmann-La Roche AG |
Antigen binding molecules comprising a tnf family ligand trimer and pd1 binding moiety
|
|
KR20190007026A
(ko)
|
2016-05-17 |
2019-01-21 |
제넨테크, 인크. |
면역요법에서의 진단 및 사용을 위한 기질 유전자 특질
|
|
ES2858151T3
(es)
|
2016-05-20 |
2021-09-29 |
Hoffmann La Roche |
Conjugados de PROTAC-anticuerpo y procedimientos de uso
|
|
AU2017272111B2
(en)
|
2016-05-23 |
2024-05-16 |
Momenta Pharmaceuticals, Inc. |
Compositions and methods related to engineered Fc constructs
|
|
CN109475627B
(zh)
*
|
2016-05-26 |
2023-01-06 |
齐鲁普吉湾生物治疗公司 |
抗体混合物
|
|
EP3465221B1
(en)
|
2016-05-27 |
2020-07-22 |
H. Hoffnabb-La Roche Ag |
Bioanalytical method for the characterization of site-specific antibody-drug conjugates
|
|
US20210177896A1
(en)
|
2016-06-02 |
2021-06-17 |
Novartis Ag |
Therapeutic regimens for chimeric antigen receptor (car)- expressing cells
|
|
AU2018276419A1
(en)
|
2016-06-02 |
2019-10-17 |
F. Hoffmann-La Roche Ag |
Type II anti-CD20 antibody and anti-CD20/CD3 bispecific antibody for treatment of cancer
|
|
EP3252078A1
(en)
|
2016-06-02 |
2017-12-06 |
F. Hoffmann-La Roche AG |
Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer
|
|
WO2017214024A1
(en)
|
2016-06-06 |
2017-12-14 |
Genentech, Inc. |
Silvestrol antibody-drug conjugates and methods of use
|
|
EP3468586B1
(en)
|
2016-06-14 |
2024-08-07 |
Xencor, Inc. |
Bispecific checkpoint inhibitor antibodies
|
|
CN109563124A
(zh)
|
2016-06-17 |
2019-04-02 |
豪夫迈·罗氏有限公司 |
多特异性抗体的纯化
|
|
EP3472200A4
(en)
|
2016-06-17 |
2020-04-01 |
Chugai Seiyaku Kabushiki Kaisha |
ANTI-MYOSTATIN ANTIBODIES AND METHODS OF USE THEREOF
|
|
WO2017223405A1
(en)
|
2016-06-24 |
2017-12-28 |
Genentech, Inc. |
Anti-polyubiquitin multispecific antibodies
|
|
US20190233533A1
(en)
|
2016-06-28 |
2019-08-01 |
Umc Utrecht Holding B.V. |
Treatment Of IgE-Mediated Diseases With Antibodies That Specifically Bind CD38
|
|
WO2018005706A1
(en)
|
2016-06-28 |
2018-01-04 |
Xencor, Inc. |
Heterodimeric antibodies that bind somatostatin receptor 2
|
|
EP3478830B1
(en)
|
2016-07-01 |
2024-04-10 |
Resolve Therapeutics, LLC |
Optimized binuclease fusions and methods
|
|
CN109415435B
(zh)
|
2016-07-04 |
2024-01-16 |
豪夫迈·罗氏有限公司 |
新型抗体形式
|
|
US11091557B2
(en)
|
2016-07-14 |
2021-08-17 |
Genmab A/S |
Methods of producing multispecific antibodies against CD40 and CD137
|
|
JP7219376B2
(ja)
|
2016-07-15 |
2023-02-08 |
ノバルティス アーゲー |
キメラ抗原受容体をキナーゼ阻害薬と併用して使用したサイトカイン放出症候群の治療及び予防
|
|
AU2017296040C1
(en)
|
2016-07-15 |
2023-06-22 |
Acceleron Pharma Inc. |
Compositions and methods for treating pulmonary hypertension
|
|
CN109476763B
(zh)
*
|
2016-07-19 |
2023-11-07 |
伊班绰斯有限责任公司 |
双特异性蛋白质及其制备方法
|
|
WO2018014260A1
(en)
|
2016-07-20 |
2018-01-25 |
Nanjing Legend Biotech Co., Ltd. |
Multispecific antigen binding proteins and methods of use thereof
|
|
KR102435801B1
(ko)
|
2016-07-22 |
2022-08-25 |
암젠 인크 |
Fc-함유 단백질의 정제 방법
|
|
CA3031909A1
(en)
|
2016-07-27 |
2018-02-01 |
Acceleron Pharma Inc. |
Methods and compositions for treating myelofibrosis
|
|
AU2017302668B9
(en)
|
2016-07-28 |
2023-06-22 |
Novartis Ag |
Combination therapies of chimeric antigen receptors and PD-1 inhibitors
|
|
EP3492496A4
(en)
|
2016-07-29 |
2020-07-29 |
Chugai Seiyaku Kabushiki Kaisha |
BISPECIFIC ANTIBODIES PRESENTING AN INCREASED ALTERNATIVE FUNCTIONAL ACTIVITY OF COFACTOR FVIII
|
|
BR112019002035A2
(pt)
|
2016-08-01 |
2019-05-14 |
Novartis Ag |
tratamento de câncer usando um receptor de antígeno quimérico em combinação com um inibidor de uma molécula pró-macrófago m2
|
|
WO2018026942A1
(en)
*
|
2016-08-02 |
2018-02-08 |
Merrimack Pharmaceuticals, Inc. |
Heteromeric polypeptides
|
|
IL264626B
(en)
|
2016-08-05 |
2022-07-01 |
Chugai Pharmaceutical Co Ltd |
Composition for prophylaxis or treatment of il-8 related diseases
|
|
CN109963871A
(zh)
|
2016-08-05 |
2019-07-02 |
豪夫迈·罗氏有限公司 |
具有激动活性的多价及多表位抗体以及使用方法
|
|
BR112019002394B1
(pt)
|
2016-08-10 |
2021-12-21 |
Ajou University Industry-Academic Cooperation Foundation |
Proteína heterodimérica fundida com fc e seu uso
|
|
JP7093767B2
(ja)
|
2016-08-11 |
2022-06-30 |
ジェネンテック， インコーポレイテッド |
ピロロベンゾジアゼピンプロドラッグ及びその抗体コンジュゲート
|
|
JP7125347B2
(ja)
|
2016-08-22 |
2022-08-24 |
中外製薬株式会社 |
ヒトｇｐｃ３ポリペプチドを発現する遺伝子改変非ヒト動物
|
|
US10793632B2
(en)
|
2016-08-30 |
2020-10-06 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
|
SG10201607778XA
(en)
|
2016-09-16 |
2018-04-27 |
Chugai Pharmaceutical Co Ltd |
Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
|
|
CN109689682B
(zh)
|
2016-09-19 |
2022-11-29 |
豪夫迈·罗氏有限公司 |
基于补体因子的亲和层析
|
|
NZ790629A
(en)
|
2016-09-23 |
2025-11-28 |
Genentech Inc |
Uses of il-13 antagonists for treating atopic dermatitis
|
|
BR112019006074A2
(pt)
|
2016-09-29 |
2019-06-18 |
Beijing Hanmi Pharmaceutical Co., Ltd. |
heterodímero, método de produção do heterodímero, métodos de produção de um heterodímero, ácido nucleico, vetor ou sistema de vetores, célula, composição farmacêutica e método de tratamento ou prevenção de uma doença ou distúrbio em um sujeito em necessidade do mesmo
|
|
JP6785372B2
(ja)
|
2016-09-30 |
2020-11-18 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
多重特異性分子の機能分析のためのｓｐｒに基づく二重結合アッセイ
|
|
EP3519437B1
(en)
|
2016-09-30 |
2021-09-08 |
F. Hoffmann-La Roche AG |
Bispecific antibodies against p95her2
|
|
WO2018065501A1
(en)
|
2016-10-05 |
2018-04-12 |
F. Hoffmann-La Roche Ag |
Methods for preparing antibody drug conjugates
|
|
KR20190075078A
(ko)
|
2016-10-05 |
2019-06-28 |
악셀레론 파마 인코포레이티드 |
ALK4:ActRIIB 이형다량체 및 이의 용도
|
|
KR102595559B1
(ko)
|
2016-10-05 |
2023-10-30 |
악셀레론 파마 인코포레이티드 |
변이체 actriib 단백질 및 이의 용도
|
|
EP4026556B1
(en)
|
2016-10-05 |
2025-07-30 |
Acceleron Pharma Inc. |
Compositions for use in treating kidney fibrosis in kidney disease
|
|
MX2019003934A
(es)
|
2016-10-06 |
2019-07-10 |
Genentech Inc |
Métodos terapéuticos y de diagnóstico para el cáncer.
|
|
SG10201913823VA
(en)
|
2016-10-07 |
2020-03-30 |
Novartis Ag |
Chimeric antigen receptors for the treatment of cancer
|
|
WO2018068201A1
(en)
|
2016-10-11 |
2018-04-19 |
Nanjing Legend Biotech Co., Ltd. |
Single-domain antibodies and variants thereof against ctla-4
|
|
MX2019004327A
(es)
|
2016-10-14 |
2019-10-14 |
Xencor Inc |
Proteinas de fusion heterodimericas biespecificas que contienen proteinas de fusion fc il-15/il-15ra y fragmentos de anticuerpo pd-1.
|
|
WO2018075692A2
(en)
|
2016-10-19 |
2018-04-26 |
Invenra Inc. |
Antibody constructs
|
|
EP3532091A2
(en)
|
2016-10-29 |
2019-09-04 |
H. Hoffnabb-La Roche Ag |
Anti-mic antibidies and methods of use
|
|
CN110461868A
(zh)
|
2016-11-01 |
2019-11-15 |
根马布私人有限公司 |
多肽变体及其用途
|
|
JP2019534044A
(ja)
|
2016-11-08 |
2019-11-28 |
クイル ピュージェット サウンド バイオセラピューティクス コーポレーション |
抗ｐｄ１および抗ｃｔｌａ４抗体
|
|
CN110461349B
(zh)
|
2016-11-10 |
2024-08-13 |
科乐斯疗法公司 |
激活素受体iia型变体及其使用方法
|
|
US20230137351A1
(en)
|
2016-11-14 |
2023-05-04 |
Amgen Inc. |
Bispecific or biparatopic antigen binding proteins and uses thereof
|
|
WO2018093821A1
(en)
|
2016-11-15 |
2018-05-24 |
Genentech, Inc. |
Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
|
|
TN2019000161A1
(en)
|
2016-11-18 |
2020-10-05 |
Beijing Hanmi Pharmaceutical Co Ltd |
Anti-pd-1/anti-her2 natural antibody structure-like bispecific antibody of heterodimeric form and preparation thereof
|
|
TW201829463A
(zh)
|
2016-11-18 |
2018-08-16 |
瑞士商赫孚孟拉羅股份公司 |
抗hla-g抗體及其用途
|
|
JOP20190100A1
(ar)
|
2016-11-19 |
2019-05-01 |
Potenza Therapeutics Inc |
بروتينات ربط مولد ضد مضاد لـ gitr وطرق استخدامها
|
|
EP3545002A2
(en)
|
2016-11-23 |
2019-10-02 |
Bioverativ Therapeutics Inc. |
Mono- and bispecific antibodies binding to coagulation factor ix and coagulation factor x
|
|
KR20230146126A
(ko)
|
2016-12-07 |
2023-10-18 |
제넨테크, 인크. |
항-타우 항체 및 이의 이용 방법
|
|
CA3045294A1
(en)
|
2016-12-07 |
2018-06-14 |
Genentech, Inc. |
Anti-tau antibodies and methods of use
|
|
EP3555620A1
(en)
|
2016-12-13 |
2019-10-23 |
H. Hoffnabb-La Roche Ag |
Method to determine the presence of a target antigen in a tumor sample
|
|
MX2019006955A
(es)
|
2016-12-19 |
2019-08-01 |
Hoffmann La Roche |
Terapia de combinacion con agonistas de 4-1bb orientados (cd137).
|
|
EP3559034B1
(en)
|
2016-12-20 |
2020-12-02 |
H. Hoffnabb-La Roche Ag |
Combination therapy of anti-cd20/anti-cd3 bispecific antibodies and 4-1bb (cd137) agonists
|
|
CN110088292A
(zh)
|
2016-12-21 |
2019-08-02 |
豪夫迈·罗氏有限公司 |
用于体外糖工程化抗体的方法
|
|
EP3559666A1
(en)
|
2016-12-21 |
2019-10-30 |
H. Hoffnabb-La Roche Ag |
Assay for determining antibody or ligand binding and function
|
|
EP3559248B2
(en)
|
2016-12-21 |
2024-11-20 |
F. Hoffmann-La Roche AG |
In vitro glycoengineering of antibodies
|
|
CN110100007B
(zh)
|
2016-12-21 |
2024-05-28 |
豪夫迈·罗氏有限公司 |
用于体外糖工程化抗体的酶的再使用
|
|
EP3360898A1
(en)
|
2017-02-14 |
2018-08-15 |
Boehringer Ingelheim International GmbH |
Bispecific anti-tnf-related apoptosis-inducing ligand receptor 2 and anti-cadherin 17 binding molecules for the treatment of cancer
|
|
US20190322767A1
(en)
|
2016-12-23 |
2019-10-24 |
Innate Pharma |
Heterodimeric antigen binding proteins
|
|
EP3565843A1
(en)
|
2017-01-03 |
2019-11-13 |
H. Hoffnabb-La Roche Ag |
Bispecific antigen binding molecules comprising anti-4-1bb clone 20h4.9
|
|
SG10202107391YA
(en)
|
2017-01-06 |
2021-08-30 |
Momenta Pharmaceuticals Inc |
Compositions and methods related to engineered fc constructs
|
|
US11274157B2
(en)
|
2017-01-12 |
2022-03-15 |
Eureka Therapeutics, Inc. |
Constructs targeting histone H3 peptide/MHC complexes and uses thereof
|
|
WO2018140725A1
(en)
|
2017-01-26 |
2018-08-02 |
Novartis Ag |
Cd28 compositions and methods for chimeric antigen receptor therapy
|
|
US20190367611A1
(en)
|
2017-02-01 |
2019-12-05 |
CentryMed Pharmaceutical Inc. |
Monomeric human igg1 fc and bispecific antibodies
|
|
BR112019016204A2
(pt)
|
2017-02-07 |
2020-07-07 |
Daiichi Sankyo Company, Limited |
anticorpo ou fragmento de ligação a antígeno do anticorpo, polinucleotídeo, vetor, célula, imunócito artificial, métodos para produzir um anticorpo ou um fragmento de ligação a antígeno do anticorpo, para produzir uma molécula que se liga ao cd3 humano e cd3 de macaco cinomolgo e ao gprc5d humano, composição medicinal para tratamento e/ou prevenção, moléculas tendo atividade de ligação a antígeno e que se ligam ao cd3 humano e cd3 de macaco cinomolgo e ao gprc5d humano, e, usos para preparar um medicamento para tratar e/ou prevenir um câncer, para induzir citotoxicidade para as células expressando gprc5d e para redirecionamento de células t para as células expressando gprc5d
|
|
US11834506B2
(en)
|
2017-02-08 |
2023-12-05 |
Dragonfly Therapeutics, Inc. |
Multi-specific binding proteins that bind NKG2D, CD16, and a tumor-associated antigen for activation of natural killer cells and therapeutic uses thereof to treat cancer
|
|
KR20190115469A
(ko)
*
|
2017-02-10 |
2019-10-11 |
드래곤플라이 쎄라퓨틱스, 인크. |
Bcma, nkg2d 및 cd16에 결합하는 단백질
|
|
MA47459A
(fr)
|
2017-02-10 |
2019-12-18 |
Hoffmann La Roche |
Anticorps anti-tryptase, compositions les contenant et leurs utilisations
|
|
UA128814C2
(uk)
|
2017-02-10 |
2024-10-30 |
Генмаб Б.В. |
Поліпептид та його застосування
|
|
WO2018151820A1
(en)
|
2017-02-16 |
2018-08-23 |
Elstar Therapeutics, Inc. |
Multifunctional molecules comprising a trimeric ligand and uses thereof
|
|
ES2955074T3
(es)
|
2017-02-20 |
2023-11-28 |
Dragonfly Therapeutics Inc |
Proteínas que se unen a HER2, NKG2D Y CD16
|
|
JP7556687B2
(ja)
|
2017-02-24 |
2024-09-26 |
中外製薬株式会社 |
薬学的組成物、抗原結合分子、治療方法、およびスクリーニング方法
|
|
PL3589754T3
(pl)
|
2017-03-01 |
2023-10-09 |
F. Hoffmann-La Roche Ag |
Sposoby diagnostyczne i terapeutyczne w chorobach nowotworowych
|
|
US11685776B2
(en)
|
2017-03-02 |
2023-06-27 |
Novartis Ag |
Engineered heterodimeric proteins
|
|
KR102745587B1
(ko)
|
2017-03-09 |
2024-12-24 |
젠맵 에이/에스 |
Pd-l1에 대한 항체
|
|
PE20191360A1
(es)
|
2017-03-10 |
2019-10-01 |
Hoffmann La Roche |
Metodo para producir anticuerpos multiespecificos
|
|
MX2019011141A
(es)
|
2017-03-22 |
2019-11-05 |
Genentech Inc |
Composiciones de anticuerpo optimizadas para el tratamiento de trastornos oculares.
|
|
SG11201908547VA
(en)
|
2017-03-22 |
2019-10-30 |
Genentech Inc |
Hydrogel cross-linked hyaluronic acid prodrug compositions and methods
|
|
SG10201911225WA
(en)
|
2017-03-28 |
2020-01-30 |
Genentech Inc |
Methods of treating neurodegenerative diseases
|
|
JP7205995B2
(ja)
|
2017-03-29 |
2023-01-17 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
共刺激性ｔｎｆ受容体に対する二重特異性抗原結合分子
|
|
CN110573528B
(zh)
|
2017-03-29 |
2023-06-09 |
豪夫迈·罗氏有限公司 |
针对共刺激性tnf受体的双特异性抗原结合分子
|
|
EA201992063A1
(ru)
|
2017-03-31 |
2020-03-26 |
Мерус Н.В. |
СВЯЗЫВАЮЩИЕ ErbB-2 И ErbB-3 БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА ДЛЯ ПРИМЕНЕНИЯ ДЛЯ ЛЕЧЕНИЯ КЛЕТОК, КОТОРЫЕ СОДЕРЖАТ СЛИТЫЙ ГЕН NRG-1
|
|
IL269645B2
(en)
|
2017-03-31 |
2025-05-01 |
Genmab Holding B V |
Bispecific anti-cd37 antibodies, monoclonal anti-cd37 antibodies and methods of use thereof
|
|
JP7579703B2
(ja)
|
2017-04-01 |
2024-11-08 |
北京韓美薬品有限公司 |
抗ｐｄ－ｌ１／抗ｐｄ－１天然抗体構造様ヘテロダイマー二重特異性抗体およびその調製方法
|
|
EP3606946B1
(en)
|
2017-04-03 |
2022-08-24 |
F. Hoffmann-La Roche AG |
Immunoconjugates of an anti-pd-1 antibody with a mutant il-2 or with il-15
|
|
MX2019011769A
(es)
|
2017-04-03 |
2019-11-07 |
Hoffmann La Roche |
Anticuerpos que se unen a steap-1.
|
|
CN110382525B
(zh)
|
2017-04-03 |
2023-10-20 |
豪夫迈·罗氏有限公司 |
免疫缀合物
|
|
CN110914300A
(zh)
|
2017-04-03 |
2020-03-24 |
安康乐济股份有限公司 |
使用ps靶向抗体与免疫肿瘤学药剂治疗癌症的方法
|
|
MA49039A
(fr)
|
2017-04-04 |
2020-02-12 |
Hoffmann La Roche |
Nouvelles molécules bispécifiques de liaison à l'antigène capables de se lier spécifiquement à cd40 et à fap
|
|
IL268527B2
(en)
|
2017-04-05 |
2024-03-01 |
Hoffmann La Roche |
Bispecific antibodies specifically binding to pd1 and lag3
|
|
DK3606954T3
(en)
|
2017-04-05 |
2022-09-26 |
Hoffmann La Roche |
Anti-LAG3-antistoffer
|
|
CN110770255B
(zh)
|
2017-04-11 |
2025-07-01 |
因荷布瑞克斯生物科学公司 |
具有受限cd3结合的多特异性多肽构建体及其使用方法
|
|
KR20190136076A
(ko)
|
2017-04-13 |
2019-12-09 |
에프. 호프만-라 로슈 아게 |
암 치료 방법에 사용하기 위한 인터루킨-2 면역접합체, cd40 작용제 및 임의적인 pd-1 축 결합 길항제
|
|
JOP20190248A1
(ar)
|
2017-04-21 |
2019-10-20 |
Amgen Inc |
بروتينات ربط مولد ضد trem2 واستخداماته
|
|
KR20190141686A
(ko)
|
2017-04-21 |
2019-12-24 |
제넨테크, 인크. |
질환 치료를 위한 klk5 길항제의 용도
|
|
WO2018200586A1
(en)
|
2017-04-26 |
2018-11-01 |
Eureka Therapeutics, Inc. |
Constructs specifically recognizing glypican 3 and uses thereof
|
|
US20200179511A1
(en)
|
2017-04-28 |
2020-06-11 |
Novartis Ag |
Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
|
|
US20200055948A1
(en)
|
2017-04-28 |
2020-02-20 |
Novartis Ag |
Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
|
|
AU2018271157C1
(en)
|
2017-05-17 |
2021-11-18 |
Merus N.V. |
Combination of an ErbB-2/ErbB-3 bispecific antibody with endocrine therapy for breast cancer
|
|
WO2018222901A1
(en)
|
2017-05-31 |
2018-12-06 |
Elstar Therapeutics, Inc. |
Multispecific molecules that bind to myeloproliferative leukemia (mpl) protein and uses thereof
|
|
CN111328335A
(zh)
|
2017-06-07 |
2020-06-23 |
根马布私人有限公司 |
基于突变igg六聚体的治疗性抗体
|
|
UY37758A
(es)
|
2017-06-12 |
2019-01-31 |
Novartis Ag |
Método de fabricación de anticuerpos biespecíficos, anticuerpos biespecíficos y uso terapéutico de dichos anticuerpos
|
|
WO2018237157A1
(en)
|
2017-06-22 |
2018-12-27 |
Novartis Ag |
CD73 BINDING ANTIBODY MOLECULES AND USES THEREOF
|
|
JP2020525483A
(ja)
|
2017-06-27 |
2020-08-27 |
ノバルティス アーゲー |
抗ｔｉｍ−３抗体のための投与レジメンおよびその使用
|
|
EP3645122A1
(en)
|
2017-06-30 |
2020-05-06 |
Xencor, Inc. |
Targeted heterodimeric fc fusion proteins containing il-15/il-15ra and antigen binding domains
|
|
AR112603A1
(es)
|
2017-07-10 |
2019-11-20 |
Lilly Co Eli |
Anticuerpos biespecíficos inhibidores de punto de control
|
|
CN111278858B
(zh)
|
2017-07-11 |
2024-07-23 |
指南针制药有限责任公司 |
结合人cd137的激动剂抗体及其用途
|
|
IL319798A
(en)
|
2017-07-20 |
2025-05-01 |
Novartis Ag |
ANTI-LAG-3 Antibody Dosage Regimens and Their Uses
|
|
MX2020000604A
(es)
|
2017-07-21 |
2020-09-10 |
Genentech Inc |
Métodos terapéuticos y de diagnóstico para el cáncer.
|
|
JP7122370B2
(ja)
|
2017-07-26 |
2022-08-19 |
フォーティ セブン， インコーポレイテッド |
抗ｓｉｒｐ－アルファ抗体及び関連方法
|
|
KR102758346B1
(ko)
|
2017-08-04 |
2025-01-24 |
젠맵 에이/에스 |
Pd-l1 및 cd137에 결합하는 결합제 및 그의 용도
|
|
TWI874301B
(zh)
|
2017-08-09 |
2025-03-01 |
荷蘭商美勒斯公司 |
結合表皮生長因子受體(EGFR)及cMET的抗體
|
|
AU2018316343B2
(en)
|
2017-08-11 |
2025-06-12 |
Genentech, Inc. |
Anti-CD8 antibodies and uses thereof
|
|
AU2018321359B2
(en)
|
2017-08-22 |
2023-11-30 |
Sanabio, Llc |
Soluble interferon receptors and uses thereof
|
|
MX2020002710A
(es)
|
2017-09-29 |
2020-07-20 |
Chugai Pharmaceutical Co Ltd |
Molecula de union al antigeno multiespecifica que tiene actividad de sustitucion de la funcion de cofactor del factor viii de coagulacion de sangre (fviii) y formulacion farmaceutica que contiene tal molecula como ingrediente activo.
|
|
EP3694890A4
(en)
|
2017-10-12 |
2021-11-03 |
Immunowake Inc. |
VEGFR ANTIBODY LIGHT CHAIN FUSION PROTEIN
|
|
TW201932142A
(zh)
|
2017-10-20 |
2019-08-16 |
瑞士商赫孚孟拉羅股份公司 |
自單特異性抗體產生多特異性抗體之方法
|
|
IL274071B2
(en)
*
|
2017-10-30 |
2025-10-01 |
Hoffmann La Roche |
Method for generating in vivo multispecific antibodies from monospecific antibodies
|
|
WO2019089753A2
(en)
|
2017-10-31 |
2019-05-09 |
Compass Therapeutics Llc |
Cd137 antibodies and pd-1 antagonists and uses thereof
|
|
EP3703821A2
(en)
|
2017-11-01 |
2020-09-09 |
F. Hoffmann-La Roche AG |
Bispecific 2+1 contorsbodies
|
|
MX2020004196A
(es)
|
2017-11-01 |
2020-11-09 |
Hoffmann La Roche |
Trifab-contorsbody.
|
|
IL274265B1
(en)
|
2017-11-01 |
2025-09-01 |
Chugai Pharmaceutical Co Ltd |
Variant and isoform of an antibody with attenuated biological activity
|
|
JP2021500902A
(ja)
|
2017-11-01 |
2021-01-14 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
新規ｔｎｆファミリーリガンド三量体含有抗原結合分子
|
|
BR112020007630A2
(pt)
|
2017-11-01 |
2020-11-17 |
F. Hoffmann-La Roche Ag |
anticorpo biespecífico ox40, produto farmacêutico, composição farmacêutica e anticorpos biespecíficos anti-fap/ anti-ox40
|
|
EP3704150A1
(en)
|
2017-11-01 |
2020-09-09 |
F. Hoffmann-La Roche AG |
The compbody - a multivalent target binder
|
|
TW201923089A
(zh)
|
2017-11-06 |
2019-06-16 |
美商建南德克公司 |
癌症之診斷及治療方法
|
|
US10981992B2
(en)
|
2017-11-08 |
2021-04-20 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
|
WO2019094637A1
(en)
|
2017-11-08 |
2019-05-16 |
Xencor, Inc. |
Bispecific and monospecific antibodies using novel anti-pd-1 sequences
|
|
EP3706777B1
(en)
|
2017-11-09 |
2024-05-22 |
Keros Therapeutics, Inc. |
Activin receptor type iia variants and methods of use thereof
|
|
JP7731196B2
(ja)
|
2017-11-14 |
2025-08-29 |
中外製薬株式会社 |
抗Ｃ１ｓ抗体および使用方法
|
|
WO2019099838A1
(en)
|
2017-11-16 |
2019-05-23 |
Novartis Ag |
Combination therapies
|
|
EP3713961A2
(en)
|
2017-11-20 |
2020-09-30 |
Compass Therapeutics LLC |
Cd137 antibodies and tumor antigen-targeting antibodies and uses thereof
|
|
CA3079363A1
(en)
|
2017-11-21 |
2019-05-31 |
Innate Pharma |
Multispecific antigen binding proteins
|
|
SG11202005732XA
(en)
|
2017-12-19 |
2020-07-29 |
Xencor Inc |
Engineered il-2 fc fusion proteins
|
|
AR114001A1
(es)
|
2017-12-21 |
2020-07-08 |
Hoffmann La Roche |
Anticuerpos que se unen a hla- a2 / wt1
|
|
EP3502140A1
(en)
|
2017-12-21 |
2019-06-26 |
F. Hoffmann-La Roche AG |
Combination therapy of tumor targeted icos agonists with t-cell bispecific molecules
|
|
WO2019122054A1
(en)
|
2017-12-22 |
2019-06-27 |
F. Hoffmann-La Roche Ag |
Depletion of light chain mispaired antibody variants by hydrophobic interaction chromatography
|
|
US20190211098A1
(en)
|
2017-12-22 |
2019-07-11 |
Genentech, Inc. |
Use of pilra binding agents for treatment of a disease
|
|
CA3078849A1
(en)
|
2017-12-28 |
2019-07-04 |
Nanjing Legend Biotech Co., Ltd. |
Antibodies and variants thereof against pd-l1
|
|
JP7369127B2
(ja)
|
2017-12-28 |
2023-10-25 |
ナンジン レジェンド バイオテック カンパニー，リミテッド |
Ｔｉｇｉｔに対する単一ドメイン抗体及びその変異体
|
|
CN119431582A
(zh)
|
2017-12-29 |
2025-02-14 |
艾莱克特有限责任公司 |
抗tmem106b抗体及其使用方法
|
|
WO2019129679A1
(en)
|
2017-12-29 |
2019-07-04 |
F. Hoffmann-La Roche Ag |
Method for improving vegf-receptor blocking selectivity of an anti-vegf antibody
|
|
CN118955720A
(zh)
|
2018-01-04 |
2024-11-15 |
伊科尼克治疗公司 |
抗组织因子抗体、抗体-药物缀合物及相关方法
|
|
US12247060B2
(en)
|
2018-01-09 |
2025-03-11 |
Marengo Therapeutics, Inc. |
Calreticulin binding constructs and engineered T cells for the treatment of diseases
|
|
JP7394767B2
(ja)
|
2018-01-12 |
2023-12-08 |
ジェンザイム・コーポレーション |
ポリペプチドの定量化方法
|
|
TWI802633B
(zh)
|
2018-01-15 |
2023-05-21 |
大陸商南京傳奇生物科技有限公司 |
針對pd-1之單域抗體及其變異體
|
|
WO2019143636A1
(en)
|
2018-01-16 |
2019-07-25 |
Lakepharma, Inc. |
Bispecific antibody that binds cd3 and another target
|
|
WO2019145455A1
(en)
|
2018-01-24 |
2019-08-01 |
Genmab B.V. |
Polypeptide variants and uses thereof
|
|
US20210038659A1
(en)
|
2018-01-31 |
2021-02-11 |
Novartis Ag |
Combination therapy using a chimeric antigen receptor
|
|
US20200354457A1
(en)
|
2018-01-31 |
2020-11-12 |
Hoffmann-La Roche Inc. |
Bispecific antibodies comprising an antigen-binding site binding to lag3
|
|
US11472874B2
(en)
|
2018-01-31 |
2022-10-18 |
Alector Llc |
Anti-MS4A4A antibodies and methods of use thereof
|
|
CN111630063A
(zh)
|
2018-01-31 |
2020-09-04 |
豪夫迈·罗氏有限公司 |
稳定化的免疫球蛋白结构域
|
|
WO2019148410A1
(en)
|
2018-02-01 |
2019-08-08 |
Merck Sharp & Dohme Corp. |
Anti-pd-1 antibodies
|
|
WO2019148412A1
(en)
|
2018-02-01 |
2019-08-08 |
Merck Sharp & Dohme Corp. |
Anti-pd-1/lag3 bispecific antibodies
|
|
CN111699004A
(zh)
|
2018-02-06 |
2020-09-22 |
豪夫迈·罗氏有限公司 |
眼科疾病的治疗
|
|
ES2986967T3
(es)
|
2018-02-08 |
2024-11-13 |
Dragonfly Therapeutics Inc |
Combinaciones de dominios variables de anticuerpos dirigidas al receptor NKG2D
|
|
MX2020008333A
(es)
|
2018-02-08 |
2020-09-21 |
Dragonfly Therapeutics Inc |
Terapia de combinacion del cancer que incluye proteinas de union multiespecificas que activan a las celulas asesinas naturales.
|
|
MA51793A
(fr)
|
2018-02-08 |
2020-12-16 |
Hoffmann La Roche |
Molécules bispécifiques de liaison à l'antigène et procédés d'utilisation
|
|
WO2019153200A1
(zh)
|
2018-02-08 |
2019-08-15 |
北京韩美药品有限公司 |
抗pd-1/抗her2天然抗体结构样异源二聚体形式双特异抗体及其制备
|
|
MA51741A
(fr)
|
2018-02-09 |
2021-05-19 |
Hoffmann La Roche |
Procédés thérapeutiques et de diagnostic pour des maladies inflammatoires médiées par des mastocytes
|
|
TWI829667B
(zh)
|
2018-02-09 |
2024-01-21 |
瑞士商赫孚孟拉羅股份公司 |
結合gprc5d之抗體
|
|
EP3750920A4
(en)
|
2018-02-11 |
2021-11-10 |
Beijing Hanmi Pharmaceutical Co., Ltd. |
BISPECIFIC ANTIBODY WITH HETERODIMERAL FORM SIMILAR TO A NATURAL ANTI-PD-1 / ANTI-VEGF ANTIBODY STRUCTURE AND ASSOCIATED PREPARATION
|
|
US20200399373A1
(en)
|
2018-02-14 |
2020-12-24 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule and combination
|
|
BR112020016939A2
(pt)
|
2018-02-20 |
2020-12-15 |
Dragonfly Therapeutics, Inc. |
Proteínas de ligação multiespecíficas que se ligam a cd33, nkg2d, e cd16 e métodos de uso
|
|
CN111971298B
(zh)
|
2018-03-12 |
2025-06-20 |
健玛保 |
抗体
|
|
BR112020015568A2
(pt)
|
2018-03-13 |
2020-12-29 |
F. Hoffmann-La Roche Ag |
Agonista de 4-1bb (cd137), produto farmacêutico, composição farmacêutica, uso de uma combinação de um agonista de 4-1bb e método para tratar ou retardar a progressão do câncer
|
|
TWI841551B
(zh)
|
2018-03-13 |
2024-05-11 |
瑞士商赫孚孟拉羅股份公司 |
使用靶向4-1bb (cd137)之促效劑的組合療法
|
|
US20210009711A1
(en)
|
2018-03-14 |
2021-01-14 |
Elstar Therapeutics, Inc. |
Multifunctional molecules and uses thereof
|
|
US20200040103A1
(en)
|
2018-03-14 |
2020-02-06 |
Genentech, Inc. |
Anti-klk5 antibodies and methods of use
|
|
WO2019178362A1
(en)
|
2018-03-14 |
2019-09-19 |
Elstar Therapeutics, Inc. |
Multifunctional molecules that bind to calreticulin and uses thereof
|
|
TWI827585B
(zh)
|
2018-03-15 |
2024-01-01 |
日商中外製藥股份有限公司 |
對茲卡病毒具有交叉反應性的抗登革病毒抗體及其使用方法
|
|
AR115318A1
(es)
|
2018-03-29 |
2020-12-23 |
Genentech Inc |
Modulación de la actividad lactogénica en células de mamífero
|
|
KR102876940B1
(ko)
|
2018-03-30 |
2025-10-24 |
난징 레전드 바이오테크 씨오., 엘티디. |
Lag-3에 대한 단일-도메인 항체 및 이의 용도
|
|
JP7104458B2
(ja)
|
2018-04-02 |
2022-07-21 |
上海博威生物医薬有限公司 |
リンパ球活性化遺伝子－３（ｌａｇ－３）結合抗体およびその使用
|
|
TW202011029A
(zh)
|
2018-04-04 |
2020-03-16 |
美商建南德克公司 |
偵測及定量fgf21之方法
|
|
EP3773911A2
(en)
|
2018-04-04 |
2021-02-17 |
Xencor, Inc. |
Heterodimeric antibodies that bind fibroblast activation protein
|
|
MA52205A
(fr)
|
2018-04-09 |
2021-02-17 |
Amgen Inc |
Protéines de fusion du facteur de différenciation de croissance 15
|
|
MX2020010638A
(es)
|
2018-04-11 |
2021-01-08 |
Inhibrx Inc |
Constructos de polipeptidos multiespecificos que tienen union a cd3 restringida y metodos y usos relacionados.
|
|
US20210147547A1
(en)
|
2018-04-13 |
2021-05-20 |
Novartis Ag |
Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof
|
|
EP3774900A1
(en)
|
2018-04-13 |
2021-02-17 |
F. Hoffmann-La Roche AG |
Her2-targeting antigen binding molecules comprising 4-1bbl
|
|
WO2019204665A1
(en)
|
2018-04-18 |
2019-10-24 |
Xencor, Inc. |
Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof
|
|
AU2019256529A1
(en)
|
2018-04-18 |
2020-11-26 |
Xencor, Inc. |
TIM-3 targeted heterodimeric fusion proteins containing IL-15/IL-15Ra Fc-fusion proteins and TIM-3 antigen binding domains
|
|
AR115052A1
(es)
|
2018-04-18 |
2020-11-25 |
Hoffmann La Roche |
Anticuerpos multiespecíficos y utilización de los mismos
|
|
AR114789A1
(es)
|
2018-04-18 |
2020-10-14 |
Hoffmann La Roche |
Anticuerpos anti-hla-g y uso de los mismos
|
|
KR20210003813A
(ko)
|
2018-04-18 |
2021-01-12 |
젠코어 인코포레이티드 |
IL-15/IL-15Rα Fc-융합 단백질 및 LAG-3 항원 결합 도메인을 함유하는 LAG-3 표적화 이종이량체 융합 단백질
|
|
CN112105645A
(zh)
|
2018-04-18 |
2020-12-18 |
Xencor股份有限公司 |
Il-15/il-15ra异二聚体fc融合蛋白及其用途
|
|
EP3784351A1
(en)
|
2018-04-27 |
2021-03-03 |
Novartis AG |
Car t cell therapies with enhanced efficacy
|
|
MA52485A
(fr)
|
2018-05-03 |
2021-03-10 |
Genmab Bv |
Combinaisons de variants d'anticorps et utilisations associées
|
|
JP7206297B2
(ja)
|
2018-05-18 |
2023-01-17 |
エフ．ホフマン－ラ ロシュ アーゲー |
大核酸の細胞内標的指向送達
|
|
WO2019226658A1
(en)
|
2018-05-21 |
2019-11-28 |
Compass Therapeutics Llc |
Multispecific antigen-binding compositions and methods of use
|
|
JP2021525243A
(ja)
|
2018-05-21 |
2021-09-24 |
コンパス セラピューティクス リミテッド ライアビリティ カンパニー |
Ｎｋ細胞による標的細胞の殺傷を増進するための組成物および方法
|
|
EP3802602A1
(en)
|
2018-05-25 |
2021-04-14 |
Alector LLC |
Anti-sirpa antibodies and methods of use thereof
|
|
WO2019227003A1
(en)
|
2018-05-25 |
2019-11-28 |
Novartis Ag |
Combination therapy with chimeric antigen receptor (car) therapies
|
|
WO2019232244A2
(en)
|
2018-05-31 |
2019-12-05 |
Novartis Ag |
Antibody molecules to cd73 and uses thereof
|
|
PE20210320A1
(es)
|
2018-06-01 |
2021-02-16 |
Novartis Ag |
Moleculas de union contra bcma y usos de las mismas
|
|
TW202519270A
(zh)
|
2018-06-07 |
2025-05-16 |
美商思進公司 |
喜樹鹼結合物
|
|
TWI848953B
(zh)
|
2018-06-09 |
2024-07-21 |
德商百靈佳殷格翰國際股份有限公司 |
針對癌症治療之多特異性結合蛋白
|
|
JP7438988B2
(ja)
|
2018-06-13 |
2024-02-27 |
ノバルティス アーゲー |
Ｂｃｍａキメラ抗原受容体及びその使用
|
|
AU2019288136A1
(en)
|
2018-06-18 |
2021-01-07 |
Eureka Therapeutics, Inc. |
Constructs targeting prostate-specific membrane antigen (PSMA) and uses thereof
|
|
KR20210035173A
(ko)
|
2018-06-19 |
2021-03-31 |
아타르가, 엘엘씨 |
보체 성분 5에 대한 항체분자 및 이의 용도
|
|
US12275797B2
(en)
|
2018-06-22 |
2025-04-15 |
Genmab Holding B.V. |
Anti-CD37 antibodies and anti-CD20 antibodies, compositions and methods of use thereof
|
|
MA53015A
(fr)
|
2018-06-29 |
2021-05-05 |
Alector Llc |
Anticorps anti-sirp-bêta1 et procédés d'utilisation associés
|
|
CA3105448A1
(en)
|
2018-07-03 |
2020-01-09 |
Elstar Therapeutics, Inc. |
Anti-tcr antibody molecules and uses thereof
|
|
JP2021528988A
(ja)
|
2018-07-04 |
2021-10-28 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
新規の二重特異性アゴニスト４−１ｂｂ抗原結合分子
|
|
AR116109A1
(es)
|
2018-07-10 |
2021-03-31 |
Novartis Ag |
Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
|
|
ES2940311T3
(es)
|
2018-07-13 |
2023-05-05 |
Alector Llc |
Anticuerpos anti-sortilina y métodos de uso de los mismos
|
|
EP3820890A1
(en)
|
2018-07-13 |
2021-05-19 |
Genmab A/S |
Trogocytosis-mediated therapy using cd38 antibodies
|
|
SG11202012993SA
(en)
|
2018-07-13 |
2021-02-25 |
Genmab As |
Variants of cd38 antibody and uses thereof
|
|
WO2020018879A1
(en)
|
2018-07-20 |
2020-01-23 |
Surface Oncology, Inc. |
Anti-cd112r compositions and methods
|
|
JP7651450B2
(ja)
|
2018-07-24 |
2025-03-26 |
インヒブルクス バイオサイエンシズ インコーポレイテッド |
制約されたｃｄ３結合ドメインおよび受容体結合領域を含有する多重特異性ポリペプチド構築物ならびにそれを使用する方法
|
|
WO2020021465A1
(en)
|
2018-07-25 |
2020-01-30 |
Advanced Accelerator Applications (Italy) S.R.L. |
Method of treatment of neuroendocrine tumors
|
|
KR20210040989A
(ko)
|
2018-08-03 |
2021-04-14 |
추가이 세이야쿠 가부시키가이샤 |
서로 연결된 2개의 항원 결합 도메인을 포함하는 항원 결합 분자
|
|
SG11202100883SA
(en)
|
2018-08-08 |
2021-02-25 |
Dragonfly Therapeutics Inc |
Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use
|
|
EA202091888A1
(ru)
|
2018-08-08 |
2020-10-23 |
Драгонфлай Терапьютикс, Инк. |
Вариабельные домены антител, нацеленные на рецептор nkg2d
|
|
KR102835308B1
(ko)
|
2018-08-08 |
2025-07-21 |
드래곤플라이 쎄라퓨틱스, 인크. |
Nkg2d, cd16 및 종양 관련 항원에 결합하는 단백질
|
|
CA3051549A1
(en)
|
2018-08-09 |
2020-02-09 |
Regeneron Pharmaceuticals, Inc. |
Methods for assessing binding affinity of an antibody variant to the neonatal fc receptor
|
|
WO2020032230A1
(ja)
|
2018-08-10 |
2020-02-13 |
中外製薬株式会社 |
抗ｃｄ１３７抗原結合分子およびその使用
|
|
TW202021618A
(zh)
|
2018-08-17 |
2020-06-16 |
美商２３與我有限公司 |
抗ｉｌ１ｒａｐ抗體及其使用方法
|
|
WO2020045545A1
(ja)
|
2018-08-29 |
2020-03-05 |
中外製薬株式会社 |
抗体半分子、および抗体半分子のホモ二量体形成を抑制する方法
|
|
GB201814281D0
(en)
|
2018-09-03 |
2018-10-17 |
Femtogenix Ltd |
Cytotoxic agents
|
|
AU2019340647A1
(en)
|
2018-09-10 |
2021-03-11 |
Genentech, Inc. |
Systems and methods for affinity capillary electrophoresis
|
|
US11573226B2
(en)
|
2018-09-10 |
2023-02-07 |
Genentech, Inc. |
Systems and methods for affinity capillary electrophoresis
|
|
CN112789293B
(zh)
|
2018-09-10 |
2024-05-10 |
南京传奇生物科技有限公司 |
针对cll1的单结构域抗体及其构建体
|
|
AU2019342099A1
(en)
|
2018-09-19 |
2021-04-08 |
Genentech, Inc. |
Therapeutic and diagnostic methods for bladder cancer
|
|
US11667721B2
(en)
|
2018-09-24 |
2023-06-06 |
Medical College Of Wisconsin, Inc. |
CD30 bispecific antibodies and method of immunotherapy of CD30+ malignancies
|
|
WO2020070041A1
(en)
|
2018-10-01 |
2020-04-09 |
F. Hoffmann-La Roche Ag |
Bispecific antigen binding molecules comprising anti-fap clone 212
|
|
JP2022511396A
(ja)
|
2018-10-01 |
2022-01-31 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
Ｃｄ４０への三価結合を伴う二重特異性抗原結合分子
|
|
SG11202103192RA
(en)
|
2018-10-03 |
2021-04-29 |
Xencor Inc |
Il-12 heterodimeric fc-fusion proteins
|
|
AU2019354105A1
(en)
|
2018-10-04 |
2021-04-29 |
Genmab Holding B.V. |
Pharmaceutical compositions comprising bispecific anti-CD37 antibodies
|
|
JP2022504802A
(ja)
|
2018-10-11 |
2022-01-13 |
インヒブルクス インコーポレイテッド |
５ｔ４シングルドメイン抗体およびその治療組成物
|
|
CA3115285A1
(en)
|
2018-10-11 |
2020-04-16 |
Inhibrx, Inc. |
Pd-1 single domain antibodies and therapeutic compositions thereof
|
|
CA3115089A1
(en)
|
2018-10-11 |
2020-04-16 |
Inhibrx, Inc. |
Dll3 single domain antibodies and therapeutic compositions thereof
|
|
JP2022512684A
(ja)
|
2018-10-11 |
2022-02-07 |
インヒブルクス インコーポレイテッド |
Ｂ７ｈ３シングルドメイン抗体およびその治療用組成物
|
|
MX2021004059A
(es)
|
2018-10-12 |
2021-09-23 |
Xencor Inc |
Proteínas de fusión de il-15/il-15ralfa-fc dirigidas a pd-1 y usos de las mismas en terapias combinadas.
|
|
CA3116324A1
(en)
|
2018-10-18 |
2020-04-23 |
Genentech, Inc. |
Diagnostic and therapeutic methods for sarcomatoid kidney cancer
|
|
BR112021007175A2
(pt)
|
2018-10-23 |
2021-08-10 |
Dragonfly Therapeutics, Inc. |
proteínas fundidas a fc heterodimérico
|
|
CA3115110A1
(en)
|
2018-10-24 |
2020-04-30 |
F. Hoffmann-La Roche Ag |
Conjugated chemical inducers of degradation and methods of use
|
|
US20220170097A1
(en)
|
2018-10-29 |
2022-06-02 |
The Broad Institute, Inc. |
Car t cell transcriptional atlas
|
|
BR112021007946A2
(pt)
|
2018-10-29 |
2021-08-03 |
F. Hoffmann-La Roche Ag |
formulação de anticorpo
|
|
EP3877409A1
(en)
|
2018-11-06 |
2021-09-15 |
Genmab A/S |
Antibody formulation
|
|
CA3119161A1
(en)
|
2018-11-13 |
2020-05-22 |
Compass Therapeutics Llc |
Multispecific binding constructs against checkpoint molecules and uses thereof
|
|
US20230183379A1
(en)
|
2018-11-20 |
2023-06-15 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Bispecific antibody targeting transferrin receptor 1 and soluble antigen
|
|
US20220041719A1
(en)
|
2018-12-05 |
2022-02-10 |
Morphosys Ag |
Multispecific antigen-binding molecules
|
|
KR20210100668A
(ko)
|
2018-12-06 |
2021-08-17 |
제넨테크, 인크. |
항-CD79b 면역접합체, 알킬화제 및 항-CD20 항체를 포함하는 미만성 큰 B-세포 림프종의 조합 요법
|
|
JP2022513198A
(ja)
|
2018-12-10 |
2022-02-07 |
ジェネンテック， インコーポレイテッド |
Ｆｃ含有タンパク質への部位特異的コンジュゲーションのための光架橋性ペプチド
|
|
KR20210105890A
(ko)
|
2018-12-17 |
2021-08-27 |
레비토프 리미티드 |
트윈 면역 세포 인게이저
|
|
TWI874341B
(zh)
|
2018-12-18 |
2025-03-01 |
美商健生生物科技公司 |
產生異二聚體抗體之方法
|
|
WO2020132646A1
(en)
|
2018-12-20 |
2020-06-25 |
Xencor, Inc. |
Targeted heterodimeric fc fusion proteins containing il-15/il-15ra and nkg2d antigen binding domains
|
|
JP2022514290A
(ja)
|
2018-12-20 |
2022-02-10 |
ジェネンテック， インコーポレイテッド |
改変抗体ｆｃおよび使用方法
|
|
AR117327A1
(es)
|
2018-12-20 |
2021-07-28 |
23Andme Inc |
Anticuerpos anti-cd96 y métodos de uso de estos
|
|
CA3122727A1
(en)
|
2018-12-20 |
2020-06-25 |
Novartis Ag |
Pharmaceutical combinations
|
|
WO2020128972A1
(en)
|
2018-12-20 |
2020-06-25 |
Novartis Ag |
Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
|
|
US20200223925A1
(en)
|
2018-12-21 |
2020-07-16 |
Hoffmann-La Roche Inc. |
Tumor-targeted superagonistic cd28 antigen binding molecules
|
|
SG11202105093RA
(en)
|
2018-12-21 |
2021-06-29 |
Hoffmann La Roche |
Tumor-targeted agonistic cd28 antigen binding molecules
|
|
EA202191656A1
(ru)
|
2018-12-21 |
2021-10-26 |
23Эндми, Инк. |
Анти-il-36 антитела и способы их применения
|
|
CN113195056B
(zh)
|
2018-12-21 |
2024-05-07 |
豪夫迈·罗氏有限公司 |
与cd3结合的抗体
|
|
SG11202106525TA
(en)
|
2018-12-24 |
2021-07-29 |
Sanofi Sa |
Multispecific binding proteins with mutant fab domains
|
|
MX2021007677A
(es)
|
2018-12-24 |
2021-12-10 |
Sanofi Sa |
Proteinas de union multiespecificas basadas en pseudofab.
|
|
US20220073630A1
(en)
|
2018-12-28 |
2022-03-10 |
Hoffmann-La Roche, Inc. |
A peptide-mhc-i-antibody fusion protein for therapeutic use in a patient with amplified immune response
|
|
CN113227789B
(zh)
|
2018-12-30 |
2024-12-24 |
豪夫迈·罗氏有限公司 |
基于pH梯度SPR的结合测定
|
|
AU2020204992A1
(en)
|
2019-01-04 |
2021-07-15 |
Resolve Therapeutics, Llc |
Treatment of sjogren's disease with nuclease fusion proteins
|
|
CN113329759A
(zh)
*
|
2019-01-07 |
2021-08-31 |
沙塔克实验室有限公司 |
用于调节γδT细胞的异二聚体蛋白
|
|
TWI852977B
(zh)
|
2019-01-10 |
2024-08-21 |
美商健生生物科技公司 |
前列腺新抗原及其用途
|
|
CA3127025A1
(en)
|
2019-01-18 |
2020-07-23 |
Janssen Biotech, Inc. |
Gprc5d chimeric antigen receptors and cells expressing the same
|
|
US20220089770A1
(en)
|
2019-01-24 |
2022-03-24 |
Chugai Seiyaku Kabushiki Kaisha |
Novel cancer antigens and antibodies of said antigens
|
|
GB201901197D0
(en)
|
2019-01-29 |
2019-03-20 |
Femtogenix Ltd |
G-A Crosslinking cytotoxic agents
|
|
US10871640B2
(en)
|
2019-02-15 |
2020-12-22 |
Perkinelmer Cellular Technologies Germany Gmbh |
Methods and systems for automated imaging of three-dimensional objects
|
|
AU2020222346B2
(en)
|
2019-02-15 |
2021-12-09 |
Novartis Ag |
Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
MX2021009763A
(es)
|
2019-02-15 |
2021-09-08 |
Novartis Ag |
Derivados de 3-(1-oxo-5-(piperidin-4-il)isoindolin-2-il)piperidina -2,6-diona y usos de los mismos.
|
|
WO2020172571A1
(en)
|
2019-02-21 |
2020-08-27 |
Elstar Therapeutics, Inc. |
Multifunctional molecules that bind to t cell related cancer cells and uses thereof
|
|
CN119039441A
(zh)
|
2019-02-21 |
2024-11-29 |
马伦戈治疗公司 |
与nkp30结合的抗体分子及其用途
|
|
JP7706373B2
(ja)
|
2019-02-21 |
2025-07-11 |
マレンゴ・セラピューティクス，インコーポレーテッド |
カルレティキュリンに結合する多機能性分子およびその使用
|
|
EP3927745A1
(en)
|
2019-02-21 |
2021-12-29 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to t cells and uses thereof to treat autoimmune disorders
|
|
JP2022521751A
(ja)
|
2019-02-21 |
2022-04-12 |
マレンゴ・セラピューティクス，インコーポレーテッド |
抗ｔｃｒ抗体分子およびその使用
|
|
WO2020172553A1
(en)
|
2019-02-22 |
2020-08-27 |
Novartis Ag |
Combination therapies of egfrviii chimeric antigen receptors and pd-1 inhibitors
|
|
EP3931224A4
(en)
|
2019-02-26 |
2023-03-01 |
Janssen Biotech, Inc. |
COMBINATION TREATMENTS AND PATIENT STRATIFICATION WITH ANTI-EGFR/C-MET BISPECIFIC ANTIBODIES
|
|
SG11202109406TA
(en)
|
2019-03-01 |
2021-09-29 |
Xencor Inc |
Heterodimeric antibodies that bind enpp3 and cd3
|
|
WO2020180811A1
(en)
|
2019-03-04 |
2020-09-10 |
Qilu Puget Sound Biotherapeutics Corporation |
Anti-sirp-alpha antibodies
|
|
TWI892981B
(zh)
|
2019-03-08 |
2025-08-11 |
美商建南德克公司 |
用於偵測且量化膜相關蛋白之方法
|
|
KR20210141555A
(ko)
|
2019-03-14 |
2021-11-23 |
제넨테크, 인크. |
Her2xcd3 이중특이적 항체 및 항-her2 mab를 병용한 암의 치료
|
|
CA3135430A1
(en)
|
2019-03-29 |
2020-10-08 |
Atarga, Llc |
Anti fgf23 antibody
|
|
EP3947440A1
(en)
|
2019-03-29 |
2022-02-09 |
F. Hoffmann-La Roche AG |
Method for generating avid-binding multispecific antibodies
|
|
JP7249432B2
(ja)
|
2019-03-29 |
2023-03-30 |
エフ． ホフマン－ラ ロシュ アーゲー |
多価分子の機能分析のための、ｓｐｒをベースとする結合アッセイ
|
|
EP3952996A1
(en)
|
2019-04-12 |
2022-02-16 |
F. Hoffmann-La Roche AG |
Bispecific antigen binding molecules comprising lipocalin muteins
|
|
TW202043291A
(zh)
|
2019-04-19 |
2020-12-01 |
美商建南德克公司 |
抗mertk抗體及使用方法
|
|
KR20220004062A
(ko)
|
2019-04-25 |
2022-01-11 |
에프. 호프만-라 로슈 아게 |
반감기가 연장된 활성화 가능한 치료용 다중특이적 폴리펩티드
|
|
CN113924314B
(zh)
|
2019-04-25 |
2024-10-18 |
豪夫迈·罗氏有限公司 |
通过多肽链交换活化的治疗性多特异性多肽
|
|
MX2021012871A
(es)
|
2019-04-25 |
2021-11-17 |
Hoffmann La Roche |
Generacion de polipeptidos derivados de anticuerpos mediante intercambio de cadenas polipeptidicas.
|
|
BR112021021972A2
(pt)
|
2019-05-03 |
2021-12-21 |
Hoffmann La Roche |
Métodos de redução de uma taxa de atividade de hidrólise enzimática, de redução do nível de uma ou mais enzimas hidrolíticas e de redução da degradação de um polissorbato, composições farmacêuticas e composições de porção de anticorpo formulada
|
|
CN113795514B
(zh)
|
2019-05-09 |
2025-05-02 |
豪夫迈·罗氏有限公司 |
制备抗体的方法
|
|
US20220315661A1
(en)
|
2019-05-09 |
2022-10-06 |
Genmab B.V. |
Dosage regimens for a combination of anti-dr5 antibodies for use in treating cancer
|
|
JP7273195B2
(ja)
|
2019-05-13 |
2023-05-12 |
エフ． ホフマン－ラ ロシュ アーゲー |
干渉抑制薬物動態イムノアッセイ
|
|
KR20220007136A
(ko)
|
2019-05-14 |
2022-01-18 |
제넨테크, 인크. |
소포 림프종을 치료하기 위한 항-CD79b 면역접합체의 사용 방법
|
|
WO2020236795A2
(en)
|
2019-05-21 |
2020-11-26 |
Novartis Ag |
Trispecific binding molecules against bcma and uses thereof
|
|
UY38701A
(es)
|
2019-05-21 |
2020-12-31 |
Novartis Ag |
Moléculas de unión a cd19, conjugados, composiciones que las comprenden y usos de las mismas
|
|
WO2020236797A1
(en)
|
2019-05-21 |
2020-11-26 |
Novartis Ag |
Variant cd58 domains and uses thereof
|
|
AU2020282791A1
(en)
|
2019-05-31 |
2021-12-09 |
ALX Oncology Inc. |
Methods of treating cancer with SIRP alpha Fc fusion in combination with an immune checkpoint inhibitor
|
|
JP7082245B2
(ja)
|
2019-06-10 |
2022-06-07 |
中外製薬株式会社 |
サイトカイン阻害剤と組み合わせて使用するための抗ｔ細胞抗原結合分子
|
|
EP3983441A1
(en)
|
2019-06-11 |
2022-04-20 |
Alector LLC |
Anti-sortilin antibodies for use in therapy
|
|
WO2020254355A1
(en)
|
2019-06-19 |
2020-12-24 |
F. Hoffmann-La Roche Ag |
Method for the generation of a bivalent, bispecific antibody expressing cell by targeted integration of multiple expression cassettes in a defined organization
|
|
WO2020254352A1
(en)
|
2019-06-19 |
2020-12-24 |
F. Hoffmann-La Roche Ag |
Method for the generation of a trivalent antibody expressing cell by targeted integration of multiple expression cassettes in a defined organization
|
|
EP3986928A1
(en)
|
2019-06-19 |
2022-04-27 |
F. Hoffmann-La Roche AG |
Method for the generation of a protein expressing cell by targeted integration using cre mrna
|
|
EP3986927A1
(en)
|
2019-06-19 |
2022-04-27 |
F. Hoffmann-La Roche AG |
Method for the generation of a multivalent, bispecific antibody expressing cell by targeted integration of multiple expression cassettes in a defined organization
|
|
CA3140192A1
(en)
|
2019-06-19 |
2020-12-24 |
Johannes Auer |
Method for the generation of a multivalent, multispecific antibody expressing cell by targeted integration of multiple expression cassettes in a defined organization
|
|
JP2022538075A
(ja)
|
2019-06-26 |
2022-08-31 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
抗体結合ｃｅａ及び４－１ｂｂｌの融合
|
|
EP3990646B1
(en)
|
2019-06-26 |
2025-03-05 |
F. Hoffmann-La Roche AG |
Mammalian cell lines with sirt-1 gene knockout
|
|
WO2020260326A1
(en)
|
2019-06-27 |
2020-12-30 |
F. Hoffmann-La Roche Ag |
Novel icos antibodies and tumor-targeted antigen binding molecules comprising them
|
|
MX2021015791A
(es)
|
2019-06-28 |
2022-04-01 |
Amgen Inc |
Proteínas de unión al antígeno biespecificas anti-receptor de cgrp/anti-receptor pac1.
|
|
JP2022538139A
(ja)
|
2019-07-02 |
2022-08-31 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
変異体インターロイキン－２及び抗ｃｄ８抗体を含む免疫複合体
|
|
AR119382A1
(es)
|
2019-07-12 |
2021-12-15 |
Hoffmann La Roche |
Anticuerpos de pre-direccionamiento y métodos de uso
|
|
AR119393A1
(es)
|
2019-07-15 |
2021-12-15 |
Hoffmann La Roche |
Anticuerpos que se unen a nkg2d
|
|
CA3147239A1
(en)
|
2019-07-16 |
2021-01-21 |
Sanofi |
Neutralizing anti-amyloid beta antibodies for the treatment of alzheimer's disease
|
|
KR20220058540A
(ko)
|
2019-07-31 |
2022-05-09 |
알렉터 엘엘씨 |
항-ms4a4a 항체 및 이의 사용 방법
|
|
BR112022001460A2
(pt)
|
2019-07-31 |
2022-03-22 |
Hoffmann La Roche |
Moléculas de ligação ao antígeno biespecíficas, um ou mais polinucleotídeos isolados, célula hospedeira, método para produzir uma molécula de ligação ao antígeno biespecífica e para tratar uma doença em um indivíduo, composição farmacêutica, uso da molécula de ligação ao antígeno biespecífica e invenção
|
|
EP4004045A1
(en)
|
2019-07-31 |
2022-06-01 |
F. Hoffmann-La Roche AG |
Antibodies binding to gprc5d
|
|
CN114641490B
(zh)
|
2019-08-06 |
2023-06-06 |
新旭生技股份有限公司 |
结合至病理性tau种类的抗体及其用途
|
|
EP4010371A1
(en)
|
2019-08-08 |
2022-06-15 |
Regeneron Pharmaceuticals, Inc. |
Novel antigen binding molecule formats
|
|
BR112022002666A2
(pt)
|
2019-08-13 |
2022-08-09 |
Amgen Inc |
Muteínas de interleucina-2 para a expansão de células t reguladoras
|
|
EP4025240B1
(en)
|
2019-09-03 |
2024-10-30 |
Amgen Inc. |
Il-22 oral, intra-rectal, or other gut-related compositions and methods of use thereof
|
|
EP4028054B1
(en)
|
2019-09-12 |
2025-12-31 |
F. Hoffmann-La Roche AG |
COMPOUNDS AND METHODS FOR THE TREATMENT OF LUPUS NEPHRITIS
|
|
BR112022004972A2
(pt)
|
2019-09-18 |
2022-06-28 |
Genentech Inc |
Anticorpos, ácidos nucleicos isolados, células hospedeiras isoladas, métodos de produção de um anticorpo, de produção de um anticorpo biespecífico e de tratamento de um indivíduo, anticorpos biespecíficos, composição farmacêutica, anticorpo, anticorpo biespecífico ou composição farmacêutica, combinação de um anticorpo, uso do anticorpo, uso de uma combinação do anticorpo e métodos para reduzir a inflamação e para melhorar a descamação e/ou de erupção cutânea e combinação para uso
|
|
MX2022003266A
(es)
|
2019-09-20 |
2022-04-11 |
Genentech Inc |
Dosis para anticuerpos anti-triptasa.
|
|
US20220281997A1
(en)
|
2019-09-27 |
2022-09-08 |
Nanjing GenScript Biotech Co., Ltd. |
Anti-VHH Domain Antibodies and Use Thereof
|
|
TWI878355B
(zh)
|
2019-10-02 |
2025-04-01 |
德商百靈佳殷格翰國際股份有限公司 |
用於癌症治療之多重專一性結合蛋白
|
|
TW202128757A
(zh)
|
2019-10-11 |
2021-08-01 |
美商建南德克公司 |
具有改善之特性的 PD-1 標靶 IL-15/IL-15Rα FC 融合蛋白
|
|
JP7413519B2
(ja)
|
2019-10-18 |
2024-01-15 |
ジェネンテック， インコーポレイテッド |
びまん性大細胞型ｂ細胞リンパ腫を処置するための抗ｃｄ７９ｂ免疫抱合体の使用方法
|
|
KR20220087498A
(ko)
|
2019-10-21 |
2022-06-24 |
노파르티스 아게 |
Tim-3 억제제 및 그의 용도
|
|
MX2022004766A
(es)
|
2019-10-21 |
2022-05-16 |
Novartis Ag |
Terapias combinadas con venetoclax e inhibidores de tim-3.
|
|
JP7785669B2
(ja)
|
2019-11-05 |
2025-12-15 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
Ｎ末端ｓｃＦｖ多重特異性結合分子
|
|
EP4055046A1
(en)
|
2019-11-06 |
2022-09-14 |
Genmab B.V. |
Antibody variant combinations and uses thereof
|
|
US20220389119A1
(en)
*
|
2019-11-08 |
2022-12-08 |
Amgen Inc. |
ENGINEERING CHARGE PAIR MUTATIONS FOR PAIRING OF HETERO-IgG MOLECULES
|
|
TWI895295B
(zh)
|
2019-11-12 |
2025-09-01 |
美商方得生醫療公司 |
偵測編碼新生抗原之融合基因之方法
|
|
CA3152314A1
(en)
|
2019-11-15 |
2021-05-20 |
Andrea ALLMENDINGER |
Prevention of visible particle formation in aqueous protein solutions
|
|
BR112022009602A2
(pt)
|
2019-11-18 |
2022-09-20 |
Janssen Biotech Inc |
Anticorpos anti-cd79 ch38c-cd79 chctric, células car-t, e usos dos mesmos
|
|
AU2020386005A1
(en)
|
2019-11-19 |
2022-05-26 |
Amgen Inc. |
Novel multispecific antibody format
|
|
JP7714545B2
(ja)
|
2019-11-26 |
2025-07-29 |
ノバルティス アーゲー |
キメラ抗原受容体及びその使用
|
|
CN113135996A
(zh)
|
2019-12-09 |
2021-07-20 |
启愈生物技术(上海)有限公司 |
一种双特异抗体及其应用
|
|
TWI897903B
(zh)
|
2019-12-13 |
2025-09-21 |
美商建南德克公司 |
抗ly6g6d抗體及其使用方法
|
|
AU2020407208A1
(en)
|
2019-12-17 |
2022-06-02 |
Amgen Inc. |
Dual interleukin-2 /tnf receptor agonist for use in therapy
|
|
US11702474B2
(en)
|
2019-12-17 |
2023-07-18 |
Pfizer Inc. |
Antibodies specific for CD47, PD-L1, and uses thereof
|
|
BR112022012010A2
(pt)
|
2019-12-18 |
2022-08-30 |
Hoffmann La Roche |
Anticorpos, ácido nucleico isolado, célula hospedeira, formulação farmacêutica, uso do anticorpo, método de produção de um anticorpo, método de tratamento de um indivíduo que tem câncer e método de tratamento de um indivíduo que tem uma doença inflamatória ou autoimune
|
|
MX2022007635A
(es)
|
2019-12-18 |
2022-07-19 |
Hoffmann La Roche |
Anticuerpos que se unen a hla-a2/mage-a4.
|
|
JP7751581B2
(ja)
|
2019-12-20 |
2025-10-08 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
Ｉｌ－３７融合タンパク質及びその使用
|
|
IL293834A
(en)
|
2019-12-20 |
2022-08-01 |
Novartis Ag |
Combination of anti tim-3 antibody mbg453 and anti tgf-beta antibody nis793, with or without decitabine or the anti pd-1 antibody spartalizumab, for treating myelofibrosis and myelodysplastic syndrome
|
|
IL293978A
(en)
|
2019-12-20 |
2022-08-01 |
Regeneron Pharma |
New il2 agonists and methods of using them
|
|
EP4081294A2
(en)
|
2019-12-23 |
2022-11-02 |
Genentech, Inc. |
Apolipoprotein l1-specific antibodies and methods of use
|
|
US20230058982A1
(en)
|
2019-12-27 |
2023-02-23 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-ctla-4 antibody and use thereof
|
|
TWI766512B
(zh)
|
2020-01-02 |
2022-06-01 |
瑞士商赫孚孟拉羅股份公司 |
用於判定腦中的治療性抗體量之方法
|
|
JP2023509708A
(ja)
|
2020-01-03 |
2023-03-09 |
マレンゴ・セラピューティクス，インコーポレーテッド |
抗ｔｃｒ抗体分子およびその使用
|
|
EP4084821A4
(en)
|
2020-01-03 |
2024-04-24 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to cd33 and uses thereof
|
|
MX2022008214A
(es)
|
2020-01-09 |
2022-08-08 |
Hoffmann La Roche |
Nuevas moleculas de union al antigeno que contienen el trimero de 4-1bbl.
|
|
CN110818795B
(zh)
|
2020-01-10 |
2020-04-24 |
上海复宏汉霖生物技术股份有限公司 |
抗tigit抗体和使用方法
|
|
CN114981284A
(zh)
|
2020-01-15 |
2022-08-30 |
豪夫迈·罗氏有限公司 |
减少来自重组蛋白生产过程中的杂质的方法
|
|
CN114980927A
(zh)
|
2020-01-16 |
2022-08-30 |
健玛保 |
Cd38抗体的配制剂及其用途
|
|
WO2021146636A1
(en)
|
2020-01-17 |
2021-07-22 |
Becton, Dickinson And Company |
Methods and compositions for single cell secretomics
|
|
KR20220128389A
(ko)
|
2020-01-17 |
2022-09-20 |
노파르티스 아게 |
골수이형성 증후군 또는 만성 골수단핵구성 백혈병을 치료하는데 사용하기 위한 tim-3 억제제 및 저메틸화제를 포함하는 조합물
|
|
MX2022009306A
(es)
|
2020-01-29 |
2022-09-26 |
Inhibrx Inc |
Loseta de nucleo de espuma densificada (dfc) con linea de anticuerpos de dominio individual de cd28 y constructos multivalentes y multiespecíficas de los mismos.
|
|
WO2021155916A1
(en)
|
2020-02-04 |
2021-08-12 |
BioNTech SE |
Treatment involving antigen vaccination and binding agents binding to pd-l1 and cd137
|
|
WO2021160155A1
(zh)
|
2020-02-10 |
2021-08-19 |
上海诗健生物科技有限公司 |
密蛋白18.2的抗体及其用途
|
|
WO2021160154A1
(zh)
|
2020-02-10 |
2021-08-19 |
上海诗健生物科技有限公司 |
Cldn18.2抗体及其用途
|
|
TWI895351B
(zh)
|
2020-02-12 |
2025-09-01 |
日商中外製藥股份有限公司 |
用於癌症之治療的抗cd137抗原結合分子
|
|
WO2021173844A1
(en)
|
2020-02-26 |
2021-09-02 |
Biograph 55, Inc. |
C19 c38 bispecific antibodies
|
|
JP2023516195A
(ja)
|
2020-02-26 |
2023-04-18 |
バイオグラフ ５５，インク． |
Ｃ１９ ｃ３８二特異性抗体
|
|
KR20220147109A
(ko)
|
2020-02-27 |
2022-11-02 |
노파르티스 아게 |
키메라 항원 수용체 발현 세포의 제조 방법
|
|
BR112022018254A2
(pt)
|
2020-03-13 |
2022-10-25 |
Genentech Inc |
Anticorpos isolados, ácido nucleico isolado, vetor ou conjunto de vetores, célula hospedeira, métodos para produzir um anticorpo, para tratar um distúrbio e para tratar ag em um paciente, composição e uso de um anticorpo
|
|
AU2021236906A1
(en)
|
2020-03-18 |
2022-08-18 |
Genmab A/S |
Antibodies binding to B7H4
|
|
CN117510630B
(zh)
|
2020-03-19 |
2025-03-04 |
基因泰克公司 |
同种型选择性抗TGF-β抗体及使用方法
|
|
WO2021194913A1
(en)
|
2020-03-24 |
2021-09-30 |
Genentech, Inc. |
Tie2-binding agents and methods of use
|
|
IL296428A
(en)
|
2020-03-25 |
2022-11-01 |
Lilly Co Eli |
Multispecific binding proteins and methods of developing the same
|
|
EP4127153A2
(en)
|
2020-03-26 |
2023-02-08 |
Genentech, Inc. |
Modified mammalian cells having reduced host cell proteins
|
|
WO2021195513A1
(en)
|
2020-03-27 |
2021-09-30 |
Novartis Ag |
Bispecific combination therapy for treating proliferative diseases and autoimmune disorders
|
|
EP4144370A4
(en)
|
2020-03-30 |
2024-05-15 |
Mie University |
BISPECIFIC ANTIBODY
|
|
AR121706A1
(es)
|
2020-04-01 |
2022-06-29 |
Hoffmann La Roche |
Moléculas de unión a antígeno biespecíficas dirigidas a ox40 y fap
|
|
JP7692404B2
(ja)
|
2020-04-02 |
2025-06-13 |
中外製薬株式会社 |
多重特異性抗原結合分子を含む組成物における不純物分子の分析方法
|
|
CN115698717A
(zh)
|
2020-04-03 |
2023-02-03 |
基因泰克公司 |
癌症的治疗和诊断方法
|
|
PH12022552436A1
(en)
|
2020-04-15 |
2024-01-03 |
Hoffmann La Roche |
Immunoconjugates
|
|
WO2021211753A1
(en)
|
2020-04-15 |
2021-10-21 |
Voyager Therapeutics, Inc. |
Tau binding compounds
|
|
KR20230005172A
(ko)
|
2020-04-24 |
2023-01-09 |
에프. 호프만-라 로슈 아게 |
설프히드릴 화합물 및 이의 유도체를 사용한 효소 및 경로 조절
|
|
CN115843312A
(zh)
|
2020-04-24 |
2023-03-24 |
马伦戈治疗公司 |
结合至t细胞相关癌细胞的多功能性分子及其用途
|
|
EP4139359A1
(en)
|
2020-04-24 |
2023-03-01 |
Genentech, Inc. |
Methods of using anti-cd79b immunoconjugates
|
|
WO2021222167A1
(en)
|
2020-04-28 |
2021-11-04 |
Genentech, Inc. |
Methods and compositions for non-small cell lung cancer immunotherapy
|
|
EP4142722A1
(en)
|
2020-04-30 |
2023-03-08 |
Bristol-Myers Squibb Company |
Methods of treating cytokine-related adverse events
|
|
WO2021220215A1
(en)
|
2020-05-01 |
2021-11-04 |
Novartis Ag |
Engineered immunoglobulins
|
|
JP2023527962A
(ja)
|
2020-05-03 |
2023-07-03 |
レヴィーナ （スジョウ） バイオファーマ カンパニー， リミテッド |
抗ｔｒｏｐ２抗体を含む抗体薬物複合体（ａｄｃ）、かかるａｄｃを含む組成物、ならびにそれらを作製および使用する方法
|
|
AU2021268340A1
(en)
|
2020-05-06 |
2022-12-08 |
Dragonfly Therapeutics, Inc. |
Proteins binding NKG2D, CD16 and CLEC12A
|
|
JP2023524149A
(ja)
|
2020-05-08 |
2023-06-08 |
ジェンマブ エー／エス |
Ｃｄ３およびｃｄ２０に対する二重特異性抗体
|
|
CA3177288A1
(en)
|
2020-05-11 |
2021-11-18 |
F.Hoffmann-La Roche Ag |
Combination therapy with modified pbmcs and an immunoconjugate
|
|
WO2021231447A1
(en)
|
2020-05-12 |
2021-11-18 |
Regeneron Pharmaceuticals, Inc. |
Novel il10 agonists and methods of use thereof
|
|
WO2021231976A1
(en)
|
2020-05-14 |
2021-11-18 |
Xencor, Inc. |
Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3
|
|
WO2021228917A1
(en)
|
2020-05-15 |
2021-11-18 |
F. Hoffmann-La Roche Ag |
Prevention of visible particle formation in parenteral protein solutions
|
|
JP7547507B2
(ja)
|
2020-05-18 |
2024-09-09 |
山▲東▼先声生物制▲薬▼有限公司 |
ヒトｉｌ－１５変異体およびその使用
|
|
EP4153130A1
(en)
|
2020-05-19 |
2023-03-29 |
F. Hoffmann-La Roche AG |
The use of chelators for the prevention of visible particle formation in parenteral protein solutions
|
|
KR20230012559A
(ko)
|
2020-05-19 |
2023-01-26 |
베링거 인겔하임 인터내셔날 게엠베하 |
암 치료를 위한 결합 분자
|
|
US11787861B2
(en)
|
2020-05-29 |
2023-10-17 |
23Andme, Inc. |
Anti-CD200R1 antibodies and methods of use thereof
|
|
BR112022024996A2
(pt)
|
2020-06-08 |
2022-12-27 |
Hoffmann La Roche |
Anticorpos, ácido nucleico, célula hospedeira, método para produzir um anticorpo, composição farmacêutica, agente terapêutico, uso do anticorpo e método para tratar um indivíduo com hepatite b
|
|
CN115698719A
(zh)
|
2020-06-12 |
2023-02-03 |
基因泰克公司 |
用于癌症免疫疗法的方法和组合物
|
|
KR20230025672A
(ko)
|
2020-06-19 |
2023-02-22 |
에프. 호프만-라 로슈 아게 |
Cd3 및 cd19에 결합하는 항체
|
|
AU2021291407A1
(en)
|
2020-06-19 |
2022-09-29 |
F. Hoffmann-La Roche Ag |
Antibodies binding to CD3
|
|
EP4168446A1
(en)
|
2020-06-19 |
2023-04-26 |
F. Hoffmann-La Roche AG |
Antibodies binding to cd3 and folr1
|
|
CR20230014A
(es)
|
2020-06-19 |
2023-02-17 |
Chugai Pharmaceutical Co Ltd |
Molécula de unión al antígeno anti-células t para usarse en combinación con un inhibidor de angiogénesis
|
|
AU2021291405A1
(en)
|
2020-06-19 |
2022-09-29 |
F. Hoffmann-La Roche Ag |
Immune activating Fc domain binding molecules
|
|
WO2021255146A1
(en)
|
2020-06-19 |
2021-12-23 |
F. Hoffmann-La Roche Ag |
Antibodies binding to cd3 and cea
|
|
AU2021291002A1
(en)
|
2020-06-19 |
2022-10-13 |
F. Hoffmann-La Roche Ag |
Protease-activated T cell bispecific antibodies
|
|
WO2021259880A1
(en)
|
2020-06-22 |
2021-12-30 |
Almirall, S.A. |
Anti-il-36 antibodies and methods of use thereof
|
|
CN115702168A
(zh)
|
2020-06-23 |
2023-02-14 |
豪夫迈·罗氏有限公司 |
靶向Her2的激动性CD28抗原结合分子
|
|
KR20230027056A
(ko)
|
2020-06-23 |
2023-02-27 |
노파르티스 아게 |
3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체를 포함하는 투약 요법
|
|
CA3184747A1
(en)
|
2020-06-24 |
2021-12-30 |
Genentech, Inc. |
Apoptosis resistant cell lines
|
|
EP4172203A1
(en)
|
2020-06-25 |
2023-05-03 |
F. Hoffmann-La Roche AG |
Anti-cd3/anti-cd28 bispecific antigen binding molecules
|
|
EP4171614A1
(en)
|
2020-06-29 |
2023-05-03 |
Resolve Therapeutics, LLC |
Treatment of sjogren's syndrome with nuclease fusion proteins
|
|
EP4175664A2
(en)
|
2020-07-06 |
2023-05-10 |
Janssen Biotech, Inc. |
Prostate neoantigens and their uses
|
|
EP4178529A1
(en)
|
2020-07-07 |
2023-05-17 |
F. Hoffmann-La Roche AG |
Alternative surfactants as stabilizers for therapeutic protein formulations
|
|
US20230272116A1
(en)
|
2020-07-10 |
2023-08-31 |
Hoffmann-La Roche Inc. |
Antibodies which bind to cancer cells and target radionuclides to said cells
|
|
CA3176556A1
(en)
|
2020-07-16 |
2022-01-20 |
Novartis Ag |
Anti-betacellulin antibodies, fragments thereof, and multi-specific binding molecules
|
|
WO2022016119A1
(en)
|
2020-07-17 |
2022-01-20 |
Simurx, Inc. |
Chimeric myd88 receptors for redirecting immunosuppressive signaling and related compositions and methods
|
|
EP4182348A1
(en)
|
2020-07-17 |
2023-05-24 |
Genentech, Inc. |
Anti-notch2 antibodies and methods of use
|
|
AU2021312225A1
(en)
|
2020-07-21 |
2023-02-16 |
Genentech, Inc. |
Antibody-conjugated chemical inducers of degradation of BRM and methods thereof
|
|
US20230293680A1
(en)
|
2020-07-23 |
2023-09-21 |
Genmab B.V. |
A composition of anti-dr5 antibodies and an immunomodulatory imide drug for use in treating multiple myeloma
|
|
WO2022026592A2
(en)
|
2020-07-28 |
2022-02-03 |
Celltas Bio, Inc. |
Antibody molecules to coronavirus and uses thereof
|
|
GB2597532A
(en)
|
2020-07-28 |
2022-02-02 |
Femtogenix Ltd |
Cytotoxic compounds
|
|
KR20230048059A
(ko)
|
2020-07-31 |
2023-04-10 |
추가이 세이야쿠 가부시키가이샤 |
키메라 수용체를 발현하는 세포를 포함하는 의약 조성물
|
|
US20230271940A1
(en)
|
2020-08-03 |
2023-08-31 |
Novartis Ag |
Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
US20230287088A1
(en)
|
2020-08-06 |
2023-09-14 |
BioNTech SE |
Binding agents for coronavirus s protein
|
|
EP4200332A1
(en)
|
2020-08-19 |
2023-06-28 |
Xencor, Inc. |
Anti-cd28 and/or anti-b7h3 compositions
|
|
CA3190766A1
(en)
|
2020-08-26 |
2022-03-03 |
Marengo Therapeutics, Inc. |
Antibody molecules that bind to nkp30 and uses thereof
|
|
CA3190755A1
(en)
|
2020-08-26 |
2022-03-03 |
Andreas Loew |
Multifunctional molecules that bind to calreticulin and uses thereof
|
|
EP4204458A4
(en)
|
2020-08-26 |
2024-10-09 |
Marengo Therapeutics, Inc. |
METHODS FOR DETECTION OF TRBC1 OR TRBC2
|
|
CN116648507A
(zh)
|
2020-08-28 |
2023-08-25 |
基因泰克公司 |
宿主细胞蛋白的CRISPR/Cas9多重敲除
|
|
US20230416371A1
(en)
|
2020-08-28 |
2023-12-28 |
Chugai Seiyaku Kabushiki Kaisha |
Heterodimer fc polypeptide
|
|
WO2022043558A1
(en)
|
2020-08-31 |
2022-03-03 |
Advanced Accelerator Applications International Sa |
Method of treating psma-expressing cancers
|
|
EP4204021A1
(en)
|
2020-08-31 |
2023-07-05 |
Advanced Accelerator Applications International S.A. |
Method of treating psma-expressing cancers
|
|
US20230310599A1
(en)
|
2020-09-02 |
2023-10-05 |
Genmab A/S |
Antibody therapy
|
|
CA3192251A1
(en)
|
2020-09-10 |
2022-03-17 |
Genmab A/S |
Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma
|
|
KR20230066391A
(ko)
|
2020-09-10 |
2023-05-15 |
젠맵 에이/에스 |
여포성 림프종을 치료하기 위한 조합 요법에서의 cd3 및 cd20에 대한 이중특이적 항체
|
|
AU2021342342A1
(en)
|
2020-09-10 |
2023-04-13 |
Genmab A/S |
Bispecific antibodies against CD3 and CD20 for treating chronic lymphocytic leukemia
|
|
JP2023542092A
(ja)
|
2020-09-10 |
2023-10-05 |
ジェンマブ エー／エス |
びまん性大細胞型ｂ細胞リンパ腫を治療するための併用療法におけるｃｄ３及びｃｄ２０に対する二重特異性抗体
|
|
US20230312758A1
(en)
|
2020-09-10 |
2023-10-05 |
Genmab A/S |
Bispecific antibody against cd3 and cd20 in combination therapy for treating follicular lymphoma
|
|
CA3192255A1
(en)
|
2020-09-10 |
2022-03-17 |
Brian Elliott |
Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma
|
|
MX2023002901A
(es)
|
2020-09-14 |
2023-06-01 |
Ichnos Sciences SA |
Anticuerpos que se unen a la proteína auxiliar del receptor de interleucina-1 (il1rap) y usos de estos.
|
|
CN116323674A
(zh)
|
2020-09-21 |
2023-06-23 |
基因泰克公司 |
多特异性抗体的纯化
|
|
TW202223092A
(zh)
|
2020-09-24 |
2022-06-16 |
瑞士商赫孚孟拉羅股份公司 |
具有基因剔除的哺乳動物細胞株
|
|
JP2023547329A
(ja)
|
2020-10-02 |
2023-11-10 |
ジェンマブ エー／エス |
Ｒｏｒ２へと結合することができる抗体ならびにｒｏｒ２およびｃｄ３に結合する二重特異性抗体
|
|
WO2022072882A1
(en)
|
2020-10-02 |
2022-04-07 |
Keros Therapeutics, Inc. |
Methods of using activin receptor type ii variants
|
|
AU2021358031A1
(en)
|
2020-10-05 |
2023-05-04 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
|
AR123767A1
(es)
|
2020-10-13 |
2023-01-11 |
Janssen Biotech Inc |
Inmunidad mediada por células t mediante bioingeniería, materiales y otros métodos para modular el cúmulo de diferenciación iv y/o viii
|
|
TW202233671A
(zh)
|
2020-10-20 |
2022-09-01 |
美商建南德克公司 |
Ｐｅｇ結合抗ｍｅｒｔｋ抗體及其使用方法
|
|
CA3190782A1
(en)
|
2020-10-20 |
2022-04-28 |
F. Hoffmann-La Roche Ag |
Combination therapy of pd-1 axis binding antagonists and lrrk2 inhibitors
|
|
TW202233668A
(zh)
|
2020-10-21 |
2022-09-01 |
德商百靈佳殷格翰國際股份有限公司 |
用於治療眼部疾病之雙特異性抗-VEGF及抗-TrkB結合分子
|
|
TW202233674A
(zh)
|
2020-10-28 |
2022-09-01 |
美商健生生物科技公司 |
用於調節δγ鏈介導之免疫的組成物及方法
|
|
US20230374147A1
(en)
|
2020-11-02 |
2023-11-23 |
Hummingbird Bioscience Pte. Ltd. |
Bcma/taci antigen-binding molecules
|
|
CA3199839A1
(en)
|
2020-11-06 |
2022-05-12 |
Novartis Ag |
Anti-cd19 agent and b cell targeting agent combination therapy for treating b cell malignancies
|
|
AU2021373366A1
(en)
|
2020-11-06 |
2023-06-01 |
Novartis Ag |
Cd19 binding molecules and uses thereof
|
|
JP2023548249A
(ja)
|
2020-11-10 |
2023-11-15 |
上海齊魯制藥研究中心有限公司 |
クローディン１８ａ２及びｃｄ３に対する二重特異性抗体及びその使用
|
|
IL302700A
(en)
|
2020-11-13 |
2023-07-01 |
Novartis Ag |
Combination therapies with chimeric antigen receptor (car)-expressing cells
|
|
EP4244254A1
(en)
|
2020-11-16 |
2023-09-20 |
F. Hoffmann-La Roche AG |
Combination therapy with fap-targeted cd40 agonists
|
|
MX2023005581A
(es)
|
2020-11-16 |
2023-05-29 |
Hoffmann La Roche |
Glucoformas de fab ricas en manosa.
|
|
EP4255930A1
(en)
|
2020-12-02 |
2023-10-11 |
Alector LLC |
Methods of use of anti-sortilin antibodies
|
|
WO2022116877A1
(en)
|
2020-12-02 |
2022-06-09 |
Shanghai Henlius Biotech, Inc. |
ANTI-GARP/TGFβ ANTIBODIES AND METHODS OF USE
|
|
CR20230219A
(es)
|
2020-12-04 |
2023-07-07 |
Hoffmann La Roche |
Polipéptidos de interleucina-2 mutante dependientes del ph
|
|
PE20231953A1
(es)
|
2020-12-07 |
2023-12-06 |
UCB Biopharma SRL |
Anticuerpos multiespecificos y combinaciones de anticuerpos
|
|
KR20230118128A
(ko)
|
2020-12-07 |
2023-08-10 |
유씨비 바이오파마 에스알엘 |
인터루킨-22에 대한 항체
|
|
MX2023007133A
(es)
|
2020-12-17 |
2023-06-27 |
Hoffmann La Roche |
Anticuerpos anti-hla-g y uso de estos.
|
|
WO2022129313A1
(en)
|
2020-12-18 |
2022-06-23 |
F. Hoffmann-La Roche Ag |
Precursor proteins and kit for targeted therapy
|
|
EP4267734A1
(en)
|
2020-12-22 |
2023-11-01 |
F. Hoffmann-La Roche AG |
Oligonucleotides targeting xbp1
|
|
MX2023007846A
(es)
|
2021-01-06 |
2023-07-07 |
Hoffmann La Roche |
Tratamiento conjunto que usa un anticuerpo biespecifico contra pd1-lag3 y un anticuerpo biespecifico de linfocitos t cd20.
|
|
WO2022148853A1
(en)
|
2021-01-11 |
2022-07-14 |
F. Hoffmann-La Roche Ag |
Immunoconjugates
|
|
PE20240690A1
(es)
|
2021-01-12 |
2024-04-10 |
Hoffmann La Roche |
Anticuerpos split que se unen a celulas cancerosas y dirigen radionuclidos a dichas celulas
|
|
KR20230131205A
(ko)
|
2021-01-13 |
2023-09-12 |
에프. 호프만-라 로슈 아게 |
병용 요법
|
|
WO2022162587A1
(en)
|
2021-01-27 |
2022-08-04 |
Centre Hospitalier Universitaire Vaudois (C.H.U.V.) |
Anti-sars-cov-2 antibodies and use thereof in the treatment of sars-cov-2 infection
|
|
EP4284510A1
(en)
|
2021-01-29 |
2023-12-06 |
Novartis AG |
Dosage regimes for anti-cd73 and anti-entpd2 antibodies and uses thereof
|
|
EP4288458A1
(en)
|
2021-02-03 |
2023-12-13 |
Genentech, Inc. |
Multispecific binding protein degrader platform and methods of use
|
|
US20240101673A1
(en)
|
2021-02-03 |
2024-03-28 |
Mozart Therapeutics, Inc. |
Binding agents and methods of using the same
|
|
CN117794566A
(zh)
|
2021-02-05 |
2024-03-29 |
Vib研究所 |
沙贝病毒结合剂
|
|
AU2022224508A1
(en)
|
2021-02-16 |
2023-10-05 |
Janssen Biotech, Inc. |
Materials and methods for enhanced linker targeting
|
|
CN116888473A
(zh)
|
2021-02-18 |
2023-10-13 |
豪夫迈·罗氏有限公司 |
用于解析复杂、多步骤抗体相互作用的方法
|
|
JP7773238B2
(ja)
|
2021-02-19 |
2025-11-19 |
シャペロン インク． |
Ｐｄ－ｌ１に対する単一ドメイン抗体及びその用途
|
|
EP4296282A4
(en)
|
2021-02-19 |
2025-02-26 |
SHAPERON Inc. |
SINGLE DOMAIN ANTIBODIES AGAINST CD47 AND USE THEREOF
|
|
WO2022184082A1
(en)
|
2021-03-03 |
2022-09-09 |
Sorrento Therapeutics, Inc. |
Antibody-drug conjugates comprising an anti-bcma antibody
|
|
US12377144B2
(en)
|
2021-03-03 |
2025-08-05 |
Dragonfly Therapeutics, Inc. |
Methods of treating cancer using multi-specific binding proteins that bind NKG2D, CD16 and a tumor-associated antigen
|
|
EP4305067A1
(en)
|
2021-03-09 |
2024-01-17 |
Xencor, Inc. |
Heterodimeric antibodies that bind cd3 and cldn6
|
|
KR20230156051A
(ko)
|
2021-03-09 |
2023-11-13 |
에프. 호프만-라 로슈 아게 |
Pd-1-표적화 il-2 변이체 면역접합체 및 fap/4-1bb 결합 분자의 병용 요법
|
|
US20240262913A1
(en)
|
2021-03-09 |
2024-08-08 |
Hoffmann-La Roche Inc. |
Combination therapy of pd-1-targeted il-2 variant immunoconjugate and anti-tyrp1/anti-cd3 bispecific antibodies
|
|
JP2024509274A
(ja)
|
2021-03-10 |
2024-02-29 |
ゼンコア インコーポレイテッド |
Ｃｄ３及びｇｐｃ３に結合するヘテロ二量体抗体
|
|
CN117062839A
(zh)
|
2021-03-12 |
2023-11-14 |
基因泰克公司 |
抗klk7抗体、抗klk5抗体、多特异性抗klk5/klk7抗体和使用方法
|
|
MX2023010567A
(es)
|
2021-03-12 |
2023-09-21 |
Genmab As |
Variantes de anticuerpos no activadoras.
|
|
BR112023018621A2
(pt)
|
2021-03-15 |
2023-10-24 |
Hoffmann La Roche |
Métodos para tratar nefrite lúpica, esgotar células b periféricas, kits para tratar nefrite lúpica e anticorpos anti-cd20 tipo ii
|
|
WO2022197947A1
(en)
|
2021-03-18 |
2022-09-22 |
Alector Llc |
Anti-tmem106b antibodies and methods of use thereof
|
|
WO2022197877A1
(en)
|
2021-03-19 |
2022-09-22 |
Genentech, Inc. |
Methods and compositions for time delayed bio-orthogonal release of cytotoxic agents
|
|
WO2022204274A1
(en)
|
2021-03-23 |
2022-09-29 |
Alector Llc |
Anti-tmem106b antibodies for treating and preventing coronavirus infections
|
|
AU2022244453A1
(en)
|
2021-03-24 |
2023-11-09 |
Janssen Biotech, Inc. |
Antibody targeting cd22 and cd79b
|
|
AU2022246275A1
(en)
|
2021-03-26 |
2023-11-09 |
Janssen Biotech, Inc. |
Humanized antibodies against paired helical filament tau and uses thereof
|
|
WO2022200525A1
(en)
|
2021-03-26 |
2022-09-29 |
Innate Pharma |
Multispecific proteins comprising an nkp46-binding site, a cancer antgienge binding site fused to a cytokine for nk cell engaging
|
|
BR112023017510A2
(pt)
|
2021-03-29 |
2023-10-10 |
Daiichi Sankyo Co Ltd |
Molécula multiespecífica estável e uso da mesma
|
|
CA3237992A1
(en)
|
2021-03-31 |
2022-10-06 |
Jiangsu Hengrui Pharmaceuticals Co., Ltd. |
Truncated taci polypeptide and fusion protein and use thereof
|
|
TW202304994A
(zh)
|
2021-04-02 |
2023-02-01 |
美商泰尼歐生物公司 |
促效性抗ｉｌ－２ｒ抗體及使用方法
|
|
TW202304979A
(zh)
|
2021-04-07 |
2023-02-01 |
瑞士商諾華公司 |
抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
|
|
KR20240004462A
(ko)
|
2021-04-08 |
2024-01-11 |
마렝고 테라퓨틱스, 인크. |
Tcr에 결합하는 다기능성 분자 및 이의 용도
|
|
EP4320444A1
(en)
|
2021-04-09 |
2024-02-14 |
F. Hoffmann-La Roche AG |
Process for selecting cell clones expressing a heterologous polypeptide
|
|
WO2022217022A1
(en)
|
2021-04-10 |
2022-10-13 |
Profoundbio Us Co. |
Folr1 binding agents, conjugates thereof and methods of using the same
|
|
AR125344A1
(es)
|
2021-04-15 |
2023-07-05 |
Chugai Pharmaceutical Co Ltd |
Anticuerpo anti-c1s
|
|
CA3215965A1
(en)
|
2021-04-19 |
2022-10-27 |
Amy Shen |
Modified mammalian cells
|
|
AU2022262644A1
(en)
|
2021-04-23 |
2023-11-09 |
Genmab A/S |
Anti-cd70 antibodies, conjugates thereof and methods of using the same
|
|
AU2021443318A1
(en)
|
2021-04-30 |
2023-09-07 |
F. Hoffmann-La Roche Ag |
Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate
|
|
AU2021443863A1
(en)
|
2021-04-30 |
2023-10-26 |
F. Hoffmann-La Roche Ag |
Dosing for treatment with anti-cd20/anti-cd3 bispecific antibody
|
|
JP2024516305A
(ja)
|
2021-05-03 |
2024-04-12 |
ユーシービー バイオファルマ エスアールエル |
抗体
|
|
CN117597365A
(zh)
|
2021-05-04 |
2024-02-23 |
再生元制药公司 |
多特异性fgf21受体激动剂及其应用
|
|
TW202307007A
(zh)
|
2021-05-04 |
2023-02-16 |
美商再生元醫藥公司 |
多特異性fgf21受體促效劑及其等用途
|
|
WO2022234146A1
(en)
|
2021-05-07 |
2022-11-10 |
Genmab A/S |
PHARMACEUTICAL COMPOSITIONS COMPRISING BISPECIFIC ANTIBODIES BINDING TO B7H4 and CD3
|
|
WO2022238481A1
(en)
|
2021-05-11 |
2022-11-17 |
Modiquest B.V. |
Antibodies
|
|
AU2022273063A1
(en)
|
2021-05-12 |
2023-11-23 |
Genentech, Inc. |
Methods of using anti-cd79b immunoconjugates to treat diffuse large b-cell lymphoma
|
|
CA3218542A1
(en)
|
2021-05-12 |
2022-11-17 |
Hua Ying |
Antigen binding molecule specifically binding to rankl and ngf, and medical use thereof
|
|
US12098214B2
(en)
|
2021-05-13 |
2024-09-24 |
ALX Oncology Inc. |
Combination therapies for treating cancer
|
|
AU2022273737A1
(en)
|
2021-05-14 |
2023-11-16 |
Jiangsu Hengrui Pharmaceuticals Co., Ltd. |
Antigen-binding molecule
|
|
US12384844B2
(en)
|
2021-05-14 |
2025-08-12 |
Genentech, Inc. |
Agonists of TREM2
|
|
AR125874A1
(es)
|
2021-05-18 |
2023-08-23 |
Novartis Ag |
Terapias de combinación
|
|
WO2022243261A1
(en)
|
2021-05-19 |
2022-11-24 |
F. Hoffmann-La Roche Ag |
Agonistic cd40 antigen binding molecules targeting cea
|
|
WO2022246259A1
(en)
|
2021-05-21 |
2022-11-24 |
Genentech, Inc. |
Modified cells for the production of a recombinant product of interest
|
|
CN113278071B
(zh)
|
2021-05-27 |
2021-12-21 |
江苏荃信生物医药股份有限公司 |
抗人干扰素α受体1单克隆抗体及其应用
|
|
AR126009A1
(es)
|
2021-06-02 |
2023-08-30 |
Hoffmann La Roche |
Moléculas agonistas de unión al antígeno cd28 que se dirigen a epcam
|
|
AR126054A1
(es)
|
2021-06-04 |
2023-09-06 |
Chugai Pharmaceutical Co Ltd |
Anticuerpos anti-ddr2 y usos de estos
|
|
MX2023014645A
(es)
|
2021-06-09 |
2024-01-31 |
Innate Pharma |
Proteinas acopladoras de celulas nk de union a nkp46 especificas de cd20.
|
|
WO2022258662A1
(en)
|
2021-06-09 |
2022-12-15 |
Innate Pharma |
Multispecific proteins binding to nkp46, a cytokine receptor, a tumour antigen and cd16a
|
|
WO2022258678A1
(en)
|
2021-06-09 |
2022-12-15 |
Innate Pharma |
Multispecific proteins binding to nkp30, a cytokine receptor, a tumour antigen and cd16a
|
|
WO2022258691A1
(en)
|
2021-06-09 |
2022-12-15 |
Innate Pharma |
Multispecific proteins binding to nkg2d, a cytokine receptor, a tumour antigen and cd16a
|
|
JP2024521579A
(ja)
|
2021-06-09 |
2024-06-03 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
がんの治療における使用のための特定のｂｒａｆ阻害剤（パラドックスブレーカー）とｐｄ－１軸結合アンタゴニストとの組み合わせ
|
|
JP2024527493A
(ja)
|
2021-06-16 |
2024-07-25 |
アレクトル エルエルシー |
一価の抗ＭｅｒＴＫ抗体及びその使用方法
|
|
US20240279341A1
(en)
|
2021-06-16 |
2024-08-22 |
Alector Llc |
Bispecific anti-mertk and anti-pdl1 antibodies and methods of use thereof
|
|
JP2024523033A
(ja)
|
2021-06-17 |
2024-06-25 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
新規の三重特異的結合分子
|
|
WO2022263638A1
(en)
|
2021-06-17 |
2022-12-22 |
Centre Hospitalier Universitaire Vaudois (C.H.U.V.) |
Anti-sars-cov-2 antibodies and use thereof in the treatment of sars-cov-2 infection
|
|
CN117500829A
(zh)
|
2021-06-18 |
2024-02-02 |
豪夫迈·罗氏有限公司 |
双特异性抗ccl2抗体
|
|
JP2024523438A
(ja)
|
2021-06-21 |
2024-06-28 |
ジェンマブ エー／エス |
Ｃｄ１３７結合物質とｐｄ－ｌ１結合物質の組合せ投薬レジメン
|
|
TW202306989A
(zh)
|
2021-06-22 |
2023-02-16 |
瑞士商諾華公司 |
用於在治療化膿性汗腺炎中使用的雙特異性抗體
|
|
TW202306999A
(zh)
|
2021-06-24 |
2023-02-16 |
美商艾瑞斯卡公司 |
抗egfr抗體及其用途
|
|
US12448451B2
(en)
|
2021-06-25 |
2025-10-21 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-CTLA-4 antibody and use thereof
|
|
EP4361176A4
(en)
|
2021-06-25 |
2025-03-12 |
Chugai Seiyaku Kabushiki Kaisha |
USE OF ANTI-CTLA-4 ANTIBODIES
|
|
BR112023022992A2
(pt)
|
2021-06-25 |
2024-01-23 |
Chugai Pharmaceutical Co Ltd |
Anticorpo anti-ctla-4
|
|
CN117580865A
(zh)
|
2021-06-29 |
2024-02-20 |
山东先声生物制药有限公司 |
Cd16抗体及其应用
|
|
JP2024525381A
(ja)
|
2021-07-02 |
2024-07-12 |
ジェネンテック， インコーポレイテッド |
がんを治療するための方法及び組成物
|
|
TW202320857A
(zh)
|
2021-07-06 |
2023-06-01 |
美商普方生物製藥美國公司 |
連接子、藥物連接子及其結合物及其使用方法
|
|
WO2023281120A1
(en)
|
2021-07-09 |
2023-01-12 |
Luxembourg Institute Of Health (Lih) |
Dimeric protein complexes and uses thereof
|
|
KR20240032930A
(ko)
|
2021-07-13 |
2024-03-12 |
제넨테크, 인크. |
사이토카인 방출 증후군을 예측하기 위한 다변량 모델
|
|
EP4370553A1
(en)
|
2021-07-14 |
2024-05-22 |
Genentech, Inc. |
Anti-c-c motif chemokine receptor 8 (ccr8) antibodies and methods of use
|
|
KR20240032959A
(ko)
|
2021-07-14 |
2024-03-12 |
지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 |
Hgfr 및 egfr에 특이적으로 결합하는 항원-결합 분자, 및 이의 약학적 용도
|
|
TW202321282A
(zh)
|
2021-07-19 |
2023-06-01 |
美商再生元醫藥公司 |
Il12受體促效劑及其使用方法
|
|
CA3219606A1
(en)
|
2021-07-22 |
2023-01-26 |
F. Hoffmann-La Roche Ag |
Heterodimeric fc domain antibodies
|
|
JP2024526880A
(ja)
|
2021-07-22 |
2024-07-19 |
ジェネンテック， インコーポレイテッド |
脳標的化組成物及びその使用方法
|
|
WO2023006809A1
(en)
|
2021-07-27 |
2023-02-02 |
Morphosys Ag |
Combinations of antigen binding molecules
|
|
EP4377338A2
(en)
|
2021-07-27 |
2024-06-05 |
Novab, Inc. |
Engineered vlrb antibodies with immune effector functions
|
|
EP4377351A1
(en)
|
2021-07-28 |
2024-06-05 |
F. Hoffmann-La Roche AG |
Methods and compositions for treating cancer
|
|
CN117794953A
(zh)
|
2021-08-03 |
2024-03-29 |
豪夫迈·罗氏有限公司 |
双特异性抗体及使用方法
|
|
EP4384553A1
(en)
|
2021-08-13 |
2024-06-19 |
Genentech, Inc. |
Dosing for anti-tryptase antibodies
|
|
AU2022331241A1
(en)
|
2021-08-16 |
2024-03-28 |
Regeneron Pharmaceuticals, Inc. |
Novel il27 receptor agonists and methods of use thereof
|
|
IL310662A
(en)
|
2021-08-23 |
2024-04-01 |
Immunitas Therapeutics Inc |
Anti-CD161 antibodies and their uses
|
|
AU2022332303A1
(en)
|
2021-08-27 |
2024-02-01 |
Genentech, Inc. |
Methods of treating tau pathologies
|
|
WO2023034750A1
(en)
|
2021-08-30 |
2023-03-09 |
Genentech, Inc. |
Anti-polyubiquitin multispecific antibodies
|
|
CN113603775B
(zh)
|
2021-09-03 |
2022-05-20 |
江苏荃信生物医药股份有限公司 |
抗人白介素-33单克隆抗体及其应用
|
|
CN113683694B
(zh)
|
2021-09-03 |
2022-05-13 |
江苏荃信生物医药股份有限公司 |
一种抗人tslp单克隆抗体及其应用
|
|
US20230109496A1
(en)
|
2021-09-06 |
2023-04-06 |
Genmab B.V. |
Antibodies capable of binding to cd27, variants thereof and uses thereof
|
|
WO2023044483A2
(en)
|
2021-09-20 |
2023-03-23 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of her2 positive cancer
|
|
JP2024534531A
(ja)
|
2021-09-23 |
2024-09-20 |
江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司 |
抗ｋｌｂ抗体及び使用
|
|
KR20240067099A
(ko)
|
2021-09-30 |
2024-05-16 |
지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 |
항-il23 항체 융합 단백질 및 용도
|
|
CN118562019A
(zh)
*
|
2021-09-30 |
2024-08-30 |
宁波三生生物科技股份有限公司 |
重组促卵泡激素融合蛋白
|
|
US20240404622A1
(en)
|
2021-10-08 |
2024-12-05 |
Chugai Seiyaku Kabushiki Kaisha |
Method for preparing prefilled syringe formulation
|
|
IL311805A
(en)
|
2021-10-08 |
2024-05-01 |
Genmab As |
Antibodies that bind to CD30 and CD3
|
|
EP4429706A1
(en)
|
2021-10-14 |
2024-09-18 |
F. Hoffmann-La Roche AG |
Alternative pd1-il7v immunoconjugates for the treatment of cancer
|
|
PE20241627A1
(es)
|
2021-10-14 |
2024-08-07 |
Hoffmann La Roche |
Nuevos inmunoconjugados de interleucina-7
|
|
US20230192843A1
(en)
|
2021-10-14 |
2023-06-22 |
Teneobio, Inc. |
Mesothelin binding proteins and uses thereof
|
|
US20240425572A1
(en)
|
2021-10-15 |
2024-12-26 |
Regenxbio Inc. |
Antibodies and methods of using thereof
|
|
WO2023070056A2
(en)
|
2021-10-20 |
2023-04-27 |
Synthekine, Inc. |
Heterodimeric fc cytokines and uses thereof
|
|
WO2023076876A1
(en)
|
2021-10-26 |
2023-05-04 |
Mozart Therapeutics, Inc. |
Modulation of immune responses to viral vectors
|
|
WO2023073599A1
(en)
|
2021-10-28 |
2023-05-04 |
Novartis Ag |
Engineered fc variants
|
|
EP4430072A1
(en)
|
2021-11-10 |
2024-09-18 |
Genentech, Inc. |
Anti-interleukin-33 antibodies and uses thereof
|
|
US20230279153A1
(en)
|
2021-11-11 |
2023-09-07 |
Regeneron Pharmaceuticals, Inc. |
Cd20-pd1 binding molecules and methods of use thereof
|
|
US20250034559A1
(en)
|
2021-11-17 |
2025-01-30 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of tau-related disorders
|
|
CN118284809A
(zh)
|
2021-11-25 |
2024-07-02 |
豪夫迈·罗氏有限公司 |
少量抗体副产物的定量
|
|
WO2023094569A1
(en)
|
2021-11-26 |
2023-06-01 |
F. Hoffmann-La Roche Ag |
Combination therapy of anti-tyrp1/anti-cd3 bispecific antibodies and tyrp1-specific antibodies
|
|
US20250034274A1
(en)
|
2021-11-30 |
2025-01-30 |
Daiichi Sankyo Company , Limited |
Protease-cleavable masked antibodies
|
|
KR20240011866A
(ko)
|
2021-12-01 |
2024-01-26 |
추가이 세이야쿠 가부시키가이샤 |
항체 함유 제제의 조제 방법
|
|
US20250026844A1
(en)
|
2021-12-03 |
2025-01-23 |
Shandong Simcere Biopharmaceutical Co., Ltd. |
Anti-bcma nanobody and use thereof
|
|
AR127887A1
(es)
|
2021-12-10 |
2024-03-06 |
Hoffmann La Roche |
Anticuerpos que se unen a cd3 y plap
|
|
WO2023109900A1
(en)
|
2021-12-17 |
2023-06-22 |
Shanghai Henlius Biotech, Inc. |
Anti-ox40 antibodies, multispecific antibodies and methods of use
|
|
AU2022411573A1
(en)
|
2021-12-17 |
2024-06-27 |
Shanghai Henlius Biologics Co., Ltd. |
Anti-ox40 antibodies and methods of use
|
|
CR20240246A
(es)
|
2021-12-20 |
2024-07-19 |
Hoffmann La Roche |
Anticuerpos agonistas anti-ltbr y anticuerpos biespecificos que los comprenden
|
|
EP4416301B1
(en)
|
2021-12-21 |
2025-06-11 |
F. Hoffmann-La Roche AG |
Method for the determination of hydrolytic activity
|
|
EP4454662A4
(en)
|
2021-12-23 |
2025-04-23 |
Jiangsu Hengrui Pharmaceuticals Co., Ltd. |
ANTI-DLL3 ANTIBODY AND PHARMACEUTICAL USE THEREOF, AND ANTIBODY-DRUG CONJUGATE CONTAINING AN ANTI-DLL3 ANTIBODY
|
|
CN118510805A
(zh)
|
2021-12-31 |
2024-08-16 |
山东先声生物制药有限公司 |
一种gprc5d抗体及其应用
|
|
US20250304664A1
(en)
|
2022-01-12 |
2025-10-02 |
Vib Vzw |
Human NTCP Binders For Therapeutic Use And Liver-Specific Targeted Delivery
|
|
US20230322958A1
(en)
|
2022-01-19 |
2023-10-12 |
Genentech, Inc. |
Anti-Notch2 Antibodies and Conjugates and Methods of Use
|
|
AR128331A1
(es)
|
2022-01-26 |
2024-04-17 |
Genentech Inc |
Inductores químicos de degradación conjugados con anticuerpos y métodos de estos
|
|
AR128330A1
(es)
|
2022-01-26 |
2024-04-17 |
Genentech Inc |
Inductores químicos de degradación conjugados con anticuerpo y métodos de estos
|
|
JP2025503176A
(ja)
|
2022-01-28 |
2025-01-30 |
ジェンマブ エー／エス |
びまん性大細胞型ｂ細胞リンパ腫を治療するための併用療法におけるｃｄ３及びｃｄ２０に対する二重特異性抗体
|
|
MX2024008832A
(es)
|
2022-01-28 |
2024-07-25 |
Genmab As |
Anticuerpo biespecifico contra el cumulo de diferenciacion 3 (cd3) y el cumulo de diferenciacion 20 (cd20) en terapia combinada para tratar linfoma difuso de celulas b grandes.
|
|
TW202337902A
(zh)
|
2022-02-07 |
2023-10-01 |
大陸商江蘇恆瑞醫藥股份有限公司 |
特異性結合ｐｓｍａ和ｃｄ３的抗原結合分子及其醫藥用途
|
|
JP2025505650A
(ja)
|
2022-02-07 |
2025-02-28 |
ビステラ， インコーポレイテッド |
抗イディオタイプ抗体分子及びその使用
|
|
TW202342106A
(zh)
|
2022-02-09 |
2023-11-01 |
日商第一三共股份有限公司 |
環境應答性遮蔽抗體及其利用
|
|
WO2023151661A1
(zh)
|
2022-02-11 |
2023-08-17 |
江苏恒瑞医药股份有限公司 |
免疫缀合物及其用途
|
|
KR20240141208A
(ko)
|
2022-03-03 |
2024-09-25 |
화이자 인코포레이티드 |
다중특이적 항체 및 그의 용도
|
|
US20250205350A1
(en)
|
2022-03-10 |
2025-06-26 |
Vivasor, Inc. |
Antibody-Drug Conjugates and Uses Thereof
|
|
CN119173532A
(zh)
|
2022-03-11 |
2024-12-20 |
詹森药业有限公司 |
多特异性抗体及其用途
|
|
EP4490184A1
(en)
|
2022-03-11 |
2025-01-15 |
JANSSEN Pharmaceutica NV |
Multispecific antibodies and uses thereof
|
|
CN119173530A
(zh)
|
2022-03-11 |
2024-12-20 |
詹森药业有限公司 |
多特异性抗体及其用途
|
|
CA3245807A1
(en)
|
2022-03-14 |
2025-06-13 |
Jiangsu Hengrui Pharmaceuticals Co., Ltd. |
Antigen-binding molecule specifically binding to GPRC5D and CD3 and its medical use
|
|
WO2023174521A1
(en)
|
2022-03-15 |
2023-09-21 |
Genmab A/S |
Binding agents binding to epcam and cd137
|
|
WO2023176881A1
(ja)
|
2022-03-16 |
2023-09-21 |
第一三共株式会社 |
多重特異的分子と免疫チェックポイント阻害剤の組み合わせ
|
|
IL315714A
(en)
|
2022-03-18 |
2024-11-01 |
Evolveimmune Therapeutics Inc |
Bispecific antibody fusion molecules and methods of using them
|
|
CN119584984A
(zh)
|
2022-03-23 |
2025-03-07 |
豪夫迈·罗氏有限公司 |
抗cd20/抗cd3双特异性抗体与化学疗法的组合治疗
|
|
KR20240163119A
(ko)
|
2022-03-25 |
2024-11-18 |
상하이 헨리우스 바이오테크, 인크. |
항-msln 항체 및 사용 방법
|
|
AR128876A1
(es)
|
2022-03-28 |
2024-06-19 |
Hoffmann La Roche |
Anticuerpos biespecíficos de linfocitos t activables con proteasa folr1 mejorados
|
|
EP4504780A1
(en)
|
2022-04-01 |
2025-02-12 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
|
CA3255366A1
(en)
|
2022-04-13 |
2023-10-19 |
F. Hoffmann-La Roche Ag |
Pharmaceutical compositions based on bispecific anti-CD20/anti-CD3 antibodies and methods of use
|
|
JP2025512342A
(ja)
|
2022-04-13 |
2025-04-17 |
ジェネンテック， インコーポレイテッド |
治療用タンパク質の医薬組成物および使用方法
|
|
WO2023198839A2
(en)
|
2022-04-13 |
2023-10-19 |
Genmab A/S |
Bispecific antibodies against cd3 and cd20
|
|
CN119421890A
(zh)
|
2022-04-19 |
2025-02-11 |
豪夫迈·罗氏有限公司 |
改进的生产细胞
|
|
AU2023262861A1
(en)
|
2022-04-26 |
2024-11-07 |
Chugai Seiyaku Kabushiki Kaisha |
Pharmaceutical-preparation-containing syringe equipped with filter
|
|
IL316174A
(en)
|
2022-04-26 |
2024-12-01 |
Novartis Ag |
Multiple specific antibodies targeting IL-13 and IL-18
|
|
CR20240526A
(es)
|
2022-05-03 |
2025-01-10 |
Genentech Inc |
Anticuerpos anti-ly6e, inmunoconjugados y usos de estos
|
|
US20240059799A1
(en)
|
2022-05-11 |
2024-02-22 |
Pfizer Inc. |
Anti-tl1a antibodies and methods of use thereof
|
|
KR20250008898A
(ko)
|
2022-05-11 |
2025-01-16 |
제넨테크, 인크. |
항-fcrh5/항-cd3 이중특이성 항체로 치료하기 위한 투약법
|
|
KR20250024872A
(ko)
|
2022-05-11 |
2025-02-19 |
리제너론 파마슈티칼스 인코포레이티드 |
다중특이적 결합 분자 전구단백질 및 이의 용도
|
|
CN119365215A
(zh)
|
2022-05-12 |
2025-01-24 |
健玛保 |
在组合疗法中能够结合cd27的结合剂
|
|
CN119451985A
(zh)
|
2022-05-12 |
2025-02-14 |
健玛保 |
在组合疗法中能够结合cd27的结合剂
|
|
US20250295809A1
(en)
|
2022-05-13 |
2025-09-25 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of her2 positive cancer
|
|
CA3257348A1
(en)
|
2022-05-27 |
2023-11-30 |
Regeneron Pharmaceuticals, Inc. |
INTERLEUKIN-2 PROPROTEINS AND THEIR USES
|
|
EP4532526A1
(en)
|
2022-06-03 |
2025-04-09 |
F. Hoffmann-La Roche AG |
Improved production cells
|
|
IL317373A
(en)
|
2022-06-04 |
2025-02-01 |
Regeneron Pharma |
Interleukin-2 proproteins and their uses
|
|
EP4538294A1
(en)
|
2022-06-06 |
2025-04-16 |
Shandong Simcere Biopharmaceutical Co., Ltd. |
Multi-specific antibody targeting bcma, gprc5d and t cells and application thereof
|
|
WO2023246885A1
(zh)
|
2022-06-23 |
2023-12-28 |
江苏恒瑞医药股份有限公司 |
特异性结合dll3和cd3的抗原结合分子及其医药用途
|
|
KR20250039386A
(ko)
|
2022-07-13 |
2025-03-20 |
제넨테크, 인크. |
항-fcrh5/항-cd3 이중특이적 항체를 이용한 치료를 위한 투약법
|
|
WO2024013315A1
(en)
|
2022-07-15 |
2024-01-18 |
Boehringer Ingelheim International Gmbh |
Binding molecules for the treatment of cancer
|
|
JP2025523845A
(ja)
|
2022-07-19 |
2025-07-25 |
ジェネンテック， インコーポレイテッド |
抗ｆｃｒｈ５／抗ｃｄ３二重特異性抗体による処置のための投薬
|
|
WO2024020564A1
(en)
|
2022-07-22 |
2024-01-25 |
Genentech, Inc. |
Anti-steap1 antigen-binding molecules and uses thereof
|
|
AU2023312054A1
(en)
|
2022-07-22 |
2025-01-23 |
Bristol-Myers Squibb Company |
Antibodies binding to human pad4 and uses thereof
|
|
WO2024026358A1
(en)
|
2022-07-27 |
2024-02-01 |
Teneobio, Inc. |
Mesothelin binding proteins and uses thereof
|
|
JP2025528751A
(ja)
|
2022-07-29 |
2025-09-02 |
アレクトル エルエルシー |
Ｃｄ９８ｈｃ抗原結合ドメイン及びその使用法
|
|
AU2023314807A1
(en)
|
2022-07-29 |
2025-03-06 |
Alector Llc |
Transferrin receptor antigen-binding domains and uses therefor
|
|
TW202435912A
(zh)
|
2022-08-03 |
2024-09-16 |
美商航海家醫療公司 |
用於穿過血腦屏障之組合物及方法
|
|
JP2025525829A
(ja)
|
2022-08-03 |
2025-08-07 |
ファイザー・インク |
抗ｉｌ２７ｒ抗体およびその使用の方法
|
|
WO2024030956A2
(en)
|
2022-08-03 |
2024-02-08 |
Mozart Therapeutics, Inc. |
Cd39-specific binding agents and methods of using the same
|
|
WO2024027815A1
(zh)
|
2022-08-05 |
2024-02-08 |
江苏恒瑞医药股份有限公司 |
特异性结合gucy2c和cd3的抗原结合分子及其医药用途
|
|
CN120051483A
(zh)
|
2022-08-18 |
2025-05-27 |
再生元制药公司 |
干扰素前蛋白及其用途
|
|
US20240067691A1
(en)
|
2022-08-18 |
2024-02-29 |
Regeneron Pharmaceuticals, Inc. |
Interferon receptor agonists and uses thereof
|
|
CN120153254A
(zh)
|
2022-09-01 |
2025-06-13 |
基因泰克公司 |
膀胱癌的治疗和诊断方法
|
|
WO2024052922A1
(en)
|
2022-09-11 |
2024-03-14 |
Yeda Research And Development Co. Ltd. |
Anti-klk4 antibodies and uses thereof
|
|
CA3266790A1
(en)
|
2022-09-15 |
2024-03-21 |
Voyager Therapeutics, Inc. |
TAU PROTEIN BINDING COMPOUNDS
|
|
IL319570A
(en)
|
2022-09-15 |
2025-05-01 |
Avidicure Ip B V |
Multispecific antigen-binding proteins for targeting NK cells to tumors and their uses
|
|
CN119948060A
(zh)
|
2022-09-28 |
2025-05-06 |
豪夫迈·罗氏有限公司 |
改善的蛋白酶可活化的t细胞双特异性抗体
|
|
WO2024068996A1
(en)
|
2022-09-30 |
2024-04-04 |
Centre Hospitalier Universitaire Vaudois (C.H.U.V.) |
Anti-sars-cov-2 antibodies and use thereof in the treatment of sars-cov-2 infection
|
|
EP4598958A1
(en)
|
2022-10-05 |
2025-08-13 |
Amgen Inc. |
Combination therapies comprising t-cell redirecting therapies and agonistic anti-il-2r antibodies or fragments thereof
|
|
TW202421664A
(zh)
|
2022-10-07 |
2024-06-01 |
美商建南德克公司 |
用抗ｃ—ｃ模體趨化因子受體８（ｃｃｒ８）抗體治療癌症之方法
|
|
TW202423969A
(zh)
|
2022-10-10 |
2024-06-16 |
瑞士商赫孚孟拉羅股份公司 |
Ｇｐｒｃ５ｄ ｔｃｂ及蛋白酶體抑制劑之組合療法
|
|
TW202423970A
(zh)
|
2022-10-10 |
2024-06-16 |
瑞士商赫孚孟拉羅股份公司 |
Ｇｐｒｃ５ｄ ｔｃｂ及ｃｄ３８抗體之組合療法
|
|
TW202430211A
(zh)
|
2022-10-10 |
2024-08-01 |
瑞士商赫孚孟拉羅股份公司 |
Ｇｐｒｃ５ｄ ｔｃｂ及ｉｍｉｄ之組合療法
|
|
WO2024079069A1
(en)
|
2022-10-12 |
2024-04-18 |
F. Hoffmann-La Roche Ag |
Method for classifying cells
|
|
WO2024086796A1
(en)
|
2022-10-20 |
2024-04-25 |
Alector Llc |
Anti-ms4a4a antibodies with amyloid-beta therapies
|
|
CN115724975A
(zh)
|
2022-10-20 |
2023-03-03 |
江苏荃信生物医药股份有限公司 |
抗人白介素36受体单克隆抗体及其应用
|
|
TW202426505A
(zh)
|
2022-10-25 |
2024-07-01 |
美商建南德克公司 |
癌症之治療及診斷方法
|
|
WO2024094660A1
(en)
|
2022-10-31 |
2024-05-10 |
Genmab A/S |
Cd38 antibodies and uses thereof
|
|
TW202432596A
(zh)
|
2022-11-01 |
2024-08-16 |
大陸商上海齊魯製藥研究中心有限公司 |
針對磷脂醯肌醇蛋白聚醣3的雙特異性抗體及其應用
|
|
CN120077073A
(zh)
|
2022-11-02 |
2025-05-30 |
健玛保 |
用于治疗里希特氏综合征的针对cd3和cd20的双特异性抗体
|
|
EP4612178A1
(en)
|
2022-11-03 |
2025-09-10 |
F. Hoffmann-La Roche AG |
Combination therapy with anti-cd19/anti-cd28 bispecific antibody
|
|
KR20250099701A
(ko)
|
2022-11-08 |
2025-07-02 |
제넨테크, 인크. |
소아기 발병 특발성 신증후군의 치료 조성물 및 치료 방법
|
|
WO2024102962A1
(en)
|
2022-11-10 |
2024-05-16 |
Immuvia Inc |
Cytotoxic bispecific antibodies binding to dr5 and muc16 and uses thereof
|
|
WO2024100170A1
(en)
|
2022-11-11 |
2024-05-16 |
F. Hoffmann-La Roche Ag |
Antibodies binding to hla-a*02/foxp3
|
|
WO2024102948A1
(en)
|
2022-11-11 |
2024-05-16 |
Celgene Corporation |
Fc receptor-homolog 5 (fcrh5) specific binding molecules and bispecific t-cell engaging antibodies including same and related methods
|
|
CN120187749A
(zh)
|
2022-11-15 |
2025-06-20 |
豪夫迈·罗氏有限公司 |
具有可活化效应结构域的重组结合蛋白
|
|
CN120187748A
(zh)
|
2022-11-15 |
2025-06-20 |
豪夫迈·罗氏有限公司 |
抗原结合分子
|
|
WO2024108053A1
(en)
|
2022-11-17 |
2024-05-23 |
Sanofi |
Ceacam5 antibody-drug conjugates and methods of use thereof
|
|
CN120225684A
(zh)
|
2022-11-23 |
2025-06-27 |
豪夫迈·罗氏有限公司 |
用于增加重组蛋白表达的方法
|
|
EP4624489A1
(en)
|
2022-11-25 |
2025-10-01 |
Chugai Seiyaku Kabushiki Kaisha |
Method for producing protein
|
|
EP4628507A1
(en)
|
2022-11-29 |
2025-10-08 |
Jiangsu Hengrui Pharmaceuticals Co., Ltd. |
Cldn18.2/4-1bb binding protein and medical use thereof
|
|
JP2025528316A
(ja)
|
2022-12-08 |
2025-08-28 |
ナンジン、バザイム、バイオテック、カンパニー、リミテッド |
Ｒｓｖに特異的に結合する抗体
|
|
JP2025538819A
(ja)
|
2022-12-12 |
2025-11-28 |
ジェネンテック， インコーポレイテッド |
ポリペプチドシアル酸含有量の最適化
|
|
EP4385999A1
(en)
|
2022-12-14 |
2024-06-19 |
ModiQuest B.V. |
Antibodies
|
|
WO2024126660A1
(en)
|
2022-12-15 |
2024-06-20 |
F. Hoffmann-La Roche Ag |
Combination therapy for cancer treatment
|
|
KR20250134733A
(ko)
|
2022-12-16 |
2025-09-11 |
리제너론 파아마슈티컬스, 인크. |
Aav 입자에 결합하는 항원-결합 분자 및 용도
|
|
WO2024138191A1
(en)
|
2022-12-23 |
2024-06-27 |
Regeneron Pharmaceuticals, Inc. |
Ace2 fusion proteins and uses thereof
|
|
IL322053A
(en)
|
2023-01-13 |
2025-09-01 |
Regeneron Pharma |
FGFR3 binding molecules and methods of using them
|
|
CN121013860A
(zh)
|
2023-01-13 |
2025-11-25 |
再生元制药公司 |
Il12受体激动剂及其使用方法
|
|
AR131638A1
(es)
|
2023-01-18 |
2025-04-16 |
Genentech Inc |
Anticuerpos multiespecíficos y usos de estos
|
|
CN120548192A
(zh)
|
2023-01-20 |
2025-08-26 |
豪夫迈·罗氏有限公司 |
免疫缀合物
|
|
EP4655315A1
(en)
|
2023-01-25 |
2025-12-03 |
F. Hoffmann-La Roche AG |
Payload-bearing multispecific antibodies
|
|
CN120569410A
(zh)
|
2023-01-25 |
2025-08-29 |
豪夫迈·罗氏有限公司 |
与csf1r和cd3结合的抗体
|
|
WO2024163494A1
(en)
|
2023-01-31 |
2024-08-08 |
F. Hoffmann-La Roche Ag |
Methods and compositions for treating non-small cell lung cancer and triple-negative breast cancer
|
|
WO2024163009A1
(en)
|
2023-01-31 |
2024-08-08 |
Genentech, Inc. |
Methods and compositions for treating urothelial bladder cancer
|
|
CN120584138A
(zh)
|
2023-02-06 |
2025-09-02 |
豪夫迈·罗氏有限公司 |
组合疗法及其用途
|
|
WO2024168061A2
(en)
|
2023-02-07 |
2024-08-15 |
Ayan Therapeutics Inc. |
Antibody molecules binding to sars-cov-2
|
|
EP4671282A1
(en)
|
2023-02-21 |
2025-12-31 |
Jiangsu Hengrui Pharmaceuticals Co., Ltd. |
IL-36R BINDING PROTEIN AND ITS MEDICINAL USE
|
|
AU2024226156A1
(en)
|
2023-02-21 |
2025-08-28 |
Teneobio, Inc. |
C-kit binding proteins, chimeric antigen receptors, and uses thereof
|
|
AU2024228867A1
(en)
|
2023-02-27 |
2025-09-18 |
Jiangsu Hengrui Pharmaceuticals Co., Ltd. |
Anti-dll3 antibody, and antibody-drug conjugate and pharmaceutical use thereof
|
|
IL322940A
(en)
|
2023-02-28 |
2025-10-01 |
Regeneron Pharma |
Multivalent anti-spike protein binding molecules and their uses
|
|
AU2024230156A1
(en)
|
2023-02-28 |
2025-09-11 |
Regeneron Pharmaceuticals, Inc. |
Multispecific molecules comprising a peptide-mhc complex comprising an mhc domain and an antigenic peptide and an immune cell antigen targeting moiety
|
|
EP4676519A1
(en)
|
2023-03-06 |
2026-01-14 |
F. Hoffmann-La Roche AG |
Combination therapy of an anti-egfrviii/anti-cd3 antibody and an tumor-targeted 4-1bb agonist
|
|
CN120858109A
(zh)
|
2023-03-10 |
2025-10-28 |
基因泰克公司 |
与蛋白酶的融合物及其用途
|
|
WO2024188965A1
(en)
|
2023-03-13 |
2024-09-19 |
F. Hoffmann-La Roche Ag |
Combination therapy employing a pd1-lag3 bispecific antibody and an hla-g t cell bispecific antibody
|
|
CN121263449A
(zh)
|
2023-03-21 |
2026-01-02 |
拜格拉夫55公司 |
Cd19/cd38多特异性抗体
|
|
TW202446789A
(zh)
|
2023-03-31 |
2024-12-01 |
美商建南德克公司 |
抗αｖβ８整合素抗體及使用方法
|
|
WO2024208777A1
(en)
|
2023-04-03 |
2024-10-10 |
F. Hoffmann-La Roche Ag |
All-in-one agonistic antibodies
|
|
CN120917044A
(zh)
|
2023-04-03 |
2025-11-07 |
豪夫迈·罗氏有限公司 |
激动性拆分型抗体
|
|
WO2024211235A1
(en)
|
2023-04-05 |
2024-10-10 |
Sorrento Therapeutics, Inc. |
Antibody-drug conjugates and uses thereof
|
|
WO2024211236A2
(en)
|
2023-04-05 |
2024-10-10 |
Sorrento Therapeutics, Inc. |
Antibody-drug conjugates and uses thereof
|
|
CN121240884A
(zh)
|
2023-04-05 |
2025-12-30 |
根马布股份公司 |
包含与cd30和cd3结合的抗体的药用组合物
|
|
WO2024211234A1
(en)
|
2023-04-05 |
2024-10-10 |
Sorrento Therapeutics, Inc. |
Antibody-drug conjugates and uses thereof
|
|
EP4442275A1
(en)
|
2023-04-06 |
2024-10-09 |
ModiQuest B.V. |
Anti-type ii collagen antibodies
|
|
AU2024252604A1
(en)
|
2023-04-11 |
2025-10-23 |
BioRay Pharmaceutical Co., Ltd. |
Anti-ror1 antibody and drug conjugate thereof
|
|
AU2024255174A1
(en)
|
2023-04-13 |
2025-10-09 |
Genmab A/S |
Methods of treating lymphoma with bispecific antibodies against cd3 and cd20
|
|
CN121038814A
(zh)
|
2023-04-14 |
2025-11-28 |
中外制药株式会社 |
用于稳定含蛋白质药物制剂的方法
|
|
AU2024257248A1
(en)
|
2023-04-17 |
2025-11-06 |
Peak Bio, Inc. |
Antibodies and antibody-drug conjugates and methods of use and synthetic processes and intermediates
|
|
WO2024233341A1
(en)
|
2023-05-05 |
2024-11-14 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
|
CN121127493A
(zh)
|
2023-05-08 |
2025-12-12 |
豪夫迈·罗氏有限公司 |
靶向干扰素 α 融合蛋白及使用方法
|
|
WO2024233646A1
(en)
|
2023-05-10 |
2024-11-14 |
Genentech, Inc. |
Methods and compositions for treating cancer
|
|
AU2024269008A1
(en)
|
2023-05-10 |
2025-11-27 |
Regeneron Pharmaceuticals, Inc. |
Cd20-pd1 binding molecules and methods of use thereof
|
|
US12410258B2
(en)
|
2023-05-12 |
2025-09-09 |
Ganmab A/S |
Antibodies capable of binding to OX40, variants thereof and uses thereof
|
|
WO2024238415A1
(en)
|
2023-05-12 |
2024-11-21 |
Regeneron Pharmaceuticals, Inc. |
Interferon receptor antagonists and uses thereof
|
|
WO2024238537A1
(en)
|
2023-05-16 |
2024-11-21 |
F. Hoffmann-La Roche Ag |
Pd-1 -regulated il-2 immunocytokine and uses thereof
|
|
AU2024275646A1
(en)
|
2023-05-24 |
2025-11-13 |
Mozart Therapeutics, Inc. |
Cd8-specific binding proteins and methods of using the same
|
|
AR132805A1
(es)
|
2023-06-01 |
2025-07-30 |
Hoffmann La Roche |
Moléculas de unión al antígeno inmunoestimuladoras que se unen específicamente a bcma
|
|
WO2024246083A1
(en)
|
2023-06-01 |
2024-12-05 |
F. Hoffmann-La Roche Ag |
Bispecific antibodies targeting bcma and cd28
|
|
WO2024251884A1
(en)
|
2023-06-09 |
2024-12-12 |
Innate Pharma |
Nk cell engager proteins comprising anti-cd20 and ant-nkp46 antibody, linked to il-2 in treatment of r/r b-nhl
|
|
US20250011449A1
(en)
|
2023-06-11 |
2025-01-09 |
Regeneron Pharmaceuticals, Inc. |
Circularized antibody molecules
|
|
UY40783A
(es)
|
2023-06-12 |
2024-12-31 |
Amgen Inc |
Proteínas de unión a agonistas del receptor beta de linfotoxina
|
|
WO2024256623A1
(en)
|
2023-06-16 |
2024-12-19 |
Heidelberg Immunotherapeutics Gmbh |
Novel anti-hsv antibody
|
|
AU2024311339A1
(en)
|
2023-06-21 |
2026-01-08 |
F. Hoffmann-La Roche Ag |
Combination therapy with fap-targeted lymphotoxin beta receptor agonists
|
|
WO2024263845A1
(en)
|
2023-06-22 |
2024-12-26 |
Genentech, Inc. |
Treatment of multiple myeloma
|
|
AU2024311704A1
(en)
|
2023-06-22 |
2026-01-08 |
Genentech, Inc. |
Antibodies and uses thereof
|
|
WO2024263904A1
(en)
|
2023-06-23 |
2024-12-26 |
Genentech, Inc. |
Methods for treatment of liver cancer
|
|
WO2024263195A1
(en)
|
2023-06-23 |
2024-12-26 |
Genentech, Inc. |
Methods for treatment of liver cancer
|
|
WO2025006529A1
(en)
|
2023-06-27 |
2025-01-02 |
Amgen Inc. |
Charge pair mutations to enable correct heavy-light chain pairing
|
|
WO2025007037A1
(en)
|
2023-06-28 |
2025-01-02 |
Dragonfly Therapeutics, Inc. |
Variant il-2 proteins
|
|
AR133071A1
(es)
|
2023-06-30 |
2025-08-20 |
Genmab As |
ANTICUERPOS QUE SE UNEN A LA PROTEÍNA DE ACTIVACIÓN DE FIBROBLASTOS a Y AL RECEPTOR DE MUERTE 4
|
|
US12319747B2
(en)
|
2023-07-03 |
2025-06-03 |
Medicovestor, Inc. |
Methods of using anti-SP17 immunotherapeutics
|
|
WO2025010272A1
(en)
*
|
2023-07-03 |
2025-01-09 |
Neoimmunetech, Inc. |
Heterodimeric fc molecules and uses thereof
|
|
WO2025024265A1
(en)
|
2023-07-21 |
2025-01-30 |
Bristol-Myers Squibb Company |
Methods of assessing citrullination and activity of pad4 modulators
|
|
WO2025021838A1
(en)
|
2023-07-26 |
2025-01-30 |
F. Hoffmann-La Roche Ag |
Antibodies binding to cd3
|
|
TW202521576A
(zh)
|
2023-07-30 |
2025-06-01 |
美商健生生物科技公司 |
結合至突變型鈣網蛋白之分子及其用途
|
|
WO2025034806A1
(en)
|
2023-08-08 |
2025-02-13 |
Wisconsin Alumni Research Foundation |
Single-domain antibodies and variants thereof against fibroblast activation protein
|
|
WO2025032071A1
(en)
|
2023-08-09 |
2025-02-13 |
F. Hoffmann-La Roche Ag |
Mono and multispecific anti-trem2 antibodies, methods and uses thereof
|
|
WO2025032069A1
(en)
|
2023-08-09 |
2025-02-13 |
F. Hoffmann-La Roche Ag |
Mono and multispecific anti-trem2 antibodies, methods and uses thereof
|
|
US20250051434A1
(en)
|
2023-08-11 |
2025-02-13 |
Merck Sharp & Dohme Llc |
Monovalent interleukin 12 (il-12) heterodimeric fc proteins
|
|
WO2025038668A1
(en)
|
2023-08-14 |
2025-02-20 |
Voro Therapeutics, Inc. |
Therapeutic binding agents that conditionally promote myeloid cell activity against target cells and uses thereof
|
|
WO2025036892A1
(en)
|
2023-08-14 |
2025-02-20 |
Morphosys Ag |
Cycat halfbody molecules comprising sterically occluding moieties
|
|
WO2025042742A1
(en)
|
2023-08-18 |
2025-02-27 |
Bristol-Myers Squibb Company |
Compositions comprising antibodies that bind bcma and cd3 and methods of treatment
|
|
EP4630457A1
(en)
|
2023-08-18 |
2025-10-15 |
Regeneron Pharmaceuticals, Inc. |
Bispecific antigen-binding molecules and uses thereof
|
|
WO2025040567A1
(en)
|
2023-08-18 |
2025-02-27 |
F. Hoffmann-La Roche Ag |
Protease activatable fc domain binding molecules
|
|
WO2025041077A1
(en)
|
2023-08-23 |
2025-02-27 |
Sanofi |
Ctla-4-based lysosomal degraders and uses thereof
|
|
WO2025054500A2
(en)
|
2023-09-08 |
2025-03-13 |
Mlab Biosciences, Inc. |
Bifunctional proteins and uses thereof
|
|
WO2025059162A1
(en)
|
2023-09-11 |
2025-03-20 |
Dana-Farber Cancer Institute, Inc. |
Car-engager containing il-2 variants to enhance the functionality of car t cells
|
|
WO2025059037A1
(en)
|
2023-09-11 |
2025-03-20 |
Evolveimmune Therapeutics, Inc. |
Bispecific antibody fusion molecules targeting b7-h4 and cd3 and methods of use thereof
|
|
WO2025056180A1
(en)
|
2023-09-15 |
2025-03-20 |
BioNTech SE |
Methods of treatment using agents binding to epcam and cd137 in combination with pd-1 axis binding antagonists
|
|
WO2025064890A1
(en)
|
2023-09-20 |
2025-03-27 |
Evolveimmune Therapeutics, Inc. |
Bispecific antibody fusion molecules targeting cd180 and cd3 and methods of use thereof
|
|
WO2025064885A1
(en)
|
2023-09-20 |
2025-03-27 |
Evolveimmune Therapeutics, Inc. |
Multispecific antibodies that bind cd3 and cd2 and methods of use thereof
|
|
AR133909A1
(es)
|
2023-09-25 |
2025-11-12 |
Hoffmann La Roche |
ANTICUERPO QUE SE UNE A C3bBb
|
|
TW202535954A
(zh)
|
2023-09-26 |
2025-09-16 |
丹麥商珍美寶股份有限公司 |
Ｐｔｋ７結合劑、其共軛物及使用彼等之方法
|
|
WO2025068957A1
(en)
|
2023-09-29 |
2025-04-03 |
Novartis Ag |
Bispecific antibodies for use in lowering the risk of cardiovascular disease events in subjects known to be a carrier of clonal expansion of hematopoietic cell lines with somatic mutations
|
|
WO2025082777A1
(en)
|
2023-10-17 |
2025-04-24 |
Morphosys Ag |
Dual-targeting of muc16 and mesothelin co-expressing tumor cells by functional complementation of cycat® halfbody molecules
|
|
WO2025085489A1
(en)
|
2023-10-17 |
2025-04-24 |
Bristol-Myers Squibb Company |
Gspt1-degrading compounds, anti-cd33 antibodies and antibody-drug conjugates and uses thereof
|
|
US12364777B2
(en)
|
2023-10-20 |
2025-07-22 |
Medicovestor, Inc. |
Homodimeric antibodies for use in treating cancers and methods of use
|
|
TW202540169A
(zh)
|
2023-11-08 |
2025-10-16 |
法商賽諾菲公司 |
基於ｃｄ２５的溶酶體降解物及其用途
|
|
US20250154287A1
(en)
|
2023-11-10 |
2025-05-15 |
Pfizer Inc. |
ANTI-MIGIS-alpha ANTIBODIES AND METHODS OF USE THEREOF
|
|
WO2025106469A1
(en)
|
2023-11-14 |
2025-05-22 |
Regeneron Pharmaceuticals, Inc. |
Engineered heavy chain variable domains and uses thereof
|
|
WO2025106474A1
(en)
|
2023-11-14 |
2025-05-22 |
Genentech, Inc. |
Therapeutic and diagnostic methods for treating cancer with anti-fcrh5/anti-cd3 bispecific antibodies
|
|
WO2025106634A1
(en)
|
2023-11-17 |
2025-05-22 |
Genentech, Inc. |
Mcl-1 inhibitor compounds and use in antibody drug conjugates
|
|
WO2025114541A1
(en)
|
2023-11-30 |
2025-06-05 |
Genmab A/S |
Antibodies capable of binding to ox40 in combination therapy
|
|
TW202540200A
(zh)
|
2023-12-01 |
2025-10-16 |
美商基利科學股份有限公司 |
抗ｆａｐ－ｌｉｇｈｔ融合蛋白及其用途
|
|
WO2025122634A1
(en)
|
2023-12-05 |
2025-06-12 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of tau-related disorders
|
|
WO2025122614A1
(en)
|
2023-12-05 |
2025-06-12 |
Regeneron Pharmaceuticals, Inc. |
Il18 receptor agonists and methods of use thereof
|
|
WO2025125118A1
(en)
|
2023-12-11 |
2025-06-19 |
F. Hoffmann-La Roche Ag |
Protease activatable fc domain binding molecules
|
|
WO2025129010A1
(en)
|
2023-12-14 |
2025-06-19 |
Genentech, Inc. |
Methods of structure determination using antibodies
|
|
WO2025125386A1
(en)
|
2023-12-14 |
2025-06-19 |
F. Hoffmann-La Roche Ag |
Antibodies that bind to folr1 and methods of use
|
|
WO2025137086A1
(en)
|
2023-12-20 |
2025-06-26 |
Genentech, Inc. |
Reducing alpha-gal
|
|
WO2025132503A1
(en)
|
2023-12-20 |
2025-06-26 |
F. Hoffmann-La Roche Ag |
Antibodies binding to ceacam5
|
|
WO2025137454A1
(en)
|
2023-12-21 |
2025-06-26 |
Amgen Inc. |
Stabilizing homodimer mutations for two cell heterodimer production
|
|
WO2025133042A2
(en)
|
2023-12-22 |
2025-06-26 |
F. Hoffmann-La Roche Ag |
Activatable fusion proteins and methods of use
|
|
US12116410B1
(en)
|
2023-12-26 |
2024-10-15 |
Medicovestor, Inc. |
Methods of manufacturing dimeric antibodies
|
|
US12121587B1
(en)
|
2023-12-26 |
2024-10-22 |
Medicovestor, Inc. |
Dimeric antibodies
|
|
WO2025147696A1
(en)
|
2024-01-05 |
2025-07-10 |
Resolve Therapeutics, Llc |
Treatment of symptoms associated with sars-cov viral infection or a prior sars-cov viral infection with nuclease agents
|
|
US20250296992A1
(en)
|
2024-01-10 |
2025-09-25 |
Genmab A/S |
Slitrk6 binding agents, conjugates thereof and methods of using the same
|
|
WO2025149633A1
(en)
|
2024-01-12 |
2025-07-17 |
Laigo Bio B.V. |
Bispecific antigen binding proteins
|
|
WO2025166040A1
(en)
|
2024-01-31 |
2025-08-07 |
Alector Llc |
Multi-specific binding proteins that bind to gpnmb and a blood brain barrier target and methods of use thereof
|
|
WO2025166045A1
(en)
|
2024-01-31 |
2025-08-07 |
Alector Llc |
β-GLUCOCEREBROSIDASE ENZYMES, FUSION PROTEINS AND COMPLEXES COMPRISING THE SAME, AND METHODS OF USE THEREOF
|
|
WO2025166077A1
(en)
|
2024-01-31 |
2025-08-07 |
Alector Llc |
Compositions comprising progranulin and uses thereof
|
|
WO2025166042A1
(en)
|
2024-01-31 |
2025-08-07 |
Alector Llc |
Cd98hc antigen-binding domains and uses therefor
|
|
US12378314B1
(en)
|
2024-02-02 |
2025-08-05 |
Medicovestor, Inc. |
Proteins that bind folate receptor alpha including fully-human antibodies
|
|
US12240900B1
(en)
|
2024-02-02 |
2025-03-04 |
Medicovestor, Inc. |
Nucleic acids, vectors, and cells that encode antibodies and other proteins that bind folate receptor alpha
|
|
US12258396B1
(en)
|
2024-02-02 |
2025-03-25 |
Medicovestor, Inc. |
Methods of using immunotherapeutics that bind folate receptor alpha
|
|
WO2025174974A1
(en)
|
2024-02-14 |
2025-08-21 |
Bristol-Myers Squibb Company |
Anti-cd33 antibodies and uses thereof
|
|
WO2025172924A1
(en)
|
2024-02-15 |
2025-08-21 |
Janssen Biotech, Inc. |
Anti-transferrin receptor compositions and methods thereof
|
|
US20250381289A1
(en)
|
2024-02-29 |
2025-12-18 |
Genmab A/S |
Egfr and c-met bispecific binding agents, conjugates thereof and methods of using the same
|
|
WO2025181189A1
(en)
|
2024-03-01 |
2025-09-04 |
F. Hoffmann-La Roche Ag |
Antibodies binding to cd3
|
|
WO2025191133A1
(en)
|
2024-03-15 |
2025-09-18 |
Avidicure Ip B.V. |
Il-21 muteins, fusion proteins comprising the same and uses thereof
|
|
WO2025191139A1
(en)
|
2024-03-15 |
2025-09-18 |
Avidicure Ip B.V. |
Conjugates of her2-specific antigen binding proteins and cytokines
|
|
WO2025191136A1
(en)
|
2024-03-15 |
2025-09-18 |
Avidicure Ip B.V. |
Muteins of 4-1bb ligand extracellular domain, fusion proteins comprising the same and uses thereof
|
|
WO2025199243A1
(en)
|
2024-03-20 |
2025-09-25 |
Regeneron Pharmaceuticals, Inc. |
Trivalent multispecific binding molecules and methods of use thereof
|
|
US20250295801A1
(en)
|
2024-03-21 |
2025-09-25 |
Seagen Inc. |
Cd25 antibodies, antibody drug conjugates, and uses thereof
|
|
WO2025202147A1
(en)
|
2024-03-27 |
2025-10-02 |
F. Hoffmann-La Roche Ag |
Interleukin-7 immunoconjugates
|
|
US20250313641A1
(en)
|
2024-04-09 |
2025-10-09 |
Amgen Inc. |
Agonistic anti-il-2rbg heavy-chain antibodies
|
|
WO2025215060A1
(en)
|
2024-04-11 |
2025-10-16 |
F. Hoffmann-La Roche Ag |
Antibodies that specifically bind modified oligonucleotides
|
|
WO2025222129A2
(en)
|
2024-04-19 |
2025-10-23 |
Mozart Therapeutics, Inc. |
Engineered cytokines and targeted cytokine delivery
|
|
WO2025219504A1
(en)
|
2024-04-19 |
2025-10-23 |
F. Hoffmann-La Roche Ag |
Treatment of ophthalmologic diseases
|
|
WO2025226808A1
(en)
|
2024-04-24 |
2025-10-30 |
Genentech, Inc. |
Compositions and methods of treating lupus nephritis
|
|
WO2025233825A1
(en)
|
2024-05-06 |
2025-11-13 |
Janssen Pharmaceutica Nv |
Enrichment of cells expressing a bird linker
|
|
WO2025233431A1
(en)
|
2024-05-07 |
2025-11-13 |
Immatics Biotechnologies Gmbh |
Heteromeric proteins comprising three heteromerization improving substitution, production, combinations and applications thereof
|
|
WO2025233304A1
(en)
|
2024-05-08 |
2025-11-13 |
F. Hoffmann-La Roche Ag |
Recombinant fc domain – il7 variant polypeptides and combination therapy with membrane-anchored antigen binding polypeptides
|
|
WO2025240335A1
(en)
|
2024-05-13 |
2025-11-20 |
Regeneron Pharmaceuticals, Inc. |
Fgfr3 binding molecules and methods of use thereof
|
|
WO2025237931A1
(en)
|
2024-05-15 |
2025-11-20 |
F. Hoffmann-La Roche Ag |
Recombinant binding proteins with conditionally activatable t cell and nk cell recruiting effector domains
|
|
WO2025240670A2
(en)
|
2024-05-15 |
2025-11-20 |
Abalytics Oncology, Inc. |
Anti-pd-1 antibodies and related binding molecules and methods and uses thereof
|
|
WO2025240781A2
(en)
|
2024-05-15 |
2025-11-20 |
Werewolf Therapeutics, Inc. |
Modified antibodies and immunoglobulin formats
|
|
WO2025238133A1
(en)
|
2024-05-17 |
2025-11-20 |
UCB Biopharma SRL |
Multispecific antibody with binding specificity for il-11 and il-17
|
|
WO2025238135A2
(en)
|
2024-05-17 |
2025-11-20 |
UCB Biopharma SRL |
Antibody with binding specificity for il-11
|
|
WO2025250969A1
(en)
|
2024-05-31 |
2025-12-04 |
Vertex Pharmaceuticals Incorporated |
Anti-cd74 antibodies, conjugates and uses thereof
|
|
WO2025253337A2
(en)
|
2024-06-05 |
2025-12-11 |
Sanofi |
Monospecific and bispecific tau binding proteins and compositions thereof
|
|
US20250376511A1
(en)
|
2024-06-05 |
2025-12-11 |
Genzyme Corporation |
BINDING PROTEINS THAT TARGET aC1s, TfR, OR BOTH, AND COMPOSITIONS THEREOF
|
|
US20250376536A1
(en)
|
2024-06-06 |
2025-12-11 |
Bristol-Myers Squibb Company |
Multispecific anti-cd40 / anti-fap antibodies and uses thereof
|
|
US20250376524A1
(en)
|
2024-06-07 |
2025-12-11 |
Regeneron Pharmaceuticals, Inc. |
Tetravalent multispecific binding molecules and methods of use thereof
|
|
WO2025255452A2
(en)
|
2024-06-07 |
2025-12-11 |
Regeneron Pharmaceuticals, Inc. |
Antigen-binding molecules that bind to aav particles and uses thereof
|
|
WO2025259718A2
(en)
|
2024-06-11 |
2025-12-18 |
Regeneron Pharmaceuticals, Inc. |
Vegf antagonists and methods of use thereof
|
|
WO2025257181A1
(en)
|
2024-06-11 |
2025-12-18 |
Institut National de la Santé et de la Recherche Médicale |
Antibodies targeting trans-active response dna-binding protein-43 (tdp-43)
|
|
WO2025256597A1
(en)
|
2024-06-14 |
2025-12-18 |
Keymed Biosciences (Chengdu) Co., Ltd. |
Antibodies targeting ox40l and il-13 and uses thereof
|
|
WO2025259871A1
(en)
|
2024-06-14 |
2025-12-18 |
Gilead Sciences, Inc. |
Anti-ccr8 antibodies and uses thereof
|
|
WO2025264572A1
(en)
|
2024-06-17 |
2025-12-26 |
Alector Llc |
Transferrin receptor antigen-binding domains and uses therefor
|
|
WO2025261943A1
(en)
|
2024-06-18 |
2025-12-26 |
F. Hoffmann-La Roche Ag |
Anti-cancer combinations comprising mosperafenib and folfox or folfiri
|
|
WO2026006162A2
(en)
|
2024-06-24 |
2026-01-02 |
Genentech, Inc. |
B vitamin modulation
|
|
WO2026003224A2
(en)
|
2024-06-26 |
2026-01-02 |
Iomx Therapeutics Ag |
Bispecific antigen binding proteins (abp) targeting immune checkpoint molecules and both leukocyte immunoglobulin-like receptor subfamily b1 (lilrb1) and lilrb2; combinations and uses thereof
|